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The Extended Amygdala in Appetitive Motivation for Reward: 








Chair: Kent C. Berridge 
 
 The extended amygdala is an emerging neuroanatomical concept for a basal 
forebrain macrosystem, containing the bed nucleus of the stria terminalis (BNST) and 
several other highly interconnected nuclei. BNST has received increasing attention 
following the discovery that it connects to limbic brain regions involved in stress, 
homeostasis, and reward. Most of the literature on BNST function emphasizes its role in 
aversive motivational processes such as stress, anxiety and drug withdrawal. However, 
some circumstantial evidence suggests that BNST also plays a role in appetitive 
motivation (e.g., reward ‘wanting’), although direct tests have not yet been made. Here, I 
present a series of experiments designed to provide the first direct evidence for a role of 
BNST in appetitive motivation for food reward. I found that stimulation of !-opioid 
receptors in BNST potently increased eating behavior in non-deprived rats.  By contrast, 
temporary suppression of BNST yielded increased aversive behaviors such as defensive 
treading and escape dashes. Was eating caused by BNST stimulation truly appetitive or 
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only instead due to aversive stress? I found that rats exhibited a conditioned place 
preference for an environment paired with !-opioid stimulation in BNST, confirming that 
this stimulation produced primarily appetitive effects. I also found that opioid stimulation 
in BNST diffusely increased the motivational magnet qualities of a conditioned stimulus 
for a food reward in an autoshaping test. This stimulation spilled elevated motivation into 
inappropriate moments, enhancing responding even when the reward cue was absent. By 
contrast, stimulation of another limbic structure, nucleus accumbens, only increased 
motivational attractiveness in the presence of the cue. Accordingly, stimulation of 
nucleus accumbens, but not BNST, also elevated an animal’s willingness to earn 
presentations of the autoshaping conditioned stimulus in conditioned instrumental 
reinforcement testing. Finally, I showed that increased feeding after !-opioid stimulation 
in BNST occurs in spite of decreased hedonic ‘liking’ for sweet taste. Together, these 
experiments provide direct evidence that BNST mediates appetitive motivation, and 









 The extended amygdala is an emerging neuroanatomical concept that lies in the 
basal forebrain and contains several independent but highly interconnected brain nuclei, 
including the bed nucleus of the stria terminalis (BNST). This macrosystem, and BNST 
in particular, have received a great deal of attention following the discovery that it 
receives a diverse array of input from limbic brain regions and sends output to a variety 
of midbrain and brainstem nuclei involved in stress, homeostasis, and reward. Although 
much of the current literature on BNST focuses on its role in aversive motivational 
processes such as stress, anxiety and drug withdrawal, there is at least circumstantial 
evidence suggesting that BNST also plays a role in appetitive motivation, possibly via 
dense concentrations of the reward-related !-opioid receptor. In this dissertation, I 
present a series of experiments exploring the role of BNST in appetitive motivation. After 
first establishing a broad appetitive role for BNST using tests of voluntary feeding, I 
proceed to use targeted behavioral tests to examine discrete psychological processes that 
support appetitive behavior, including incentive motivation and hedonic impact. These 
experiments are designed to provide the first direct evidence that manipulation of BNST 




Studying the neural substrates of appetitive motivation and reward 
Appetitive motivation for reward often feels like a single experience, a relatively 
seamless experience that flows across the desire for, consumption, and enjoyment of a 
pleasant drink or snack. But the single word reward belies a more complicated interplay 
between multiple distinct psychological mechanisms. Berridge, Robinson, and colleagues 
have argued for three reward processes that, though often experienced simultaneously, 
can be teased apart using the experimental techniques of affective neuroscience (Berridge 
& Robinson, 2003; Berridge, Robinson, & Aldridge, 2009; Robinson & Berridge, 1993). 
These processes are 1) incentive salience ‘wanting,’ which makes rewards or reward cues 
desired and elicits approach and consumption, 2) ‘liking,’ which conveys the hedonic 
pleasure of actually consuming the reward, and 3) learning, which helps to link 
experience with previously ‘liked’ rewards to future ‘wanting’ for that same reward or 
cues that have been associated with it. 
Though at least a portion of the interest in the neuroscience of reward is surely the 
drive to understand and explain our own experiences, it is important to note that brain 
systems of reward, and especially their dysfunction or manipulation, likely underlie a 
number of serious clinical conditions. For example, the process of using and, in some 
cases, becoming addicted to drugs of abuse has been hypothesized to turn predominantly 
on structural or functional changes in brain reward systems, though a fierce debate 
continues about precisely which reward mechanism(s) and neurotransmitter system(s) are 
involved, and at what stage in the addictive process (Aston-Jones & Harris, 2004; Everitt 
et al., 1999; Koob & Le Moal, 2008; Le Moal & Koob, 2007; Redish, 2004; Robinson & 
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Berridge, 1993, 2000; Stewart, 2000). Though drugs of abuse are rather novel 
(evolutionarily speaking) and can essentially hijack brain mechanisms of reward (Nesse 
& Berridge, 1997), naturally rewarding stimuli, like food or sex, and behavioral 
addictions, such as gambling, likely tap into the same brain networks (Davis, Strachan, & 
Berkson, 2004; Goudriaan, Oosterlaan, de Beurs, & Van den Brink, 2004; Grant, Brewer, 
& Potenza, 2006; Volkow, Wang, Fowler, & Telang, 2008; Wang, Volkow, Thanos, & 
Fowler, 2004). Interestingly, but perhaps not surprisingly, each of these clinical 
conditions shows dramatic individual differences in both initial susceptibility and also the 
probability of recovery once the disease is acquired. This adds an additional layer of 
difficulty, requiring not only the uncovering of which brain regions and neurotransmitter 
systems mediate reward, but also how responding to reward may differ across 
individuals, and if possible how those differences in behavior relate back to differences in 
the brain (Cecchi, Capriles, Watson, & Akil, 2007; Flagel, Akil, & Robinson, 2009; 
Yacubian & Buchel, 2009). 
Many different neurotransmitter systems, acting in a distributed network of brain 
regions, have been implicated in reward. Limbic brain regions, so named because they 
reside on the “rim” of the cerebrum adjacent to evolutionarily older structures in the 
midbrain, have received particular attention, including the nucleus accumbens (both core 
and shell) (Carlezon & Thomas, 2009; Pecina, Smith, & Berridge, 2006; Thorpe & Kotz, 
2005; Zhang, Balmadrid, & Kelley, 2003), ventral pallidum (K. S. Smith, Tindell, 
Aldridge, & Berridge, 2009; Tindell, Berridge, Zhang, Pecina, & Aldridge, 2005), 
prefrontal cortical regions (de Araujo, Rolls, Kringelbach, McGlone, & Phillips, 2003; 
Knutson & Cooper, 2005; Rolls, 2006), and amygdala (El-Amamy & Holland, 2007; 
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Everitt et al., 1999; Holland, Han, & Winfield, 2002; Mahler & Berridge, 2009). The 
amygdala, in particular, has received recent attention in light of an emerging anatomical 
concept called the extended amygdala (reviewed in detail below). Briefly, this concept 
builds on the already prevalent distinction between so-called cortical regions of amygdala 
(basolateral nucleus) and sub-cortical regions (central and medial nuclei), highlighting 
the unique anatomical relationship between central/medial amygdala and a nearly 
unbroken continuum of cells extending rostrally (hence extended amygdala) all the way 
to the bed nucleus of the stria terminalis (Alheid & Heimer, 1988; Heimer, Trimble, Van 
Hoesen, & Zahm, 2007). Although much of the attention on the extended amygdala has 
focused on aversive aspects of addiction (Aston-Jones & Harris, 2004; Koob, 2003; Koob 
& Le Moal, 2008), emerging evidence suggests that the extended amygdala macrosystem 
may also play a critical role in mediating reward and appetitive motivation (Johnson, de 
Olmos, Pastuskovas, Zardetto-Smith, & Vivas, 1999; Newman, 1999; Waraczynski, 
2006). 
 
The neurobiology of extended amgydala 
The basal forebrain contains a number of distinct brain nuclei, which can be 
usefully grouped into neuroanatomic ‘macrosystems,’ based on histological, 
architectural, and developmental evidence (Figure 1). Such macrosystems, though 
composed of individual functional units, often act together as large circuits in the 
generation of behavioral responses, much like relatively autonomous states combine to 
form a larger country. Macroystems of the basal forebrain include the ventral-striato-
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pallidal system (part of the basal ganglia), the septal-diagonal band, and the extended 
amygdala. 
The extended amygdala is a forebrain macrostructure, composed of two particular 
nuclei of the amygdala (central nucleus, CeA, and medial nucleus, MeA), the 
sublenticular extended amygdala (SLEA, sometimes referred to as caudal substantia 
inominata), the interstitial nucleus of the posterior limb of the anterior commisure 
(IPAC), and BNST (Figure 1).  In volume, the BNST constitutes approximately 20-25% 
of the extended amydala.   
More controversially, the caudal shell of the nucleus accumbens has sometimes 
been included as a member of extended amygdala, due primarily to the nearly seamless 
anatomical contiguity of rostal BNST and caudal accumbens shell.  However,  substantial 
differences in output patterns between accumbens shell and other extended amygdala 
nuclei have led recent investigators to argue against including accumbens shell as a 
standard extended amygdala component (de Olmos & Heimer, 1999; Zahm, 1998).  
Proponents of the extended amygdala note the extensive intrinsic connections 
among these nuclei, parallel architecture, and common output pathways (Alheid, 2003; de 
Olmos & Heimer, 1999; Heimer et al., 2007). Though the nearly unbroken rostro-caudal 
continuum of cells extending from centro-medial amygdala through BNST was originally 
noted in the work of J.B. Johnston in the early 1920’s (Johnston, 1923), widespread 
adoption of the extended amygdala concept did not arise until the late 1980’s with the 
work of neuroanatomists George Alheid, Lennart Heimer and Jose de Olmos (Alheid & 
Heimer, 1988; Heimer & Van Hoesen, 2006). 
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Extended amygdala is now gaining acceptance as a valid and useful anatomical 
construct.  There remains some debate, however, about the appropriateness of segregating 
the extended amygdala from the neighboring striatopallidal system. The most prominent 
advocate against a separate extended amygdala system is Larry Swanson, who has argued 
that the CeA – SLEA/IPAC – BNST continuum is best viewed as following the same 
anatomical rule as the more classic striatopallidal system, with CeA as primarily striatal 
and BNST as primarily pallidal (with some noted role reversals) (Swanson, 2000, 2003, 
2005). Swanson’s view is admirably parsimonious, integrating the extended amygdala 
seamlessly into a larger master plan of descending cortical (glutamate) --> striatal 
(GABA) --> pallidal (GABA) projections that may offer a useful sense of the typical 
flow of information through the extended amygdala system. But whether one accepts the 
extended amygdala as distinct from the basal ganglia or merely a slight variation from its 
standard plan does not detract from the close anatomical relationship between the 
extended amygdala nuclei: either they are their own macrosystem or an equally similar 
functional circuit/loop within the basal ganglia, and in both cases their deeply 
interconnected neuroanatomy is an equally useful springboard for behavioral 
investigation.  
 
Central vs Medial Divisions within the extended amygdala 
There are two parallel components of the broader extended amygdala, termed the 
central and medial divisions. The central division is comprised of the central amygdala, 
dorsal SLEA, IPAC, and lateral BNST. The medial division is composed of the medial 
amygdala, ventral SLEA, and medial BNST (Alheid, 2003; de Olmos & Heimer, 1999) 
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These parallels are further evident at the level of the amygdala and BNST; subnuclei 
present in the central amygdala are nearly always mirrored by similar subnuclei in the 
later BNST. A similarly parallel relationship holds for medial amygdala and medial 
BNST. Interestingly, the two divisions of extended amygdala note show robust intrinsic 
connectivity but relative sparse connections across the central/medial division (Alheid, 
2003). 
 
Afferents and efferents 
The extended amygdala receives substantial input from a variety of limbic brain 
structures, including the basolateral amygdala complex (BLA, especially posterior 
regions), ventral hippocampus, and limbic cortex (including several medial prefrontal 
regions) (Alheid, 2003), as well as rich catecholamine innervation from brainstem and 
midbrain, including the densest population of norepinephrine terminals in forebrain 
(Aston-Jones, Delfs, Druhan, & Zhu, 1999; Forray & Gysling, 2004; R. J. Smith & 
Aston-Jones, 2008). The primary output targets include hypothalamus (medial and lateral 
divisions), midbrain dopaminergic cell population (ventral tegmental area and substantia 
nigra), a variety of brainstem nuclei including noradrenergic populations in medulla, and 
relatively weak projections to thalamic feedback loops (Alheid, 2003; de Olmos & 
Heimer, 1999). These output channels differ slightly across the two divisions of extended 
amgydala, with the central EA projecting to primarily lateral hypothalamus and the 
medial EA projecting to primarily medial hypothalamus. 
Note an important deviation from the substantial output of basal ganglia output to 
thalamus; although extended amygdala does send modest output to thalamic nuclei 
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(including medial midline intralaminar and paraventricular regions) (Dong & Swanson, 
2006a, 2006b), these projections are much less robust that the efferents from basal 
ganglia (de Olmos & Heimer, 1999; Dong, Petrovich, & Swanson, 2000; Dong & 
Swanson, 2004a). The robust projections to hypothalamus suggest a strong role for the 
extended amygdala in the modulation of the neuroendocrine access, which has been 
confirmed in behavioral studies outlining a key role for extended amygdala in processes 
of reward, stress, anxiety, and reproduction (reviewed below). 
The extended amygdala is composed primarily of GABA-ergic cells, much like 
the neighboring striato-pallidum (Cassell, Freedman, & Shi, 1999). However, the 
extended amygdala also expresses a rich array of additional neuropeptides and 
neurotransmitters, including glutamate, acetycholine, enkephalins, substance P, 
corticotropic releasing factor (CRF), angiotensin II, vasopressin, and oxytocin (Alheid, 
2003; Alheid, de Olmos, & Beltramino, 1995; de Olmos & Heimer, 1999). Although 
there is significant overlap between immunochemical staining in extended amygdala and 
the nearby striatum, there are also several notable cases of distinct macrosystem staining. 
For example, although the striatal and pallidal complexes both stain heavily for adenosine 
receptors, extended amygdala does not stain at all for these receptors (Rosin, Robeva, 
Woodard, Guyenet, & Linden, 1998). Notably, similar staining dissociations can be used 
to visualize the medial vs. central divisions of extended amygdala, such as oxytocin in the 






Neurobiology of BNST 
 BNST is a structure  at the far rostral end of the extended amygdala. It is located 
at the rostral tip of the stria terminalis, just caudal to the accumbens shell and surrounding 
the anterior commissure as it crosses the midline, and is roughly 3mm
3
 in volume in the 
rat (just slightly larger than accumbens shell). Though modest in size, BNST contains 
over a dozen distinct sub-nuclei, each with unique afferent and efferent patterns, as well 
as with occasionally divergent influences on behavior (see below for further review of the 
role of BNST in behavior). These sub-nuclei are often broadly assigned to larger 
divisions within BNST, most prominently the medial and lateral divisions. As noted 
above, the medial/lateral divisions of BNST are based primarily on interconnection with 
subcortical amygdala, with medial BNST interconnected most strongly to medial 
amygdala, and lateral BNST most strongly to central amygdala. However, further 
anatomical investigation has also revealed notable distinctions between anterior and 
posterior regions of BNST, especially in regards to regulation of hypothalamic-pituitary-
adrenal (HPA) axis activity (Choi et al., 2007). 
 In an elegant and authoritative series of neuroanatomical tract-tracing 
experiments, Hong-Wei Dong, Larry Swanson and colleagues used small injections of 
the anterograde tracer Phaseolus vulgaris leucoagglutinin (PHAL) to target individual 
sub-nuclei of BNST, revealing in exquisite detail the pattern of efferent projections 
(Dong et al., 2000; Dong, Petrovich, & Swanson, 2001; Dong, Petrovich, Watts, & 
Swanson, 2001; Dong & Swanson, 2003, 2004a, 2004b, 2006a, 2006b, 2006c). These 
studies reveal an extremely complicated and diverse set of terminal fields reflecting 
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BNST’s output to a wide range of brain regions, though the primary pattern mimics 
extended amygdala as a whole. The densest projections from BNST are to other areas of 
extended amygdala (SLEA, IPAC, and CeA/MeA), emphasizing the strong associative 
fibers that characterize the extended amygdala macrosystem. Similarly dense outputs 
target hypothalamus, and in particular the paraventricular region of hypothalamus (PVN) 
that is so critical in controlling neuroendocrine function, with medial and lateral BNST 
primarily targeting medial and lateral hypothalamus, respectively. BNST also sends 
significant outputs to midbrain (including VTA) and brainstem (in particular caudal 
medulla but also taste centers in the pontine parabrachial nucleus and the nucleus of the 
solitary tract) (Fudge & Haber, 2001; Kang & Lundy, 2009; C. S. Li & Cho, 2006). 
 As with efferents, afferent projections to BNST are densest from other regions of 
extended amygdala. The CeA and MeA appear to be the richest source of upstream 
information to BNST, sending dense projections to both medial and lateral divisions of 
BNST (Dong, Petrovich, & Swanson, 2001). BNST receives only weak direct input from 
BLA (Dong, Petrovich, & Swanson, 2001), with most of the link between BNST and 
BLA occurs via CeA, in support of Swanson’s cortex—striatum—pallidum role for 
BNST, CeA, and BLA, respectively (Swanson, 2003). Other limbic projections to BNST 
include hippocampus and limbic cortex, in particular the infralimbic region of medial 
prefrontal cortex (Massi et al., 2008), and reciprocal, though relatively weak, connections 
with the shell of the nucleus accumbens. Notably, BNST receives significant projections 
from dopaminergic regions of midbrain (particularly VTA), noradrenergic regions of the 
brainstem (primarily in anterior-ventral BNST), and also direct input of taste information 
from the parabrachial nucleus (Alden, Besson, & Bernard, 1994; Norgren, 1976). 
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 BNST, like the rest of extended amygdala, contains primarily GABA-ergic 
neurons, but also expresses a wide variety of additional receptors and neurotransmitters. 
Most notable are the dense expression of CRF (receptors and neurotransmitter) (Koob & 
Heinrichs, 1999), dopamine (receptors) (Carboni, Silvagni, Rolando, & Di Chiara, 2000), 
norepinephrine (receptors) (Aston-Jones et al., 1999; Aston-Jones & Harris, 2004; Delfs, 
Zhu, Druhan, & Aston-Jones, 2000; R. J. Smith & Aston-Jones, 2008), and opioids 
(receptors) (Casada & Dafny, 1993; Mansour, Fox, Akil, & Watson, 1995). The presence 
of this constellation of neurotransmitter systems would by itself be of interest, but it is 
their interaction that lends BNST some if its most interesting roles in behavior 
(McElligott & Winder, 2009). For example, dopamine in BNST modulates fast excitatory 
transmission of glutamate via a CRF dependent mechanism (Kash, Nobis, Matthews, & 
Winder, 2008), while norepinephrine in BNST modulates CRF release associated with 
drug withdrawal (Aston-Jones & Harris, 2004). 
 In general, dorsal regions of BNST appear to be less responsive than ventral 
regions to a range of neurochemical stimuli, including morphine, acetylcholine, and 
norepinephrine (Casada & Dafny, 1993), a finding paralleled by the subsequent report 
that the neurophysiological properties of neurons in BNST also show some differences 
along the dorso-ventral axis (Egli & Winder, 2003). Such findings have sparked 
particular interest in the characteristics of anterior-ventral BNST, which receives the bulk 
of BNST’s dense noradrenergic input. Electrical and glutamatergic stimulation of 
neurons in this region have been shown to potently increase population firing of 
dopaminergic neurons in VTA (Georges & Aston-Jones, 2001). A recent study indicates 
that this excitatory input to BNST likely arises from infralimbic cortex, where stimulation 
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can potently drive firing in anterior-ventral BNST and, one synapse on, in VTA, and 
which can be directly inhibited by cannabinoid agonists in BNST (Massi et al., 2008). 
Notably, the study by Massi et al. (2008) sampled neurons from both ventral and dorsal 
regions of BNST, suggesting that perhaps dorsal regions may also contribute to this 
cortical-BNST-midbrain circuit, as well as other circuit interactions. Indeed, only dorso-
lateral BNST neurons receiving VTA input were found to show morphine-dependent 
changes in neuroplasticity (Dumont, Rycroft, Maiz, & Williams, 2008). 
 
Established behavioral roles of BNST  
 Similar to its neurobiology, BNST is involved in a diverse array of behaviors, 
many of which are intimately intertwined. Here, I review the primary established roles 
for BNST in the modulation of aversive aspects of motivated behavior, derived mostly 
from studies in rodents. 
 
Stress 
 BNST is perhaps best known for its role in the brain’s stress network, and a large 
body of literature describes both the neuroanatomical and behavioral functions of BNST 
in both acute and chronic stress circuitry. 
 Though early lesion studies sometimes generated inconclusive results regarding 
the roles of BNST in altering activity of stress circuitry (Crane, Buller, & Day, 2003; 
Gray et al., 1993), possibly due to the large extent of the lesioned area, Dennis Choi, 
James Herman and colleagues (2007) utilized restricted lesions of anterior and posterior 
regions to clarify the role of BNST in modulating the HPA axis in response to acute 
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stress. They found that lesions of anterior BNST markedly reduced plasma corticosterone 
and decreased c-Fos expression in the paraventricular nucleus of the hypothalamus 
(PVN), while lesions of posterior BNST had roughly the opposite effect (Choi et al., 
2007). This suggests that anterior BNST typically acts to excite, while posterior BNST 
tonically inhibits, HPA axis activity. Further studies by this group have confirmed these 
opposing roles for anterior vs. posterior BNST, and additionally speculated that these 
roles especially relevant to acute stressors (Choi, Evanson et al., 2008; Choi, Furay et al., 
2008), though see (Dallman et al., 2003) for indication of a role for BNST in chronic 
stress. 
 Behaviorally, the largest body of research linking BNST and stress involves the 
study of immobilization and restraint. Electrophysiological recording during acute 
immobilization stress revealed potent modulation of firing of BNST neurons (both 
excitation and inhibition), and a similar response was found when rats were presented 
with a auditory tone that was previously paired with immobilization (Henke, 1984). 
Subsequent research found that immobilization and electrical stimulation of BNST 
produced a similar constellation of behaviors, including increased locomotor and 
exploratory activities, though direct stimulation of BNST resulted in extended duration (3 
hrs vs. 1 hr) of these stress-like behaviors (Casada & Dafny, 1991). BNST stimulation 
also reportedly caused more intense aversive behaviors than immobilization alone, 
causing vigorous escape attempts and even aggressive biting behavior. Finally, 
immobilization also caused dramatic increases in norepinephrine release in BNST 
(Pacak, McCarty, Palkovits, Kopin, & Goldstein, 1995). 
 14 
 Immobilization, though stressful, does not pose any immediate and life-
threatening danger to rodents, and has been termed a ‘processive’ stressor. This is in 
contrast to ‘systemic’ stressors, like hemorrhage and cardiopulmonary depression, that 
are acutely dangerous and life-threatening (Herman & Cullinan, 1997). Systemic 
stressors usually mobilize HPA responses by utilizing direct connections from brainstem 
to PVN, whereas processive stressors often engage higher-order cognitive and emotional 
regions, including limbic brain regions. Yet most limbic system nuclei lack direct 
connections to PVN, indicating the need for a limbic-HPA axis relay. Indeed, BNST, 
with afferents from a variety of limbic brain regions and the ability to bi-directionally 
modulate HPA axis activity, appears to fill precisely this role (Herman, Ostrander, 
Mueller, & Figueiredo, 2005). 
 
Anxiety 
 In addition to stress, BNST is also involved in fearful responses to environmental 
stimuli, a role that has been advanced most frequently by Michael Davis and colleagues. 
Rats will reliably display a startle response when presented with an aversive acoustic 
stimulus (such as a very loud noise), and this acoustic startle can be potentiated by either 
exposure to a cue that has previously predicted another aversive conditional stimulus (e.g. 
tone linked to footshock) or in the presence of an aversive unconditional stimulus such as 
extended exposure to a very bright light. Davis and colleagues, consistent with the work 
of others (Fendt & Fanselow, 1999; Goosens & Maren, 2001), showed that amygdala, 
and in particular CeA, was necessary for the expression of potentiated startle to a 
previously learned fear conditioned stimulus (CS) but not for the unconditioned startle to 
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the bright light. In contrast, BNST was found to be necessary for expression of the light-
potentiated startle, but not the fear CS potentiated startle (Walker & Davis, 1997; Walker, 
Toufexis, & Davis, 2003). This distinction has caused Davis and colleagues to argue for a 
role of CeA in fear, which is expressed at a particularly dreaded discrete object or 
association, and a separate role for BNST in anxiety, a more diffuse response to a non-
specific but still ominous unconditioned stimuli (M. Davis, 1998; M. Davis, Walker, & 
Lee, 1997b). 
 This perspective has been met with mixed support. Consistent with Davis’ view, 
temporary inactivation of BNST has been shown to block the freezing normally elicited 
by exposure to trimethylthiazoline, an odor found in fox feces (Fendt, Endres, & 
Apfelbach, 2003). However, in two other tests of unconditioned fearful behaviors, the 
elevated plus maze and the shock-probe test, lesions of BNST were not found to affect 
typical measures of fear and anxiety (Treit, Aujla, & Menard, 1998). Additionally, and 
also inconsistent with the view that BNST does not mediate conditioned stimuli, lesions 
of BNST were found to disrupt behavioral and neuroendocrine responses following 
exposure to a context (though not a tone) previously paired with a fear conditioning 
context (Sullivan et al., 2004). 
 In summary, though it is clear that BNST does play a role in the response to 
fearful and aversive stimuli, it remains unclear whether BNST is chiefly involved in the 
diffuse, anxious response to long-duration unconditioned stimuli, or whether it also plays 





Drugs of Abuse and Addiction 
 The extended amygdala as a whole has been implicated as a critical node in the 
development and maintenance of drug use (Everitt et al., 1999; Harris & Aston-Jones, 
2007; Koob, 1999, 2003). Research has led investigators such as George Koob to suggest 
that BNST is particularly important in two processes that accompany extended drug use: 
withdrawal and dysphoria-triggered relapse. 
 
Withdrawal 
Repeated use of many drugs of abuse can result in an aversive motivational state 
that accompanies cessation of drug use, generally known as withdrawal. Withdrawal can 
involve both physical (such as trembling) as well as psychological (such as dysphoria) 
symptoms, and has been argued by some to constitute a significant component of the 
maintenance of drug-seeking that characterizes addiction (Aston-Jones & Harris, 2004; 
Koob, 2006; Koob & Le Moal, 2008; Le Moal & Koob, 2007). 
 Precipitated removal of ethanol caused an increase in the release of CRF in 
BNST, which quickly declined to basal levels following relatively swift return of the 
ethanol-containing solution (Olive, Koenig, Nannini, & Hodge, 2002). However, 
extending the duration of ethanol removal only served to enhance CRF concentration in 
BNST, which eventually surged to nearly double baseline levels. It has recently been 
reported that extended withdrawal from heroin, alcohol, and cocaine has a significant 
impact on the excitability of neurons in the juxtacapsular nucleus of BNST, a small sub-
nuclei in the anterior-lateral region (Francesconi et al., 2009). This change in 
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neuroplasticity appeared to be dependent on CRF signaling, as the administration of a 
CRF-1 receptor antagonist normalized the intrinsic excitability of juxtacapsular neurons. 
 In addition to CRF, norepinephrine signaling in BNST is also critical to the 
expression of withdrawal symptoms, in particular to opiates. BNST neurons show 
increased activation, as measured by c-Fos expression, during withdrawal from opiates, 
an effect that can be attenuated by the ß-adrenergic antagonist propranolol (Aston-Jones 
et al., 1999). Further, animals made dependent on morphine will display robust avoidance 
of an environment that is paired with precipitated withdrawal, yet this avoidance (as well 
as somatic symptoms of withdrawal) can be abolished in rats by the disruption of 
noradrenergic signaling in BNST (Delfs et al., 2000). 
  
Relapse 
The above findings show a clear role for CRF and norepinephrine in BNST in the 
neural response to acute drug withdrawal. However, animals remain vulnerable to 
resumption of drug-seeking long after withdrawal symptoms subside, often resuming 
drug intake after weeks or months of remaining drug free. This process, known as 
relapse, can be triggered by a variety of factors, including exposure to drugs, drug cues, 
or stress (Robinson & Berridge, 2000; Shaham, Rodaros, & Stewart, 1994; Stewart, 
2000). 
 As might be suspected given its known role in modulating the HPA axis, BNST 
appears to play a crucial role in relapse due to stress, demonstrated in a series of 
experiments conducted by Jane Stewart and colleagues. Administration of a stressful 
footshock will stimulate relapse of drug-seeking in a rat where this behavior was 
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previously extinguished. However, administration of the CRF receptor antagonist D-Phe 
directly into BNST, but not in CeA, prevented relapse following footshock; moreover, 
stimulation of CRF receptors by direct microinjection of CRF into BNST – without any 
accompanying footshock – was able to trigger relapse in drug-seeking equal to that 
observed following shock exposure (Erb & Stewart, 1999). Stewart and colleagues 
subsequently found that at least a portion of the CRF projections to BNST that contribute 
to stress-induced relapse do arise from CeA, despite the absence of any effect of CRF 
infusion in CeA on relapse (Erb, Salmaso, Rodaros, & Stewart, 2001). The stress-related 
relapse circuitry in BNST was later expanded to include a role for norepinephrine, as it 
was shown that disruption of noradrenergic signaling in BNST prevented stress-induced, 
but not drug-induced, relapse in rats trained to self-administer cocaine (Leri, Flores, 
Rodaros, & Stewart, 2002). 
 In summary, BNST plays a key role in a variety of aversive motivational 
processes. It is a key node in the brain stress system, acting as an interface between the 
limbic system and the HPA axis. BNST also plays a related role in anxiety, mediating 
behavioral responses to long-duration, unconditioned cues (and perhaps some 
conditioned cues) and mobilizing behaviors adaptive for dealing with diffuse, non-
specific threats. Finally, CRF and noradrenergic transmission within BNST are critical to 







Potential role of BNST in appetitive motivation 
 There is also reason to believe BNST might play a role in appetitive motivational 
processes, in addition to the variety of aversive and stressful motivational processes 
described earlier.  The reason comes primarily from neuroanatomical and neurochemical 
considerations, with a few supporting functional observations from behavioral studies. 
 First, BNST shares strong connections with several reward-related brain regions. 
As noted earlier, BNST is able to potently modulate population firing in dopaminergic 
nuclei in the midbrain, including VTA (Georges & Aston-Jones, 2001; Kash et al., 2008; 
Massi et al., 2008). Ascending dopamine from midbrain has long been associated with 
reward processes, initially as a signal of the hedonic or euphoric qualities of rewarding 
stimuli (Wise & Bozarth, 1985; Wise & Rompre, 1989) and, more recently, as a signal of 
reward prediction (Schultz, Dayan, & Montague, 1997), a mediator of effort in obtaining 
rewarding stimuli (Salamone, 2007; Salamone, Correa, Farrar, & Mingote, 2007), and the 
primary signal of incentive salience ‘wanting’ (Berridge, 2007; Robinson & Berridge, 
1993), among others. Within extended amygdala, lateral regions of BNST shares robust 
and bidrectional connections with CeA, which has been shown to potentiate food intake 
(Gosnell, 1988; Gosnell, Morley, & Levine, 1986) as well as incentive salience ‘wanting’ 
for cues that predict a food reward (Mahler & Berridge, 2007, 2009). 
 Second, and closely related to dopamine, several pieces of evidence suggest that 
BNST is linked to the rewarding properties of drugs of abuse. For example, acute, 
systemic administration of a variety of reinforcing drugs, including morphine, cocaine, 
nicotine, and ethanol, all stimulate dopamine release in BNST (Carboni et al., 2000). 
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Further, the disruption of GABA-ergic, dopaminergic, or opioid signaling within BNST 
disrupts the reinforcing properties of ethanol, cocaine, and heroin, respectively, in rats 
taught to self-administer those drugs (Epping-Jordan, Markou, & Koob, 1998; Hyytia & 
Koob, 1995; J. R. Walker, Ahmed, Gracy, & Koob, 2000). Interestingly, BNST may play 
a particular role in instrumental responding for reward, as self-administration of cocaine 
or food pellets, but not passive receipt of indentical patterns and amounts of cocaine or 
food, enhanced excitatory synaptic transmission in BNST (Dumont, Mark, Mader, & 
Williams, 2005). 
 Finally, BNST appears to mediate at least some aspects of appetitive sexual 
behavior, particularly in males, for both birds and mammals. In a study of male Japanese 
quail, it was found that presentation of a CS that predicted the availability of a receptive 
female (a common technique to increase reproductive success) led to increased c-Fos 
expression in medial BNST and medial preoptic area (Taziaux, Kahn, Moore, Balthazart, 
& Holloway, 2008). In contrast, when posterior BNST is lesioned in male rats, the 
normal preference for a female odor over a male odor is abolished even though normal 
olfaction remains intact (Been & Petrulis, 2008). Indeed, it has been suggested that the 
entire medial extended amygdala (including medial BNST and medial amygdala) 
constitutes an important circuit in the execution of male sexual behavior (Newman, 
1999). 
 
Opioids and reward 
 The endogenous opioid system, and in particular the !-opioid receptor, is strongly 
linked to reward processing throughout limbic brain regions, and as such affords a useful 
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initial point for investigating possible appetitive roles of BNST. Opioid receptors are 
distributed throughout extended amygdala in the rat, and BNST in particular shows 
robust expression of the !-opioid receptor, in addition to " and ! receptors (Mansour et 
al., 1995). In primates, BNST also displays dense labeling for the !-opioid receptor, with 
medial regions exhibiting slightly denser staining than lateral regions (Daunais et al., 
2001). 
 The !-opioid receptor has often been implicated in the hedonic impact, or 
‘liking’, as well as ‘wanting’, of rewards (Barbano & Cador, 2007; Berridge, 2000; 
Kelley et al., 2002; Pecina, Smith et al., 2006; K. S. Smith et al., 2009). Recently in the 
rat, a pair of !–opioid hedonic hotspots have been identified in basal forebrain, one in 
rostro-dorsal accumbens shell and the other in caudal ventral pallidum (Pecina & 
Berridge, 2000, 2005; K. S. Smith & Berridge, 2005). In these small regions (each 
~1mm
3
), !-opioid receptor stimulation results in potent increases in the hedonic impact 
of a sweet sucrose reward, elevating orofacial reactions characteristic of palatable 
rewards. Interestingly, these distinct hotspots in accumbens shell and ventral pallidum 
appear to interact in the generation of reward ‘liking,’ with disruption of opioid 
transmission in one hotspot effectively vetoing the enhancement of hedonic impact 
normally generated by opioid stimulation of the other (Smith & Berridge, 2007). In 
humans, systemic opioid blockade with naloxone attenuated the reported pleasure derived 
from large rewards in a gambling task (Petrovic et al., 2008) and reduced consumption of 
sweet, high-fat foods in binge eaters (but not non-binging controls) (Drewnowski, Krahn, 
Demitrack, Nairn, & Gosnell, 1995). 
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 The latter finding, in particular, bridges the role of mediating hedonic ‘liking’ 
with !-opioid’s concomitant modulation of voluntary feeding, a measure of reward 
‘wanting.’ Opioid stimulation throughout the basal forebrain, including ventral striatal 
and central amygdala regions, has been shown to dramatically increase food intake 
(Bakshi & Kelley, 1993a, 1993b; Gosnell, 1988; Gosnell et al., 1986). In particular, !-
opioid stimulation seems to favor the intake of energy dense, high-caloric foods that are 
high in fat and sugar content (Glass, Billington, & Levine, 1999; Zhang & Kelley, 2000). 
Additionally, !-opioid stimulation has also been shown to increase ‘wanting’ for cues 
associated with rewards. Throughout nucleus accumbens, for example, the !-opioid 
receptor agonist DAMGO increases both the conditioned reinforcement value of a reward 
cue (Phillips, Robbins, & Everitt, 1994) and also facilitates the transfer of the incentive 
motivational value of a Pavlovian reward CS to an available instrumental option linked to 
the same UCS reward in the Pavlovian-to-instrumental transfer paradigm (PIT) (Pecina & 
Berridge, In Preparation). Within extended amygdala, !-opioid stimulation with 
DAMGO similarly enhances PIT (Mahler & Berridge, 2007), and also increases 
appetitive behaviors directed at a reward CS in an autoshaping (also known as sign-
tracking) test (Mahler & Berridge, 2009). 
 
Rationale 
 The goal of my dissertation is to further characterize the role of the BNST in 
reward and appetitive motivation. In particular, we chose to target primarily !-opioid 
receptors as a substrate for motivation in BNST. As noted above, these receptors are 
densely expressed throughout BNST, and have been shown in many forebrain regions to 
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modulate appetitive and rewarding processes. Indeed, if extended amygdala follows the 
general cortex-striatum-pallidum plan of the brain, then BNST would be most 
functionally equivalent to a structure such as ventral pallidum, where !-opioid 
stimulation has been shown to potently increase appetitive motivational processes, 
including feeding and hedonic ‘liking’ (K. S. Smith & Berridge, 2005, 2007; K. S. Smith 
et al., 2009). 
 We reasoned that food intake would serve as a direct and simple measure of 
appetitive motivation, and so in Experiment 1 tested the ability of direct microinjections 
in BNST to modulate feeding. Based on the evidence reviewed above that !-opioids 
mediate enhanced feeding throughout the basal forebrain, including other regions of 
extended amygdala, we chose to test the ability of the !-opioid agonist DAMGO in 
BNST to potentiate feeding. We also examined the ability of temporary lesions of BNST 
to modulate feeding, using the GABAA agonist muscimol. 
 Following our finding that DAMGO in BNST potently increased appetitive 
motivation for a food reward, we chose to investigate a series of possible discrete 
psychological mechanisms that could help explain increase in food intake. One possibility 
is that opioid stimulation in BNST increases incentive salience ‘wanting’ for rewards and 
rewards cues. In order to test this prediction, in Experiment 2 we examined the effect of 
microinjection on BNST in two different test of ‘wanting’: autoshaping and conditioned 
reinforcement. We also compared the effect of this manipulation to identical stimulation 
of !-opioid receptors in the nearby accumbens shell. This allowed us to directly compare 
the roles of !-opioid stimulation in extended amygdala and ventral striatum, and also 
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offered a novel test of the prediction that accumbens shell opioids may enhance ‘wanting’ 
for all available reward cues, rather than only an animal’s preferred cue. 
 In addition to increased reward ‘wanting,’ enhanced food intake could also be the 
result of an increase in the hedonic impact, or ‘liking,’ of the food reward. In order to test 
the prediction that !-opioid stimulation in BNST enhanced hedonic ‘liking,’ in 
Experiment 3 we utilized the taste reactivity paradigm to examine the hedonic impact of 
intra-oral injections of sweet sucrose and bitter quinine infusions following DAMGO 
microinjection in BNST. As with food intake, we also examined whether temporary 
inactivation of BNST with muscimol would impact taste reactivity. Additionally, we 
added a voluntary food intake session after taste reactivity where animals had the choice 
between palatable chocolate candies and standard lab chow to test the prediction that 
BNST !-opioid stimulation specifically enhances consumption of palatable food rewards. 
 Finally, given the BNST’s established role in stressful responding, it was important 
to test the prediction that the appetitive motivation we assigned to BNST due to increased 
feeding may instead be the result of increased stress. Indeed, stressful manipulations can 
frequently stimulate appetitive behavior, including feeding, so in Experiment 4 we 
examined whether DAMGO microinjection in BNST is inherently stressful. We utilized 
the conditioned place preference/avoidance paradigm, predicting that if DAMGO in 
BNST was indeed primarily stressful, then animals should avoid spending time in a 














Modulation of Feeding by Opioid and GABA stimulation in the  
Bed Nucleus of the Stria Terminalis 
 
Introduction 
 The extended amygdala has been an increasing focus of researchers interested in 
the neural substrates of reward (Harris & Aston-Jones, 2007; Waraczynski, 2006) and 
addiction (Aston-Jones & Harris, 2004; Everitt et al., 1999; Koob, 1999; Koob & Le 
Moal, 2008).  An important component of the extended amygdala is the bed nucleus of 
the stria terminalis (BNST), though this component has been relatively unstudied in 
experiments on reward.  The BNST is a bilateral set of forebrain nuclei sitting just caudal 
to the shell of the nucleus accumbens and just below the lateral ventricles. It is a principle 
component of the extended amygdala, an emerging forebrain neuroanatomical 
macrostructure composed of the subcortical portions of the amygdala (central and medial 
nuclei), the sublenticular extended amygdala (SLEA), the interstitial nucleus of the 
posterior limb of the anterior commissure (IPAC), and the BNST. Proponents of the 
extended amygdala note the extensive intrinsic connections among these nuclei, parallel 
architecture, and common output pathways (Alheid, 2003; de Olmos & Heimer, 1999; 
Heimer & Van Hoesen, 2006), though see (Swanson, 2003) for an alternative perspective. 
However, in order fully to understand how the extended amygdala regulates these and 
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other behaviors, it will be important to carefully explore the neurobiological and 
psychological properties of each of its component nuclei. 
 Most of the known behavioral roles of the BNST are related to aversive 
motivational states. BNST has been proposed as a major forebrain node for conveying 
stress-related information to the paraventricular nucleus of the hypothalamas (PVN) 
(Herman & Cullinan, 1997), and subsequent studies have shown that BNST lesions 
modulate Fos expression in PVN as well as plasma levels of corticosterone and ATCH 
(Choi et al., 2007). Michael Davis and colleagues have argued persuasively that BNST 
plays a particular role in diffuse anxiety (as opposed to more focused fear), based on 
experiments measuring alterations in fear-potentiated startle (M. Davis, 1998; M. Davis 
& Shi, 1999; M. Davis, Walker, & Lee, 1997a; M. Davis et al., 1997b; D. L. Walker & 
Davis, 1997; D. L. Walker et al., 2003). BNST has also been implicated in stressful facets 
of addiction to drugs of abuse, including maladaptive shifts in the allostatic response 
(Koob, 1999, 2003; Koob & Le Moal, 2008), expression of withdrawal from opiate drugs 
(Aston-Jones & Harris, 2004; Delfs et al., 2000), and relapse in drug taking after 
exposure to stress (Erb et al., 2001; Erb & Stewart, 1999). In sum, these findings paint 
BNST as a forebrain nucleus predominantly involved in aversive states and processes. 
 There are a few indications, however, that the BNST may also be involved in 
appetitive motivational processes. One indicator is anatomical: for example, mu-opioid 
activation in the central nucleus of the amygdala (CeA), another prominent extended 
amygdala structure with robust reciprocal projection to BNST (especially lateral BNST), 
is able to increase food intake (Giraudo, Billington, & Levine, 1998; Gosnell, 1988; 
Mahler & Berridge, In press), autoshaping for a conditional stimulus associated with a 
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food reward (Mahler & Berridge, In press), and Pavlovian to instrumental transfer 
(Mahler & Berridge, 2007). Another indicator is functional activation: BNST shows 
robust increases in Fos expression in response to several feeding manipulations, including 
ingestion of a small, highly palatable meal (Park & Carr, 1998) and ingestion of a sweet 
liquid sucrose solution (Mungarndee, Lundy, & Norgren, 2008). The BNST is also part 
of a network of ventral forebrain structures activated after a variety of orexigenic 
neurochemical manipulations, including central administration of neuropeptide Y (B. H. 
Li, Xu, Rowland, & Kalra, 1994), microinfusion of orexin A into lateral hypothalamus 
(Mullett, Billington, Levine, & Kotz, 2000), and microinjection of muscimol into the 
shell of the nucleus accumbens (Stratford, 2005). Finally, blockade of GABA, opioid, 
and dopamine neurotransmission in BNST result in significant disruptions of responding 
for alcohol, heroin, and cocaine, respectively (Epping-Jordan et al., 1998; Hyytia & 
Koob, 1995; J. R. Walker et al., 2000). 
 Combined, these findings provide indirect evidence for the possibility that BNST 
may play a role in appetitive motivation processes, in addition to its well established 
functions in the aversive motivational states of stress, anxiety, withdrawal, and relapse, 
yet to date there is no direct evidence of BNST’s function in appetitive motivation. The 
purpose of this study was to evaluate the role of the BNST in a simple and direct measure 
of appetitive motivation, voluntary food intake. We assessed the effect of intra-BNST 
microinjections of a mu-opioid agonist, DAMGO, and a GABAA agonist, muscimol, and 
found that both manipulations were able to potently modulate feeding and related 
behaviors. These results indicate that BNST can powerfully influence appetitive 
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motivation, though further experiments will be necessary to pinpoint precisely which 




A total of 28 Sprague-Dawley rats (females = 21, 250-500g at the time of surgery) 
were used for food intake testing. An additional 27 Sprague-Dawley rats (females, 250-
400g at the time of surgery) were used for Fos plume analysis and mapping. All animals 
were housed in pairs (~21˚C; 12hr light/dark cyle, lights on at 9am) with ad libitum 
access to food (Purina 5001 chow; Purina Mills, St. Louis, MO) and tap water. All 
procedures were approved by the University Committee on the Use and Care of Animals 
at the University of Michigan in accordance with National Institute of Health guidelines. 
  
Surgery 
 All animals were handled twice for a total of fifteen minutes prior to undergoing 
surgery. Rats were pretreated with atropine (0.04mg/kg) and then anesthetized with 
ketamine (80mg/kg) and xylazine (5mg/kg). Rats were then placed in a stereotaxic device 
and implanted with bilateral, chronic guide cannula (23 gauge, stainless steel), 14mm in 
length, aimed so that the ventral tip would rest 2mm above the BNST (AP: +0.24 to -
0.84mm; ML: +/-1.2 to 1.7mm; DV: -4.5 to -4.95mm; incisor bar: -3.3mm [flat skull]). 
Guide cannula were secured to the skull using four stainless steel screws and dental 
acrylic, and fitted with stainless steel stylets to prevent occlusion. All rats were given 
post-operative analgesic (0.3 mg/kg buprenorphine) and prophylactic antibiotic (50 
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mg/kg chloramphenicol), and allowed to recover for at least 7 days before the onset of 
behavioral testing. 
 
Drugs and Microinjections 
 All drugs were dissolved and diluted to dose in artificial cerebrospinal fluid 
(aCSF; Harvard Labs, Cambridge, MA). DAMGO was prepared at 0.05!g and 0.1!g 
doses (total bilateral dose of 0.1!g and 0.2!g, respectively), while muscimol was 
prepared at 75ng and 225ng doses (total bilateral dose of 150ng and 450ng, respectively). 
aCSF alone was used for vehicle microinjections. Microinjection schedules were counter-
balanced across subjects using a Latin Square design. 
 On test days, animals were gently handled as the stylets were removed. Rats then 
received bilateral microinjections (0.2!L per side, total bilateral volume) via 16mm 
stainless steel microinjection tips (29 gauge), which extended 2mm beyond the ventral tip 
of the guide cannula. Microinjection tips were attached via PE-20 surgical tubing to a 
microinfusion pump, which delivered the infusion over the course of 60 seconds. 
Microinjection tips were left in place for an additional 60 seconds after the infusion 
ended to allow for drug diffusion, after which the stylets were replaced and the rat placed 
immediately in the food intake test chamber. 
 
Food Intake Testing 
 During food intake testing, rats were placed in clear plastic cages containing a 
pre-measured pile of standard lab chow (~25g), a water spout, and corncob bedding. Prior 
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to food intake testing, rats were handled on two separate days for a total of 15 minutes 
and then habituated to the test environment for three additional days. 
 On test days, food intake was tested for 1 hour immediately following 
microinjection of vehicle, DAMGO, or muscimol. The entire session was videotaped for 
subsequent offline analysis. After the test was completed, remaining chow (including 
crumbs) was carefully removed from the cage and weighed. Test days were always 
separated by at least 48 hours. 
 
Food Intake Video Scoring 
 Video recordings of food intake test sessions were scored offline by observers 
blind to the experimental condition. The following behaviors were recorded: eating time 
(in seconds), eating bouts (triggered by interruptions of eating of more than 5 seconds), 
food sniffing, food carrying, drinking time (in seconds), drinking bouts (same criteria as 
eating bouts), grooming, cage crosses, sleeping, rearing, and defensive treading. Treading 
is a natural defensive behavior emitted by rodents, and involves rapid forelimb strokes 
away from the body that push debris (e.g. dirt or bedding) in the direction of a threat. 
 
Histology 
 After testing was completed, subjects used for behavioral testing were deeply 
anesthetized with sodium pentobarbital (0.2mg/kg; Fatal-Plus) and decapitated. Brains 
were extracted and placed in a 10% paraformaldehyde solution for 24-48 hours, and then 
placed in a 30% sucrose solution for 3-5 days, until the brains sank. The brains were then 
sliced on a freezing microtome (Leica) into 60!m coronal sections, mounted onto glass 
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slides, allowed to dry for at least 24 hours, and then stained with cresyl violet. Stained 
slices were viewed under light magnification and used to map the microinjection centers 
in each hemisphere on coronal sections taken from a rat brain atlas. (Paxinos & Watson, 
2007) The majority of microinjection centers were bilateral hits of BNST (n= 25), and the 
remaining were unilateral hits (n=3). 
 
Fos-Like Protein Immunohistochemistry 
 Rats utilized for Fos plume analysis underwent identical procedures for cannula 
implantation (except sham surgery control animals, who underwent surgery but did not 
receive cranial guide cannula) and pre- and post-surgical handling.  
On the day of Fos plume testing, animals were given bilateral microinjections of 
vehicle (n=5), 0.05!g DAMGO (n=5), 0.1!g DAMGO (n=4), 75ng muscimol (n=4), and 
225ng muscimol (n=4). Sham surgery animals (n=5) were handled gently for an amount 
of time equivalent to the animals receiving microinjections. Ninety minutes after 
microinjection, rats were transcardially perfused and their brains placed in 4% 
formaldehyde for 4-6 hours, then moved to a 30% sucrose solution for 3-4 days. Brains 
were then sliced on a freezing microtome in alternating 40!m coronal sections, with one 
series processed for Fos expression and the other retained for placement verification, if 
needed. 
Fos activation following neurochemical manipulations of the BNST was 
measured using immunohistochemistry and immunofluorescence.(Faure, Reynolds, 
Richard, & Berridge, 2008; Reynolds & Berridge, 2008) Briefly, sections were immersed 
and gently agitated in successive baths of 0.1M sodium phosphate buffer (SPB) and 0.2% 
 33 
Triton containing (1) 5% normal donkey serum (NDS) for 30 minutes, (2) 5% NDS and 
goat anti-c-Fos (1:10) overnight at 4˚C, (3) 5% NDS and signal enhancer for 30 minutes 
and, (4) 5% NDS and donkey anti-goat Alexa Fluor 488 (excitation: 488nm; emission: 
519nm; Invitrogen) for 1 hour. Sections were then mounted, air dried for 2-4 hours, and 
then coverslipped with ProLong Gold antifade reagent (Invitrogen). 
 
Fos Plume Mapping of Neural Activation and Suppression 
 Local Fos activation was visualized using a Leica microscope (DM 6000; 
Nussloch, Germany) equipped for both brightfield and fluourescent microscopy. A filter 
with an excitation band at 480-505nm and an emission band at 505-545 were used for 
fluorescent visualization, and images were captured at 10x magnification (2x2 tiled) 
using a Regita-SRV camera (Q-Imaging) and MCID Elite software. Fos-labeled cells 
were individually counted by an observer blind to treatment condition within ten adjacent 
sampling squares (68!m by 68!m) along each of seven radial arms extending from the 
center of the drug microinjection (45˚, 90˚, 135˚, 180˚, 225˚, 270˚, and 315˚). 
 Baseline levels of Fos expression were established by quantifying expression in 
two control conditions, (1) normal BNST tissue of sham surgery to assess expression in 
the absence of damage from guide cannula implantation and microinjector tip insertion 
and (2) following vehicle microinjection in BNST to assess expression following 
microinjection track and vehicle-induced Fos expression. These baseline values were 
compared to Fos densities in each of the four drug conditions to assess the functional 
spread of neural activation or inhibition following DAMGO or muscimol microinjection. 
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 DAMGO and muscimol Fos plumes were mapped as >500%, >300%, >200%, 
75% (-25%), and 50% (-50%) of Fos expression relative to vehicle microinjections and to 
normal tissue. In each case, the distance of each range of Fos expression was measured 
from the microinjection center along each radial arm. Spread was considered to extend to 
the furthest sampling square that contained greater than or equal to the particular level of 
activation or suppression being evaluated. Finally, the distance was averaged across all 
seven radial arms to produce an average radius of elevation or suppression. This 
procedure was repeated for every level of activation and suppression. The resulting drug-
induced change in Fos expression relative to controls was then mapped to visualize the 
plume of activation and/or suppression for each drug and dose. 
 In the final stage of mapping, the Fos plume data identifying functional drug 
spread was merged with the behavioral data. DAMGO excitatory plumes symbols were 
created based on the radius of intense (>500%), moderate (>300%), and low (>200%) 
changes in Fos expression compared to vehicle controls. Muscimol plumes were 
constructed similarly, but had a slightly different structure comprising a small inner 
excitatory plume (>300% increase) surrounded by an inhibitory anti-plume with intense 
(-50%) and moderate (-25%) regions of Fos suppression. The verified bilateral 
microinjection centers of each rat are indicated by a pair of these symbols, and then 
color-coded to indicate specific behavioral effects. Microinjection centers for each rat 
were mapped in the coronal, sagittal, and horizontal planes; for the latter two, bilateral 
placements were collapsed onto a single unilateral map. Separate maps were constructed 
for each drug treatment and dependent variable. Thus, each symbol conveys information 
for each individual subject about (1) the location of drug microinjection, (2) the 
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functional spread of drug in vivo and (3) the behavioral effect of the drug treatment on the 
particular dependent variable being presented. 
 
Statistical Analyses 
 The effect of each drug condition on all dependent variables was assessed using 
within-subjects ANOVA (drug), followed by paired-samples post hoc comparisons when 
appropriate. Between subjects ANOVA (site) was used for each drug treatment condition 
to test for regional differences in behavior within BNST, and also to compare the size of 
fos plumes and anti-plumes in the (dose,intensity). Between subjects ANOVA (injection 




In general, mu-opioid stimulation with DAMGO at sites throughout the BNST 
potently increased feeding behaviors. By contrast, BNST inhibition with muscimol 
decreased the number of feeding bouts. In addition, muscimol (but not DAMGO) 
increased fearful treading behavior and general locomotion, especially at the highest dose 
tested. The feeding suppression and fearful elicitation effects of muscimol, especially at 
the lower dose, were most prominent at more ventral sites in the BNST. No anatomical 
gradients were found for mu-opioid stimulation at either dose. 
There was no effect of drug injection order on any of the dependent variables 
tested in this study, so treatment conditions were collapsed across days. A main effect of 
sex [F(1,26)=7.71, p=0.01] was found, with males eating more across all treatment 
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conditions than females. This effect is most likely the result of the larger size of the males 
(on average 150-200g heavier than the females), and not sex differences in response to 
drug condition [all Drug*Sex interactions = n.s.]. 
 
Fos plume mapping 
Fos plumes indicating the functional spread of our neurochemical manipulations 
were constructed using histology of neural tissue from a separate group of rats. Analysis 
of Fos expression in each of the microinjection conditions used during food take testing 
indicated that for the drugs/doses/volumes used above, neuronal modulation was 
primarily limited to within BNST. (see Figure 1 and Table 1) 
DAMGO microinjections were predominately excitatory. Fos expression 
increased by five times relative to control tissue in a small, intense excitatory plume near 
the microinjection center (0.05ug mean radius = 0.11mm; 0.1ug = 0.11mm). In a larger, 
intermediate zone of excitation, DAMGO tripled Fos expression (0.05ug = 0.29mm; 
0.1ug = 0.25mm), and an even larger zone of low excitation displayed double the Fos 
expression of control tissue (0.05ug = 0.44mm; 0.1ug = 0.35mm). Assuming that these 
plumes are roughly spherical, the inner, intermediate, and outer plumes would have total 




, and 0.35 mm
3
, respectively for 0.05ug 







 for the inner, intermediate, and outer plumes, 
respectively. However, the plumes of the two DAMGO doses were not statistically 
distinct in size at any intensity level [Dose*Intensity, F(2,45)=0.919, p=n.s]. The 
estimated total volume of BNST is approximately 3mm
3
 (~2mm rostro-caudal, 0.4 to 
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1.2mm medio-lateral, and 0.6 to 2mm dorso-ventral), meaning that the outer excitatory 
plume for the 0.05ug dose of DAMGO filled only about 15% of the BNST, while the 
outer plume for the 0.1ug dose filled only about 12%. The small, more intense inner 
plume filled only 4% of BNST for both DAMGO doses. 
Interestingly, in every DAMGO microinjection at both doses of DAMGO we also 
saw outer skins of inhibition (-50% of control Fos expression). These were normally 
smaller than the regions of excitation in the same tissue, and had an average radius that 
fell between the intermediate and outer excitatory plume (data not shown). These mixed 
regions of excitation and inhibition are consistent with a prior report describing the 
reaction of BNST neurons to local microinfusion of morphine. (Casada & Dafny, 1993) 
Of the neurons sampled in that study which displayed responsiveness to morphine, 
roughly half responded with excitation while the other half responded with inhibition. 
In contrast to DAMGO, both doses of muscimol produced very small inner zones 
of moderate excitation surrounded by large inhibitory anti-plumes. The inner zone of 
triple Fos expression relative to controls was roughly the size of the inner DAMGO 
plume (75ng = 0.1mm; 225ng = 0.11mm), though weaker than the five times expression 
seen with opioid stimulation in this zone. A larger intermediate anti-plume was found that 
displayed half the Fos expression of control tissue (75ng = 0.45mm; 225ng = 0.42mm), 
and an outer anti-plume with 25% less Fos expression than control tissue was found to 
extend nearly to the edge of our sampling grid (75ng = 0.59mm; 225ng = 0.53mm). As 
with DAMGO, the two doses of muscimol tested here generated identical plumes at all 
levels of intensity [Dose*Intensity, F(2,42)=1.347, p=n.s.] Although the muscimol 
plumes were larger in total volume (75ng = 0.84mm
3
; 225ng = 0.61mm
3
) than the 
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DAMGO plumes [F(4,120)=25.1, p=0.001], the maximum volume for the plumes of both 
muscimol doses were still much small than the total estimated volume of BNST (75ng = 
28% of BNST volume; 225ng = 20%). 
 
DAMGO enhances food intake and muscimol decreases feeding bouts 
 A within-subjects ANOVA resulted in a significant main effect of drug treatment 
on total food eaten in grams [F(2.96, 77.12)=27.80, p=0.001], total time eating 
[F(2.36,63.60)=24.41, p=0.001], and number of feeding bouts [F(2.47,66.86)=23.65, 
p=0.001]. Post hoc comparisons revealed that both the 0.05ug and 0.1ug doses of 
DAMGO significantly enhanced all three of these feeding measures relative to treatment 
with vehicle by nearly 300% (Figure 2,4). However, there was no difference in the 
effectiveness of the two DAMGO doses at stimulating feeding behavior. 
 Post hoc comparisons also revealed suppression of feeding bouts with the 225ng 
dose of muscimol, which were reduced to only 50% of vehicle levels (post hoc, p<0.05; 
Figure 4), as well as non-significant reductions in both food intake in grams and total 
time eating (Figure 3,4). The 75ng dose of muscimol did not significantly impact any 
feeding behaviors in this analysis.  
 In addition to feeding behavior, rats also had access to water during the test 
session. Drug treatment moderately reduced total time spent drinking 
[F(2.63,70.94)=2.93,p=0.046], and post hoc tests revealed a significant decrease for the 
0.1ug dose of DAMGO (Figure 4). There was also a similar main effect of drug treatment 
on drinking bouts [F(3.5, 94.6)=3.61, p=0.012], which post hoc tests linked to significant 
suppression of drinking bouts by both doses of DAMGO (Figure 4). 
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Muscimol increases defensive treading behavior and locomotion 
 A significant main effect of drug treatment on defensive treading was found 
[F(2.05,55.48)=11.20, p=0.001], and post hoc comparisons revealed a significant increase 
in treading with the 225ng dose of muscimol (Figure 5,6). Treading was also increased 
with the 75ng dose, though not significantly. There was also a significant main effect of 
treatment on cage crosses [F(2.13,57.43)=20.39, p=0.001], and post hoc comparisons 
revealed significantly increased crosses with both doses the 75ng and 225ng doses of 
muscimol, with no significant dose effect (Figure 6). DAMGO had no effect on either 
treading or cage crosses (Figure 6). Rearing behavior was not affected by any drug 
treatment condition, indicating that muscimol does simply increase all locomotor 
behaviors (Figure 6). 
 The observed behavior of muscimol-treated animals helps to further clarify the 
enhancement of both treading and cage crosses. Muscimol-treated rats would typically 
stay close to the perimeter of the test chamber and make repeated circuits. Treading 
typically occurred upon an encounter with chamber corners and was generally directed 
towards the corner itself. This is consistent with previous reports of defensive treading in 
a test chamber devoid of a discrete threatening stimulus. (K. S. Smith & Berridge, 2005) 
 
Other behavioral effects 
 There was a significant main effect of drug treatment on total time spent sleeping 
during the test session [F(1.95, 52.72)=12.34, p=0.001; Figure 4]. Post hoc tests revealed 
that all drug treatment conditions decreased sleeping relative to the vehicle condition, 
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though the above results indicate that DAMGO and muscimol treatments reduced sleep 




 Given the prominent anatomical, physiological, and neurochemical differences 
along the rostro-caudal(Choi et al., 2007; Dong & Swanson, 2004b), medio-lateral(de 
Olmos & Heimer, 1999), and dorso-ventral(Casada & Dafny, 1993) axes of the BNST, 
we also examined whether the behavioral effects we observed showed any distinct 
anatomical gradients. 
Placements were classified as dorsal BNST (n=23) if they were above DV: -
6.8mm from skull surface (roughly the level of the anterior commissure), and ventral 
BNST (n=5) if they were below this line (derived from (Casada & Dafny, 1993) and 
(Massi et al., 2008)). The 75ng dose of muscimol was the only drug treatment to generate 
significant dorso-ventral gradients, which encompassed both feeding and fearful 
behaviors (Figure 7). Ventral microinjection sites of 75ng muscimol significantly 
suppressed investigatory sniffs of the chow pellets [(F1,20)=4.33, p=0.05] and marginally 
decreased time spent eating [F(1,20)=3.05, p=0.096] and number of eating bouts 
[F(1,20)=3.05, p=0.096], relative to more dorsal sites. Additionally, ventral 
microinjections of 75ng muscimol increased defensive treading behavior [F(1,20)=4.45, 
p=0.048]. It is worth noting that these gradients existed only at our lower dose of 
muscimol; at our higher 225ng dose, there were no significant dorso-ventral gradients in 
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behavior. This indicates that sites in ventral BNST are particularly sensitive to the both 
the feeding and fearful effects of muscimol. 
Along the rostro-caudal axis, placements were assigned to one of four categories: 
BNST/accumbens shell transition zone (n=5, AP: 0.84mm to 0.48mm), anterior BNST 
(n=11, AP: >0.48mm to 0.00mm), central BNST (n=9, AP: >0.00mm to -0.48mm), and 
posterior BNST (n=3, AP: >-0.48mm). No significant gradients were observed withing 
any drug condition along the rostro-caudal axis. Interestingly, anatomical mapping of 
muscimol feeding indicated possible differences on feeding time between doses in 
anterior regions of BNST (see Figure 3). In fact, when the effect of 75ng muscimol was 
compared to the effect of 225ng muscimol at regions anterior to -0.2mm behind bregma, 
it was found that the low dose of muscimol increased feeding by 234% relative to vehicle 
while the higher dose reduced feeding by 75% [t-test comparing percent change in 
feeding: t(17)=2.2, p=0.043]. 
Placements were categorized as either medial BNST (n=9) or lateral BNST 
(n=18) based on the classification scheme of (Paxinos & Watson, 2007). One rat was 
excluded from the medial-lateral analysis because both microinjection centers were 
precisely on the medial-lateral boundary. Medial placements in animals treated with 75ng 
of muscimol generated more incidents of carrying chow pellets than lateral placements 
[F(1,20)=4.93, p=0.018]. No other significant medial-lateral gradients were observed. 
 There were no significant gradients in any of the axes for either dose of DAMGO, 
indicating that the behavioral changes we observed following opioid manipulation are not 
linked to any particular sub-region of BNST, and consistent with a relative homogenous 




 We found that mu-opioid stimulation throughout BNST substantially increased 
intake of standard chow pellets in ad libitum fed rats. We also found that GABA-ergic 
disruption of neuronal activity within BNST suppressed feeding bouts at the higher of 
two doses tested and simultaneously increased locomotion and defensive treading 
behavior. Although the effect of opioid stimulation was homogenous throughout BNST at 
the doses tested here, a dorso-ventral gradient was detected for the effect of our lower 
dose of muscimol on both feeding and aversive behaviors. 
 
Mu-opioids stimulate feeding in BNST 
 Previous research has shown that BNST is one of a series of nuclei that 
consistently showed enhanced activation (as measured by Fos expression) in response to 
either food intake or infusion (centrally or locally) of feeding related neuropeptides. (B. 
H. Li et al., 1994; Mullett et al., 2000; Mungarndee et al., 2008; Park & Carr, 1998) 
BSNT has also been identified as a substrate of corticotropin releasing factor (CRF) 
induced anorexia and its subsequent reversal by the opioid peptide Nociceptin/Orphanin 
FQ (N/OFQ). (Ciccocioppo et al., 2003) N/OFQ, however, does not act alone to stimulate 
feeding, but merely rescues the standard level of feeding found in vehicle-treated animals 
(Ciccocioppo, Cippitelli, Economidou, Fedeli, & Massi, 2004). To our knowledge, the 
present study is the first to demonstrate an increase in feeding following neurochemical 
manipulation of BNST.  
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Our finding of potently increased food intake following intra-BNST mu-opioid 
stimulation is consistent with numerous reports of opioid-induced feeding at locations in 
the basal forebrain, both within and outside the extended amygdala. Opioid stimulation in 
the nucleus accumbens, ventral and dorso-medial striatum, caudal ventral pallidum, 
ventro-medial hypothalamus and PVN have all been shown to enhance food intake 
(Bakshi & Kelley, 1993a, 1993b; Giraudo et al., 1998; Gosnell et al., 1986; Kelley et al., 
2002; Pecina & Berridge, 2000, 2005; K. S. Smith & Berridge, 2005), in particular of 
highly palatable and energy dense foods (Naleid, Grace, Chimukangara, Billington, & 
Levine, 2007; Zhang & Kelley, 2000). In accumbens, opioids also to increase the 
breakpoint for responding for a food reward (Zhang et al., 2003). Within extended 
amygdala, similar feeding effects are found after opioid stimulation of the CeA (Giraudo 
et al., 1998; Gosnell, 1988), and possibly also at others sites in the extended amygdala 
including the SLEA and IPAC (Na, 2008). Together, these sites form a large network of 
opioid-sensitive feeding sites within the ventral forebrain, a virtually unbroken chain of 
nuclei extending from rostral accumbens to caudal CeA (a nearly 6mm rostro-caudal 
corridor). 
 We did not find any difference in effectiveness between the two doses of 
DAMGO (0.05ug and 0.1ug) used in this study, a finding mirrored in the highly similar 
size and intensity of the Fos plumes observed across both doses. Future studies will be 
necessary to evaluate lower DAMGO doses to establish the threshold for BNST 
sensitivity to mu-opioid induced feeding. Our doses of DAMGO are similar or indentical 
to those found to stimulate robust feeding in the shell of the nucleus accumbens (Pecina 
& Berridge, 2005), caudal ventral pallidum (K. S. Smith & Berridge, 2005), and CeA 
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(Gosnell, 1988; Mahler & Berridge, In press). Given the apparent homogeneity in the 
ability of mu-opioids to induce feeding in these sites, it would be of interest to explore 
whether there is similar homogeneity in the sensitivity of these regions to mu-opioid 
stimulation. Mu-opioid receptor binding and density does appear to be somewhat 
heterogeneous among these nuclei, with CeA displaying lower expression of both 
membrane-bound receptors and receptor mRNA than BNST, accumbens, or ventral 
pallidum (Mansour et al., 1995). 
 
Intra-BNST muscimol enhances defensive treading 
In contrast to opioid stimulation, GABA-ergic stimulation in BNST resulted in 
decreased feeding bouts and increased cage crosses and treading. Although the highest 
dose of muscimol tested here reduced several other feeding measures (including total 
intake in grams and total time eating), these reductions did not maintain statistical 
significance. One possible explanation is the low level of baseline feeding under vehicle 
treatment, likely the result of testing in non-deprived subjects using standard lab chow. 
Previous studies showing diminished food intake following intra-BNST CRF 
microinjection utilized food deprived subjects that demonstrated elevated baseline food 
intake, allowing relatively more room to observe a decline in feeding. (Ciccocioppo et al., 
2004; Ciccocioppo et al., 2003) It would be of interest in future studies to either employ 
mild food restriction before testing with intra-BNST muscimol, or to use a more palatable 
food to encourage high baseline feeding. 
Treading is a natural defensive behavior emitted by rodents as an adaptive 
response to an environmental threat, (Owings & Coss, 1977; Treit, Pinel, & Fibiger, 
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1981) and is also displayed in laboratory environments following neurochemical 
manipulations that generate fearful or aversive motivational states (Faure et al., 2008; 
Reynolds & Berridge, 2001, 2008). Although there was not a discrete aversive stimulus 
present at which the rodents might direct treading (such as a shock prod), there are 
several reasons to believe that the behavior we observed more closely resembles 
defensive treading rather than neutrally valenced locomotor stereotypy. First, we 
observed treading directed primarily at the corners of the testing chamber in conjunction 
with repeated circling of the chamber perimeter, instead of randomly oriented treading 
throughout the chamber. Second, we also observed distress vocalizations upon removal 
of many muscimol-treated animals from the testing chamber, as well as occasional escape 
attempts; similar vocalizations and escape attempts were never observed in DAMGO-
treated animals. These aversive behaviors will be more carefully quantified in additional 
studies. 
Treading has also been observed in several other forebrain sites following GABA 
agonism. Within extended amygdala, muscimol at a concentration similar to our highest 
dose generated robust treading in the CeA,(Mahler & Berridge, In press) indicating yet 
another homogeneous behavioral effect in extended amygdala. Muscimol in caudal 
accumbens shell results has also been shown to produce treading, which can be further 
enhanced by the addition of aversive environmental qualities such as bright lights and 
loud music (Reynolds & Berridge, 2001, 2008). This is in stark contrast to the effect of 
muscimol in rostral accumbens shell, where the manipulation greatly increases feeding 
and place preference (Reynolds & Berridge, 2002). The finding here of increased 
defensive treading after inactivation of BNST is consistent with previous reports of a role 
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for BNST in other aversive and stressful motivational states, including anxiety and drug 
withdrawal (M. Davis, 1998; Koob, 2003). 
 
Anatomical localization of behavioral effects 
Given the density of GABA- and opioid-sensitive feeding sites within the ventral 
forebrain, one could potentially argue that the feeding effects that we observed after 
microinjections into BNST were not, in fact, driven by BNST but instead by the diffusion 
of microinjections to other neighboring sites. However, data from our fos plume analyses 
of functional drug spread indicates that microinjection of the doses and volumes tested in 
this experiment do not spread substantially beyond the boundaries of BNST. This allows 
us to confidently conclude that BNST can now be added to the vast forebrain network of 
sites where opioids can influence feeding behavior and GABA agonism can generate 
aversive behavior, and provides strong evidence for the localization of these effects in 
BNST and not to neighboring sites such as the nucleus accumbens or ventral pallidum. 
Our DAMGO doses were equally effective at stimulating food intake throughout 
BNST. However, the lack of anatomical specificity with feeding does not preclude 
localization for other behaviors, as evidenced by the restricted mu-opioid hedonic hotspot 
located in rostro-dorsal quadrant of accumbens shell, where DAMGO stimulates feeding 
equivalently at all locations (Pecina & Berridge, 2005). We did find a significant dorso-
ventral gradient in both feeding behavior and treading for muscimol, though this gradient 
only emerged for our lower dose of muscimol. This may indicate that dorsal BNST is less 
sensitive to GABA-ergic inhibition than ventral BNST, which is supported by the lower 
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responsiveness of dorsal BNST neurons to acetylcholine, norepinephrine, and morphine 
(Casada & Dafny, 1993). 
 
What is the mechanism for BNST food intake? 
 Now that BNST has been implicated in appetitive motivational processes, it will 
be important to identify precisely what psychological mechanisms are driving the 
observed increased in feeding. Although voluntary food intake is a general measure of 
appetitive motivation, there are a number of distinct (though not exclusive) possibilities 
that could result in increased feeding. Additional studies will be required that more 
precisely test individual explanations. Previous research suggests several explanations 
that merit particular attention: stress, general appetitive motivation, and incentive salience 
‘wanting.’ 
Stress: Stress, both acute and chronic, can have dramatic impacts on feeding in 
both humans and non-human animals (Dallman et al., 2003; Rutters, Nieuwenhuizen, 
Lemmens, Born, & Westerterp-Plantenga, 2009). BNST has been repeatedly implicated 
in the regulation of hypothalamic-pituitary-adrenal (HPA) axis activity, (Choi, Evanson 
et al., 2008; Choi et al., 2007; Choi, Furay et al., 2008) and also argued to comprise part 
of brain stress and anti-reward systems that are persistently dysregulated during drug 
addiction. (Aston-Jones & Harris, 2004; Koob, 2003; Koob & Le Moal, 2008) 
Behaviorally, BNST has been linked to the acute response to stressful events such as 
immobilization (Casada & Dafny, 1991; Henke, 1984), as well as relapses in drug 
seeking following exposure to acute stressors  (Erb et al., 2001; Erb & Stewart, 1999),. 
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There are reasons to believe that our current mu-opioid feeding effect in BNST is 
not driven by stress. For one, our food intake testing was done using only standard rodent 
chow rather than a highly palatable food; studies of stress-induced feeding tend to show 
much more pronounced increases in highly palatable rather than standard food source. 
Additionally, infusion of a stress-related peptide, CRF, into BNST actually decreases 
feeding, rather than stimulating intake (Ciccocioppo et al., 2003). However, given the 
pronounced role of BNST in both acute and chronic brain stress systems, the possibility 
of stress-induced feeding must be evaluated. If, in fact, the feeding we observed was 
purely the result of stressful intake, this would be evidence against BNST’s role in 
appetitive motivational processes.   
 General appetitive motivation: Enhanced feeding could also be the result of a 
broad increase in general appetitive motivation. For example, increased BNST activity, as 
measured by c-Fos expression, has been observed after a variety of different appetitive 
manipulations, including feeding and exposure to sexual stimuli (B. H. Li et al., 1994; 
Mungarndee et al., 2008; Taziaux et al., 2008). These suggest that BNST may broadly act 
to increase adaptive appetitive behaviors in situations where reward stimuli are present or 
where cues signal that a rewarding UCS may soon become available. 
‘Wanting’: More specifically, opioid stimulation in BNST could increase 
incentive salience ‘wanting,’ a discrete mechanism of appetitive motivation, causing the 
food pellets to be more desirable and eliciting greater approach and consumption. 
(Robinson & Berridge, 1993, 2000) There are several reasons to think that BNST could 
be involved in the generation and attribution of  ‘wanting.’  
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First, BNST sends strong, excitatory projections to midbrain dopaminergic nuclei, 
including the ventral tegmental area (VTA). (Georges & Aston-Jones, 2001; Massi et al., 
2008) Dopamine is considered to be the primary neurotransmitter involved in the 
assignment of incentive salience ‘wanting,’ (Berridge, 2007; Berridge & Robinson, 1998; 
Robinson & Berridge, 1993) and BNST opioids could potentially drive increase feeding 
by enhancing the firing of dopaminergic cell populations in the VTA, and subsequently 
increasing dopamine release in limbic and cortical targets. Second, BNST is not only a 
source of excitatory projections to dopaminergic nuclei, but also a target of enhanced 
dopamine release following administration of reinforcing drugs. (Carboni et al., 2000) 
Enhanced dopaminergic transmission, either via prior sensitization or acute treatment 
with amphetamine, in both the shell of the nucleus accumbens and also the ventral 
pallidum enhance ‘wanting’ for reward cues. (Tindell et al., 2005; Wyvell & Berridge, 
2000, 2001) Finally, mu-opioid stimulation in CeA, another extended amygdala nucleus, 
directly enhances ‘wanting’ for Pavlovian reward cues in autoshaping testing, in addition 
to increasing food intake. (Mahler & Berridge, In press) CeA and BNST, in particular the 
lateral divisions of BNST, share strong reciprocal connectivity and strikingly similar 
neural architecture (Alheid, 2003; de Olmos & Heimer, 1999). Based on these strong 
anatomical similarities and the identical opioid feeding effect in both structures, it is 
possible that BNST is also a substrate for mu-opioid ‘wanting.’ 
 
Conclusion 
 In conclusion, we have shown that mu-opioid stimulation of BNST can potently 
increase feeding, while GABA-ergic agonism in the same structure inhibits some 
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measures of feeding while simultaneously enhancing a fearful defensive behavior. These 
results point to a role for BNST in mediating both appetitive and aversive motivation. 
Future studies will be necessary to precisely characterize the psychological mechanism 























Figure 2.1. Fos plumes in BNST. Target Region: Highlights the location of 
BNST in a coronal slice, taken from Paxinos & Watson (2007). Radial Arm Fos 
Sampling: An example of the radial counting grid. Each grid square measures 
68um x 68um, with 10 squares emanating from each radial arm. Grid squares 
falling in ventricles or over white matter tracts were excluded from quantification 
and analysis. Normal BNST: Representative image from uninjected, virgin tissue 
in BNST. Vehicle BNST: Representative image from vehicle microinjected tissue 
in BNST, showing a small area of increased Fos expression (relative to normal) 
near the injection site. DAMGO (0.05ug), DAMGO (0.1ug): Representative 
plumes (relative to normal and vehicle controls) from DAMGO microinjected 
tissue. Note the presence of the small inhibitory regions near the excitatory 
plumes. Muscimol (75ng), Muscimol (225ng): Representative plumes (relative to 
normal and vehicle controls) from muscimol treated tissue. All images shown are 
2x2 tiled images taken at 10x magnification. 
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Table 2.1. Fos plume radii and estimated volumes. Mean radii (left) and 
volume (right) are listed for vehicle, DAMGO (0.05ug), DAMGO (0.1ug), 
muscimol (75ng), and muscimol (225ng) conditions. Plume sizes were calculated 
compared to normal tissue alone for the vehicle condition, and compared to both 












Figure 2.2. DAMGO in BNST increases feeding time. Feeding time 
enhancements following 0.05ug (top) and 0.1ug (bottom) DAMGO 
microinjections are mapped rat-by-rat onto a horizontal view of BNST, showing 
both the within-subject change in feeding time relative to vehicle day (color) and 
the functional spread of the microinjection based on Fos plume data (size). Each 
map symbol is composed of three nested hexagons; the inner symbol shows the 
average size of intense 5x activation, the middle symbol shows 3x activation, and 
the outer symbol shows 2x activation. Bar graphs along the rostro-caudal and 
medial-lateral axes show the average drug effect within each 0.4mm wide region. 
Bar graphs showing absolute comparisons of vehicle and drug feeding time (in 
minutes) can be found above and to the left of each anatomical map. * indicates 






Figure 2.3. Muscimol in BNST does not significantly change feeding time. 
Anatomical maps of feeding time changes following intra-BNST muscimol at 
75ng (top) and 225ng (bottom). For muscimol plumes, the inner symbol shows 3x 
control activation, the middle symbol shows -50% control inhibition, and the 
























Figure 2.4. Feeding, drinking, and other behavioral effects after intra-BNST 
DAMGO and muscimol. Behavioral effects of vehicle (white bars), DAMGO 
0.05ug (light green), DAMGO 0.1ug (dark green), muscimol 75ng (light blue), 
and muscimol 225ng (dark blue) on feeding, drinking, and other behaviors. * 




   
Figure 2.5. Muscimol in BNST increases defensive treading behavior. 
Anatomical maps of changes in defensive treading following intra-BNST 
muscimol at 75ng (top) and 225ng (bottom) doses. Defensive treading is robust 







Figure 2.6. Locomotor and defensive treading changes after intra-BNST 
DAMGO and muscimol. Behavioral effects of vehicle (white bars), DAMGO 
0.05ug (light green), DAMGO 0.1ug (dark green), muscimol 75ng (light blue), 
and muscimol 225ng (dark blue) on rearing, cage crosses, and defensive treading 










Figure 2.7. Dorso-ventral gradients after intra-BNST microinjection of 75ng 
muscimol. The 75ng dose of muscimol was more effective at disrupting feeding 
related behaviors and enhancing defensive treading at sites in the ventral portion 
of BNST compared to the dorsal portion. * indicates differences from vehicle, 














Chapter 3  
Does Opioid Activation in the Bed Nucleus of the Stria Terminalis and the Shell of 
the Nucleus Accumbens Directly Increase Incentive Salience ‘Wanting:’ Tests of 
Autoshaping and Conditioned Reinforcement 
 
Introduction 
Conditional stimuli (CS) repeatedly associated with a rewarding unconditional 
stimulus (UCS) can have powerful and sustained effects on behavior. Conditional cues 
come to possess some of the motivational properties of the UCS (Berridge, 2001; Bindra, 
1978; Toates, 1986), and can act as ‘motivational magnets’, attracting UCS-appropriate 
behaviors that are phase-locked with CS presentation. One explanation for the ability of 
CS’s to attract appetitive behaviors comes from the incentive salience hypothesis of 
motivation, which suggests that the motivational magnet quality of the reward CS results 
from the attribution of incentive salience ‘wanting,’ a psychological phenomena that 
imbues the CS with incentive value (Berridge, 2001, 2007; Robinson & Berridge, 1993). 
This attribution of ‘wanting’ to Pavlovian CS’s, thereby inbuing them with some of the 
incentive properties of the linked UCS reward and thus making the CS desireable in its 
own right, is particularly helpful in explaining why animals sometimes attempt to 
consume reward CS’s (even inanimate objects like metal levers and cue lights) (Boakes, 
1977; Flagel et al., 2009; Tomie, Grimes, & Pohorecky, 2008), or why crack addicts 
occasionally “chase ghosts,” scrambling for and attempting to smoke small pebbles that 
superficially resemble crack cocaine (Berridge, 2007; Rosse et al., 1993). 
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CS-UCS relationships are deeply adaptive, allowing organisms to utilize a 
predictive stimulus to energize behavior toward receipt or pursuit of an impending 
reward, such as food (Holland & Petrovich, 2005) or sex (Pfaus, Kippin, & Centeno, 
2001; Waddell, 2005), or, in cases where the UCS is aversive, to mobilize escape or 
avoidance behavior (Eilam, 2005; Fendt & Fanselow, 1999; Misslin, 2003). However, 
cues can also potentiate maladaptive behavior, such as the intake of drugs of abuse, by 
helping to sustain continued drug taking or even by triggering a relapse in drug seeking 
after a period of abstinence (Marlatt, 1990; Robinson & Berridge, 1993, 2000; See, 2002, 
2005; Shaham et al., 1994). A significant challenge in the affective neurosciences – and 
one with potentially great clinical relevance – is to locate and characterize neural 
substrates involved in cue-triggered motivation. 
Here we chose to focus on the role of pair of forebrain nuclei in autoshaping and 
conditioned reinforcement: bed nucleus of the stria terminalis (BNST) and the shell of the 
nucleus accumbens.  Although BNST has primarily been linked to aversive motivational 
processes (M. Davis et al., 1997b; Erb & Stewart, 1999; Koob, 1999), it has recently been 
advanced as a component of a larger anatomical macrosystem, the extended amygdala 
(Alheid, 2003; de Olmos & Heimer, 1999; Heimer, 2003; Heimer & Van Hoesen, 2006).  
This exciting new macrosystem includes BNST, plus two particular components of the 
classic amygdala (the central nucleus and medial nucleus of amygdala), plus a few other 
components (sublenticular extended amydala and IPAC). With substantial inputs from 
limbic cortex and brainstem dopaminergic centers, the extended amygdala is well 
positioned to participate in the attribution and/or modulation of incentive salience.  In 
particular, recent studies from our lab showed that opioid stimulation of the central 
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nucleus of amygdala potentiated the ‘motivational magnet’ properties of a rat’s preferred 
CS in autoshaping (Mahler & Berridge, 2009).  This suggests that other components of 
extended amygdala, BNST, might also play a role in incentive salience of CSs for 
reward. 
Indeed, BNST has recently shown !-opioid dependent increases in UCS 
‘wanting’ for a food reward (see Chapter 2) at doses similar to those found to stimulate 
feeding in another extended amygdala nucleus, the central amygdala (CeA) (Gosnell, 
1988; Mahler & Berridge, 2009). Additionally, lesions of the closely related CeA have 
been shown to disrupt conditioned orienting in autoshaping (also known as Pavlovian 
conditioned approach or sign-tracking) paradigms (Gallagher, Graham, & Holland, 1990; 
Holland et al., 2002) and to completely disrupt Pavlovian to instrumental transfer (PIT) 
(Holland & Gallagher, 2003). Yet it remains unclear whether increases in ‘wanting’ for 
rewards CS’s within the extended amygdala are limited to CeA, or whether they extend 
to other structures within this macrosystem, such as the bed nucleus of the stria terminalis 
(BNST). 
It can be noted that many other structures have been shown to participate in the 
development and expression of autoshaping behavior, including the core and shell of the 
nucleus accumbens (Blaiss & Janak, 2009; Flagel, Watson, Robinson, & Akil, 2007; 
Parkinson, Olmstead, Burns, Robbins, & Everitt, 1999; Parkinson, Willoughby, Robbins, 
& Everitt, 2000; Phillips, Setzu, & Hitchcott, 2003), cingulate and prefrontal cortex 
(Bassareo, De Luca, & Di Chiara, 2007; Parkinson et al., 2000), the subthalamic nucleus 
(Uslaner, Dell'Orco, Pevzner, & Robinson, 2008), and the both basolateral and central 
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nuclei of the amygdala (El-Amamy & Holland, 2007; Gallagher et al., 1990; Holland & 
Gallagher, 2003; Mahler & Berridge, 2009).  
In accumbens shell, reversible inactivation prior to testing disrupts expression of 
autoshaping behavior (Blaiss & Janak, 2009), though excitotoxic lesions of accumbens 
shell do not (Parkinson et al., 1999; Parkinson et al., 2000). Permanent lesions of 
accumbens shell do, however, impair PIT (Corbit, Muir, & Balleine, 2001). It remains 
unclear, though, precisely how accumbens shell works to increase CS ‘wanting.’ 
Although opioid stimulation in CeA has been shown to focus ‘wanting’ on a previously 
learned and preferred CS, it has been hypothesized that accumbens shell may play a 
broader role in the generation of incentive salience. Stimulation of accumbens shell, 
therefore, might more readily be able to act as ‘a rising tide that floats all boats,’ 
elevating ‘wanting’ for all available reward CS targets in the environment (Berridge, 
2007).  By comparison, opioid stimulation of CeA may instead focus enhanced incentive 
salience upon a particular CS in a ‘winner take all fashion’ (Mahler & Berridge, 2009).   
However, it is not yet entirely clear whether opioid agonists in accumbens shell 
also potentiate ‘wanting’ directly in a CS motivation paradigm, as dopamine has been 
shown to in medial shell (Wyvell & Berridge, 2000, 2001). Some pilot PIT results 
indicate that, indeed, medial shell opioids can directly enhance CS ‘wanting’ (Pecina & 
Berridge, In Preparation). However, no one has yet investigated the effects of opioid 
stimulation of accumbens shell in an autoshaping paradigm (Mahler & Berridge, 2009). 
Here, we fill that accumbens gap, and compare its role in autoshaping to that of 
BNST, when stimulated by DAMGO.  Specifically, I test the ability of microinjections of 
the !-opioid agonist DAMGO into BNST or accumbens shell to modulate two measures 
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of CS incentive salience ‘wanting’ that remain to be explored with these manipulations: 
autoshaping and conditioned reinforcement. Although dopamine is perhaps the most 
clearly implicated neurotransmitter system in the attribution of incentive salience (Wyvell 
& Berridge, 2001), opioid neurotransmitter systems also appear able to modulate 
‘wanting’ for reward CS’s. Pre-exposure to systemic heroin increased the conditioned 
reinforcement value of a previously learned reward CS (Ranaldi, Egan, Kest, Fein, & 
Delamater, 2009). Microinjection of the !-opioid agonist DAMGO into CeA enhances 
appetitive responding in both autoshaping (Mahler & Berridge, 2009) and PIT (Mahler & 
Berridge, 2007) testing, while DAMGO in accumbens (both core and shell) has been 
shown to enhance PIT (Pecina & Berridge, In Preparation).  
It is possible that DAMGO in BNST might increase CS motivational magnet 
‘wanting’ in autoshaping and enhance the conditioned reinforcement value of the 
autoshaping CS+ for those animals who preferentially interacted with this CS during 
prior autoshaping testing, similar to the effects of DAMGO in a closely related extended 
amygdala nucleus, the CeA. Alternatively, !-opioids in BNST may only modulate 
‘wanting’ for UCS reward (as previously demonstrated in Chapter 2), but fail to affect 
reward CS’s, consistent with studies showing that BNST lesions only disrupt fearful 
responding to unconditioned, and not conditioned, cues (M. Davis, 1998). For accumbens 
shell, I predict that DAMGO will generate a broadly assigned incentive salience to CS’s, 
elevating appetitive behavior toward both preferred and non-preferred CS’s in 
autoshaping and enhancing the conditioned reinforcement value of the autoshaping CS+ 





A total of 107 Sprague-Dawley rats were used (females, 250-400g at the time of 
surgery; individual experiments utilized n’s of 57 [during testing], 37 [after testing], and 
13 [fos plume mapping]). Rats were housed in pairs (~21˚C; 12hr light/dark cyle, lights 
on at 9am) with ad libitum access to food (Purina 5001 chow; Purina Mills, St. Louis, 
MO) and tap water, except during autoshaping and conditioned reinforcement testing 
when food was slightly restricted (~15g/day/rat). During food restriction, chow was 
always delivered immediately after training or testing. All phases of the estrous cycle 
were included in testing. All procedures were approved by the University Committee on 
the Use and Care of Animals at the University of Michigan in accordance with National 
Institute of Health guidelines. 
  
Autoshaping Paradigm 
Exposure to repeated pairings of a discrete CS+ metal lever with the subsequent 
delivery of a small UCS reward (such as a sucrose pellet) into a nearby food dish (CSCup) 
will induce most rats to approach, investigate and even attempt to consume one of these 
two available CS’s (Boakes, 1977; Flagel et al., 2009; Hearst & Jenkins, 1974; Tomie et 
al., 2008). This motivational magnet quality of the rewards CS’s, or the ability to attract 
motivated behaviors, is one of three principle components of incentive salience ‘wanting’ 
(Berridge & Robinson, 2003; Berridge et al., 2009). 
Each CS possesses unique characteristics: the CS+ lever is maximally predictive 
of the UCS but is physically removed form the location of UCS delivery; conversely, the 
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CSCup is spatially proximate to the site of UCS delivery but correlates poorly to the 
temporal availability of the UCS since it is present in the chamber throughout the entire 
test session. Interestingly, after several days of testing most rats will develop a preference 
for either the CS+ lever or the CSCup that remains stable over the subsequent duration of 
autoshaping testing. This preferred CS elicits greater probability and frequency of 
approach and interaction during the CS+, and will be referred to as the ‘prepotent CS.’ 
 The ability of one of the reward CS’s to act as a motivational magnet is phasic, 
with the CS+ presentation triggering approach and consummatory behaviors, which can 
sometimes reach near frenzied levels (especially after brain limbic stimulation, such as 
opioid stimulation of CeA) (Mahler & Berridge, 2009). Appetitive and consummatory 
behaviors arise and peak during the 8 sec CS+ duration, and quickly return to much lower 
baseline levels after CS+ termination and UCS delivery. During CS+ onset rats engage in 
a range of appetitive and consummatory behaviors toward the CS’s. Both of the CS’s 
were physically discrete objects that supported behaviors such as orientation, sniffing, 
nibbling, biting, and touching with forepaws. The latency, frequency, and probability of 
such behaviors all constitute measures of the incentive salience ‘wanting’ of a given CS. 
A third stimulus, a control lever identical in shape and size to the CS+ lever (but unlit), 







 Autoshaping: All autoshaping test sessions were recorded using a digital video 
camera positioned beneath the chamber to provide a clear view of the entire chamber. For 
the autoshaping experiments where microinjections were delivered after training, a 
second camera was positioned on the side of the test chamber to provide a more detailed 
side-view of the CS’s, in particular the CSCup. Videos were scored offline in slow motion 
(1/2 to 1/10
th
 speed) by an observer blind to the experimental condition. The observer 











presentations of each scored session (and also the 8 seconds prior to cue onset when 
microinjections were delivered after training). 
 Three CS-directed behaviors were hand-scored by the observer: looks, nibbles 
and sniffs, and slow bites. “Looks” were orientations of the head toward a CS where the 
nose was within ~3cm of the CS but no physical contact with the CS was made. “Nibbles 
and sniffs” were fast (<0.5sec) investigatory movements of the mouth and nose directed 
toward either CS, requiring physical contact with the CS and resembling initial 
investigatory contact with a UCS reward, such as a food pellet. “Slow bites” were longer 
duration (~0.5-1sec), discrete interactions that resembled consummatory-type actions 
toward the CS, involved grasping and clear biting of the CS+ lever or slow, discrete dips 
into the CSCup resembling the movement required to retrieve a UCS pellet. 
 For autoshaping expression experiments, the observer also hand-scored the 
latency to the first physical interaction (either nibble/sniff or slow bite) with the CS+ 
lever. Latency was scored as the time between the first frame where the CS+ lever was 
visible and the first frame in which the initial CS+ lever nibble/sniff or slow bite began. 
Although latency to first computer-scored lever press was automatically recorded by the 
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accompanying software, hand-scoring was necessary to more accurately capture the 
latency of interactions (especially nibbles/sniffs) that were unlikely to be registered as 
discrete lever presses. 
 Food intake: Video recordings of food intake test sessions were scored offline by 
an observer blind to the experimental condition. The following behaviors were recorded: 
eating time (in seconds), eating bouts (triggered by interruptions of eating of more than 5 
seconds), food sniffing, food carrying, drinking time (in seconds), drinking bouts (same 
criteria as eating bouts), grooming, cage crosses, sleeping, rearing, and defensive 
treading. Treading is a natural defensive behavior emitted by rodents, and involves rapid 
forelimb strokes away from the body that push debris (e.g. dirt or bedding) in the 
direction of a threat (see Chapter 2 for additional details). 
 
Conditioned Reinforcement Paradigm 
While autoshaping testing captures the motivational magnet qualities of incentive 
salience ‘wanting,’ we were also interested in the ability of the CS+ lever to serve as a 
conditioned reinforcer for a novel instrumental action. Here, we utilized a briefer (4 sec) 
presentation of the lit CS+ lever and accompanying tone from autoshaping testing to 
support acquisition of a novel nose-poking behavior. If, in fact, a cue possesses incentive 
salience, then it should be able to act as a conditioned reinforcer (Berridge & Robinson, 
2003; Berridge et al., 2009), and changes in ‘wanting’ for the cue can be assessed by 
measuring differences in the effectiveness of the conditioned reinforcer under different 
neurobiological manipulations. All conditioned reinforcement testing occurred under 
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All animals were handled twice for a total of fifteen minutes prior to undergoing 
surgery. Rats were pretreated with atropine (0.04mg/kg) and then anesthetized with 
ketamine (80mg/kg) and xylazine (5mg/kg). Rats were then placed in a stereotaxic device 
and implanted with bilateral, chronic guide cannula (23 gauge, stainless steel), 14mm in 
length, aimed either so that the ventral tip would rest 2mm above the BNST (AP: +0.24 
to -0.84mm; ML: +/-1.2 to 1.7mm; DV: -4.5 to -4.95mm; incisor bar: -3.3mm [flat skull]) 
or the shell of the nucleus accumbens (AP:+3.0 to 2.7mm; ML: +/-0.9mm; DV: -5.5mm 
to -5.8mm; incisor bar: +5.0mm). Guide cannula were secured to the skull using four 
stainless steel screws and dental acrylic, and fitted with stainless steel stylets to prevent 
occlusion.  
All rats were given post-operative analgesic (0.3 mg/kg buprenorphine) and 
prophylactic antibiotic (50 mg/kg chloramphenicol), and allowed to recover for at least 7 
days before the onset of behavioral testing. 
 
Drugs and Microinjections 
DAMGO (0.1!g, total of 0.2!g bilateral dose) was dissolved and diluted to dose 
in artificial cerebrospinal fluid (aCSF; Harvard Labs, Cambridge, MA). This dose was 
chosen for its ability to induce UCS ‘wanting’ in both BNST (see Chapter 2) and 
accumbens shell (Pecina & Berridge, 2005). aCSF alone was used for vehicle 
 72 
microinjections. Microinjection schedules were counter-balanced across subjects when 
appropriate. 
On test days where animals received intracranial microinjections, animals were 
gently handled as the stylets were removed. Rats then received bilateral microinjections 
(0.2!L per side, total bilateral volume) via 16mm stainless steel microinjection tips (29 
gauge), which extended 2mm beyond the ventral tip of the guide cannula. Microinjection 
tips were attached via PE-20 surgical tubing to a microinfusion pump, which delivered 
the infusion over the course of 60 seconds. Microinjection tips were left in place for an 
additional 60 seconds after the infusion ended to allow for drug diffusion, after which the 
stylets were replaced and the rat placed immediately in the test chamber. 
 On test days where animals did not receive microinjections, the rats were gently 
handled for the same amount of time as it took to complete microinjections (~5 mins) and 
the stylets were removed, cleaned, and replaced before placing the animal in the test 
chamber. 
  
Autoshaping Testing Apparatus 
 Autoshaping chambers were 30.5cm x 24.1cm x 21.0cm, with steel plates on front 
and back and clear plastic side walls, ceiling, and floor (Med Associates, Inc.; Vermont, 
USA). A red-tinted house light was mounted atop the back wall, and was illuminated 
throughout all test sessions. The back wall also contained the speaker for a tone generator 
utilized as part of the CS+ stimulus. 
 The front wall contained a central sucrose delivery cup (the CSCup) near the floor, 
flanked by two retractable levers on either side (the CS+ lever and the control lever). The 
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CS+ lever was periodically extended and retracted during test sessions, while the control 
lever remained extended throughout the autoshaping sessions. The CS+ lever also 
contained an embedded white LED light that was illuminated during lever extension and 
extinguished during lever retraction. An infrared beam was incorporated into the CSCup to 
measure the number and duration of entries. A computer equipped with MED-PC 
software (Med Associates, Inc.; Vermont, USA) was attached to all test chambers, 
controlling sessions and recording all automated inputs (CS+ and control lever 
depressions, response latency, CSCup entry frequency and duration). 
 
Conditioned Reinforcement Testing Apparatus 
Conditioned reinforcement testing occurred in the same chamber as autoshaping 
testing. The food cup was removed from the front wall and replaced with a solid steel 
plate. A retractable lever (identical to the CS+ lever) was installed in the center of the 
back wall, flanked by two infrared nose ports installed near the floor of the chamber. One 
of the nose ports was inactive, and although entries into this port were counted they did 
not generate a response. The other nose port was active, and entries into this port would 
generate a 4 sec presentation of the illuminated, retractable lever and the 2.9KHz tone 
(identical to the autoshaping CS+). During the CS+ presentation, the attached computer 
automatically recorded lever presses. Conditioned reinforcement sessions lasted 40 
minutes. 
 
Behavioral Experiment Descriptions 
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 Pre-training: Rats were handled on 2 days for a total of fifteen minutes prior to 
training, and exposed to the UCS sucrose pellets in their home cage on the day prior to 
training. Rats then underwent 1 day of magazine training: “free” sucrose pellets on a 
variable interval (VI)-60 sec schedule for 20 minutes to habituate the rats to the process 
of retrieving pellets from the CSCup. During magazine training, the control lever was 
extended but the CS+ lever was never presented. Rats were considered to have 
successfully magazine trained if all pellets were retrieved and consumed. If pellets 
remained in the CSCup or chamber after the initial magazine training session, the rat was 
exposed to another magazine training session 2-24 hours later. Most rats required only 
one magazine training session, and all rats included in this study successfully completed 
magazine training after one or two sessions. 
 General autoshaping procedure: Autoshaping sessions were composed of twenty 
five Pavlovian pairings of the CS+ lever (illuminated during extension by an embedded 
diode) and a 2.9KHz continuous tone (8 second duration, VI-90sec schedule) with one 
45mg sucrose pellet delivered in the CSCup immediately after CS+ lever offset. Testing 
was terminated 30 seconds after the 25
th
 cue, resulting in total autoshaping sessions 
lasting ~35-45 minutes. 
Autoshaping acquisition: We first tested whether DAMGO microinjections 
throughout the duration of autoshaping testing (both initial learning and subsequent 
expression) would modulate incentive salience ‘wanting.’ Separate groups of rats 
received microinjections of either vehicle (BNST: n=3, CS+ lever prepotent; n=5, CSCup 
prepotent; Accumben shell: n=3, CS+ lever prepotent; n=15, CSCup prepotent) or 
DAMGO (BNST: n=6, CS+ lever prepotent; n=5, CSCup prepotent; Accumben shell: 
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n=16, CS+ lever prepotent; n=4, CSCup prepotent) into BNST or accumbens shell 
immediately prior to each of 6 days of autoshaping testing. Test days were spaced 24-48 
hours apart. 
 Autoshaping expression: We also tested whether DAMGO would modulate 
incentive salience if delivered after the CS-UCS relationship had been learned and a 
prepotent cue was established. Rats in this experiment received 5 days of microinjection-
free autoshaping training, followed by 2 days where rats received microinjection of 
vehicle and DAMGO (BNST: n=13, CS+ lever prepotent; n=2, CSCup prepotent; 
Accumben shell: n=14, CS+ lever prepotent; n=8, CSCup prepotent). Microinjection order 
was counterbalanced across subjects, and rats were given 48 hours between 
microinjection test days. 
 Conditioned reinforcement: Conditioned reinforcement was tested after the 
completion of autoshaping testing. For autoshaping acquisition, rats underwent 1 day of 
conditioned reinforcement testing and separate groups received either vehicle (BNST: 
n=3, CS+ lever prepotent; n=0, CSCup prepotent; Accumben shell: n=12, CS+ lever 
prepotent; n=2, CSCup prepotent) or DAMGO (BNST: n=4, CS+ lever prepotent; n=0, 
CSCup prepotent; Accumben shell: n=2, CS+ lever prepotent; n=14, CSCup prepotent) 
microinjections, consistent with what they received during acquisition testing, 
immediately prior to testing. For autoshaping expression, rats received 2 days of 
conditioned reinforcement testing with counterbalanced microinjection of vehicle and 
DAMGO (BNST: n=0, CS+ lever prepotent; n=9, CSCup prepotent; Accumben shell: n=8, 
CS+ lever prepotent; n=14, CSCup prepotent) immediately prior to testing. 
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 Food intake: In the autoshaping expression experiments, rats were also tested for 
voluntary intake of a food UCS after the completion of autoshaping and conditioned 
reinforcement testing. Autoshaping acquisition animals were not tested for food intake 
due to the large number of microinjections already administered.  
Prior to food intake testing, rats were returned to ad lib feeding for at least 48 
hours, and then habituated to the test environment for three additional days. Rats were 
placed in clear plastic cages containing a pre-measured pile of standard lab chow (~25g), 
a water spout, and corncob bedding. On test days, food intake was tested for 1 hour 
immediately following microinjection of vehicle or DAMGO. The entire session was 
videotaped for subsequent offline analysis. After the test was completed, remaining chow 
(including crumbs) was carefully removed from the cage and weighed. Test days were 
always separated by at least 48 hours. 
 
Histology 
After testing was completed, subjects used for behavioral testing were deeply 
anesthetized with sodium pentobarbital (0.2mg/kg; Fatal-Plus) and decapitated. Brains 
were extracted and placed in a 10% paraformaldehyde solution for 24-48 hours, and then 
placed in a 30% sucrose solution for 3-5 days, until the brains sank. The brains were then 
sliced on a freezing microtome (Leica Microsystems; Illinois, USA) into 60!m coronal 
sections, mounted onto glass slides, allowed to dry for at least 24 hours, and then stained 
with cresyl violet. Stained slices were viewed under light magnification and used to map 
the microinjection centers in each hemisphere on coronal sections taken from a rat brain 
atlas. (Paxinos & Watson, 2007) 
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Fos-Like Protein Immunohistochemistry 
Rats utilized for Fos plume analysis underwent identical procedures for cannula 
implantation (except sham surgery control animals, who underwent surgery but did not 
receive cranial guide cannula) and pre- and post-surgical handling. Here, we completed 
Fos plume analysis for intra-accumbens shell DAMGO (0.1!g); Fos plume analysis for 
this drug/dose in BNST was previously completed (see Chapter 2). 
On the day of Fos plume testing, animals were given bilateral microinjections of 
vehicle (n=4) or 0.1!g DAMGO (n=6). Sham surgery animals (n=3) were handled gently 
for an amount of time equivalent to the animals receiving microinjections. Ninety 
minutes after microinjection, rats were transcardially perfused and their brains placed in 
4% formaldehyde for 4-6 hours, then moved to a 30% sucrose solution for 3-4 days. 
Brains were then sliced on a freezing microtome in alternating 40!m coronal sections, 
with one series processed for Fos expression and the other retained for placement 
verification, if needed. 
Fos activation following neurochemical manipulation was measured using 
immunohistochemistry and immunofluorescence (Faure et al., 2008; Reynolds & 
Berridge, 2008). Briefly, sections were immersed and gently agitated in successive baths 
of 0.1M sodium phosphate buffer (SPB) and 0.2% Triton containing (1) 5% normal 
donkey serum (NDS) for 30 minutes, (2) 5% NDS and goat anti-c-Fos (1:10) overnight at 
4˚C, (3) 5% NDS and signal enhancer for 30 minutes and, (4) 5% NDS and donkey anti-
goat Alexa Fluor 488 (excitation: 488nm; emission: 519nm; Invitrogen) for 1 hour. 
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Sections were then mounted, air dried for 2-4 hours, and then coverslipped with ProLong 
Gold antifade reagent (Invitrogen). 
 
Fos Plume Mapping of Neuronal Activation and Suppression  
 Local Fos activation was visualized using a Leica microscope (DM 6000; 
Nussloch, Germany) equipped for both brightfield and fluourescent microscopy. A filter 
with an excitation band at 480-505nm and an emission band at 505-545 were used for 
fluorescent visualization, and images were captured at 10x magnification (2x2 tiled) 
using a Regita-SRV camera (Q-Imaging; Surrey, British Columbia) and MCID Elite 
software. Fos-labeled cells were individually counted by an observer blind to treatment 
condition within ten adjacent sampling squares (68!m by 68!m) along each of seven 
radial arms extending from the center of the drug microinjection (45˚, 90˚, 135 ,̊ 180˚, 
225˚, 270˚, and 315˚). 
 Baseline levels of Fos expression were established by quantifying expression in 
two control conditions, (1) normal tissue of sham surgery to assess expression in the 
absence of damage from guide cannula implantation and microinjector tip insertion and 
(2) following vehicle microinjection to assess expression following microinjection track 
and vehicle-induced Fos expression. These baseline values were compared to Fos 
densities in each of the four drug conditions to assess the functional spread of neural 
activation or inhibition following DAMGO or muscimol microinjection. 
 DAMGO Fos plumes were mapped as >500%, >300%, and >200% of Fos 
expression relative to vehicle microinjections and to normal tissue. In each case, the 
distance of each range of Fos expression was measured from the microinjection center 
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along each radial arm. Spread was considered to extend to the furthest sampling square 
that contained greater than or equal to the particular level of activation or suppression 
being evaluated. Finally, the distance was averaged across all seven radial arms to 
produce an average radius of elevation or suppression. This procedure was repeated for 
every level of activation and suppression. The resulting drug-induced change in Fos 
expression relative to controls was then mapped to visualize the plume of activation 
and/or suppression for each drug and dose. 
 In the final stage of mapping, the Fos plume data identifying functional drug 
spread was merged with the behavioral data. DAMGO excitatory plumes symbols were 
created based on the radius of intense (>500%), moderate (>300%), and low (>200%) 
changes in Fos expression compared to vehicle controls. The verified bilateral 
microinjection centers of each rat are indicated by a pair of these symbols, and then 
color-coded to indicate specific behavioral effects. Microinjection centers for each rat 
were mapped in the coronal, sagittal, and horizontal planes; for the latter two, bilateral 
placements were collapsed onto a single unilateral map. Separate maps were constructed 
for each drug treatment and dependent variable. Thus, each symbol conveys information 
for each individual subject about (1) the location of drug microinjection, (2) the 
functional spread of drug in vivo and (3) the behavioral effect of the drug treatment on the 
particular dependent variable being presented. 
 
Statistical Analyses 
 Autoshaping acquisition results were analyzed using mixed ANOVAs, using the 
within-subjects factor of test day and the between subjects factors of drug (vehicle vs. 
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DAMGO) and prepotent cue (CS+ lever or CSCup). Autoshaping expression results were 
also analyzed using mixed ANOVAs, with within-subjects factors of drug and cue period 
(the 8 sec prior to each scored cue vs. the 8 sec duration of each cue presentation) and the 
between subjects factor of prepotent cue. Sidak corrected t-tests and one-way ANOVAs 
were used to assess interactions. No order effects were found for drug or day in 
autoshaping expression and food intake, so data was collapsed across days. Conditioned 
reinforcement data was analyzed using ANOVA with factors of nose port (active vs. 
inactive), drug, and prepotent cue. For food intake and other general behaviors, the effect 
of DAMGO versus vehicle was assessed using paired samples t-tests. When reporting 




 Activation of !-opioid receptors in the shell of the nucleus accumbens broadly 
increased incentive salience ‘wanting’ in both autoshaping and conditioned reinforcement 
tests.  That is, accumbens shell DAMGO enhanced looks and approach and of both 
autoshaping CS+s, and increased the reinforcement value of the autoshaping CS+ in 
conditioned reinforcement testing regardless of an animal’s prepotent CS. Stimulation of 
!-opioid receptors in accumbens shell also increased ‘wanting’ for a UCS food reward in 
the same animals. We suggest that this pattern of findings indicates that !-opioid 
stimulation in accumbens shell has the ability to broadly elevate ‘wanting’ for all 
available reward cues, essentially acting as “a rising tide that floats all boats.” 
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 Conversely, DAMGO microinjection in BNST caused an even broader 
enhancement that was unfocused on the predictive CS+ lever, generating a temporal 
diffusion of appetitive and consummatory behaviors directed at a subject’s prepotent cue 
that spilled into non-CS periods.  BNST DAMGO enhanced these behaviors to the 
prepotent CS when the CS+ lever for sucrose reward was absent, and slightly decreasing 
them when the CS+ was present. DAMGO in BNST did not affect the conditioned 
reinforcement value of the compound CS+, but was able to enhance voluntary intake of a 
UCS food reward. This pattern of results suggests that BNST opioids directly increasing 
UCS ‘wanting,’ may diffusely and somewhat nonassociatively act to project ‘wanting’ to 
a preferred autoshaping reward CS, smoothing the normally sharp ebb and flow of 
incentive salience between cue and non-cue periods. 
 
Fos plumes and functional spread of drug microinjection 
Fos plumes estimating the functional spread of our neurochemical manipulations 
were constructed using histology of neural tissue from a separate group of rats. Analysis 
of Fos expression indicated that for the drugs/doses/volumes used above, neuronal 
modulation was primarily limited to within BNST and the medial shell of the nucleus 
accumbens (see Figure 1 and Table 1). Fos plume data for the 0.1!g dose of DAMGO in 
BNST were taken from a previous Fos analysis experiment using an identical dose, 
volume, and rate of infusion (see Chapter 2). 
DAMGO microinjections were predominately excitatory in both BNST and 
accumbens shell. In BNST, Fos expression increased by five times relative to control 
tissue in a small, intense excitatory plume near the microinjection center (radius = 
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0.11mm). In a larger, intermediate zone of excitation, DAMGO tripled Fos expression 
(0.25mm), and an even larger zone of low excitation displayed double the Fos expression 
of control tissue (0.35mm). Assuming that these plumes are roughly spherical, the inner, 







. The estimated total volume of BNST is approximately 3mm
3
 
(~2mm rostro-caudal, 0.4 to 1.2mm medio-lateral, and 0.6 to 2mm dorso-ventral), 
meaning that the outer plume for the 0.1ug dose filled only about 12% of the BNST’s 
total volume. The small, more intense inner plume filled only 4% of BNST. 
In accumbens shell, DAMGO caused a similar pattern of intense (0.07mm), 
moderate (0.26mm), and low (0.43mm) Fos plumes. The Fos plumes for the accumbens 
shell were not significantly different in size from those in BNST [main effect of 
placement, interaction of placement x plume intensity level: all F’s <1.7, n.s.]. Assuming 







 for these intense, moderate, and low accumbens shell plumes, respectively. 
The total volume of the medial shell of the nucleus accumbens has been previously 
estimated at ~2.87 mm
3 
(Pecina & Berridge, 2005), meaning that the intense inner plume 
would fill less than 1% of the total medial shell volume. Even the larger outer plume 
would occupy only ~12% of the medial shell volume, indicating that the functional 
spread of our microinjections was likely limited to our target structure.  
It is worth noting briefly that the absolute Fos expression we observed in 
accumbens shell was less than the levels previously reported using a comparable dose, 
volume, and rate of infusion (Pecina & Berridge, 2005; K. S. Smith & Berridge, 2007). 
The primary difference between the methods used in those papers and the current 
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experiment is the method of Fos visualization (nickel diaminobenzidine glucose 
oxidation vs. immunofluorescence), indicating possible differences in sensitivity across 
the two methods. However, the overall structure and pattern of the Fos plumes observed 
here is consistent with prior reports. 
 
Classification of prepotent CS preference 
 Each rat developed a preference for one of the two available reward cues (CS+ 
lever or CSCup), which they approached and attempted to consume much more than their 
non-prepotent cue [comparison of total prepotent vs. non-prepotent behaviors: BNST 
during training, days 4-6, t(18)=6.3, p=0.001; accumbens shell during training days 4-6: 
t(38)=10.3, p=0.001; BNST after training, t(14)=8.3, p=0.001; accumbens shell after 
training, t(21)=6.5, p=0.001] or other stimuli in the chamber. For rats tested during 
learning, the prepotent cue was approached and consumed on average 3x more than the 
non-prepotent cue during the CS+ period during days 4-6 of testing; for rats tested after 
learning, the prepotent cue was preferred to the non-propotent cue by nearly 5x. 
Individual rats in both during training and post-training experiments preferred either the 
CS+ lever (~35% for BNST, ~45% for accumbens shell) or the CSCup (~65% for BNST, 
~55% for accumbens shell). 
 We replicated previously published data showing markedly different patterns of 
behavior between CS+ lever (also called sign-tracking) and CSCup preferring (also called 
goal-tracking) animals in their latency to approach each CS, probability of approaching 
each CS, and number of responses emitted at each CS (Boakes, 1977; Flagel et al., 2009; 
Flagel, Watson, Akil, & Robinson, 2008; Flagel et al., 2007). However, these two 
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behavioral phenotypes did not differ significantly in the amount of prepotent cue 
approaches and interactions [no effect of prepotent cue on total CS+ period prepotent cue 
behaviors: BNST during training, days 4-6, F(1,15)=0.1, n.s.; accumbens shell during 
training, days 4-6, F(1,35)=0.5, n.s.; BNST after training, F(1,9)=0.2, n.s.; accumbens 
shell after training, F(1,14)=0.2, n.s.]. So although CS+ lever and CSCup animals directed 
their behaviors during the CS+ period at different targets, both phenotypes emitted 
similar numbers of motivated behaviors at their chosen prepotent cue. 
 
Accumbens shell microinjections 
DAMGO in accumbens shell enhances and broadens incentive salience 
DAMGO after autoshaping training. When microinjected into accumbens shell after 
learning the autoshaping task, DAMGO broadened the attribution of incentive salience to 
each animal’s non-prepotent cue.  Behavioral “looks” (defined as orientations of the head 
toward a CS where the nose was within ~3cm of the CS but no physical contact with the 
CS was made) at the non-prepotent cue were elevated to ~150% of vehicle levels 
[interaction of cue period x drug: F(1,20)=4.7, p=0.039], indicating an increase in the 
incentive salience of the non-prepotent cue (Figure 2). The presence of this effect after 
autoshaping training was complete suggests that it is not simply the result of altered 
learning about the non-prepotent cue during training, and at least in part due to changes in 
the dynamic attribution of incentive salience after training. 
 Additionally, we also found that when DAMGO was microinjected into 
accumbens shell after learning the autoshaping task, ’wanting’ of the prepotent cue was 
also enhanced, as evidenced by an increase in prepotent cue slow bites during the CS+ 
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period (due to a camera malfunction, slow bites could not be scored for one CSCup 
animal). Slow bites were increased by up to 270% above vehicle levels within the same 
animal (average increase = 130%) [t(20)=2.4, p=0.029] and this effect was consistent 
across both behavioral phenotypes [interaction of drug x cue preference: F<1, n.s.] 
(Figure 2). As terminal slow bites increased and began to occur earlier in the 8 sec CS+ 
period, there was an accompanying slight decrease in prepotent cue nibbles and sniffs to 
87% of vehicle levels [interaction of cue period x drug: F(1,20)=5.7, p=0.027]. 
 Although rats ‘looked’ at their non-preferred cue during CS+ more after DAMGO 
in accumbens shell, they did not approach the non-preferred cue more  [main effect of 
drug, interaction of cue * drug: all F’s < 3.7, n.s.], possibly due to their increased slow 
bites on the preferred cue, which might compete with non-prepotent responding during 
the 8-sec CS+ period. In support of this possibility, slow bites are the longest duration 
cue interaction that we observed during autoshaping, and so an increase in that category 
of behavior would by necessity diminish the amount of time available to emit other 
behaviors, either at the prepotent or non-prepotent cue. 
 
DAMGO during autoshaping training. When administered throughout training, DAMGO 
microinjections into accumbens shell broadened the attribution of incentive salience, 
which spilled over into the non-preferred cue. DAMGO elevated the number of appetitive 
and consummatory behaviors that rats directed at their non-prepotent cue, while 
preserving high levels of behaviors directed toward preferred-cue. In both behavioral 
phenotypes, looks at the non-prepotent cue increased by over 300% for all subjects over 
all 6 days of testing [F(1,34)=5.6, p=0.024] (Figure 3). Total hand-scored behaviors 
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emitted at the non-prepotent cue (looks + nibbles/sniffs + slow bites) were increased to 
over 175% of vehicle levels [F(1,34)=7.5, p=0.010]. These measures suggest a direct 
enhancement of the motivational magnet quality of the non-prepotent cue, which became 
more attractive and ‘wanted’ during the CS+ period following opioid stimulation of 
medial accumbens shell. 
The broadening of ‘wanting’ was particularly strong for rats that initially 
preferred the CS+ lever. Most prominently, CS+ lever prepotent rats showed a 
significantly increased probability of approaching both reward cues (CS+ lever and 
CSCup) during a CS+ presentation [days 4-6 of testing: F(1,17)=6.0, p=0.026] (Figure 3). 
CS+ lever rats also showed an increased probability of approaching the non-propotent 
cue [days 4-6 of testing: F(1,17)=5.6, p=0.031]. Additionally, looks at the CSCup were 
increased by an average of ~330% [F(1,17)=12.1, p=0.003] across all 6 days of testing. 
CS+ lever preferring animals also showed enhanced behavioral interactions with their 
non-prepotent cue. Total nibbles/sniffs + slow bites of the CSCup across all 6 days 
increased by ~240% after DAMGO [F(1,17)=6.1, p=0.025]. Computer-scored entries into 
the food cup increased to 240% of vehicle levels during the CS+ period during days 4-6 
for CS+ lever preferring animals [F(1,17)=4.9, p=0.041]. This enhancement of food cup 
entries spilled over into intervening non-CS+ periods, where entries increased to 208% of 
vehicle levels [F(1,17)=4.5, p=0.049], perhaps as a result of the unavailability of these 
animal’s prepotent CS (the CS+ lever which was retracted in the ITI).  
Rats preferring the CSCup also displayed an increase (~400% relative to vehicle) in 
total interactions with non-prepotent cues over all 6 days of testing [F(1,17)=5.5, 
p=0.032], but did not show increased probability of approaching the non-prepotent cue 
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[main effect of drug on non-propotent approach and both approach: F’s<1.9, n.s.]. The 
latter finding is perhaps due to the significantly lower frequency of non-prepotent cue 
nibble/sniffs and slow bites in CSCup subjects [main effect of prepotent cue preference on 
prepotent cue interactions: F(1,34)=12.0, p=0.001], which were used as the criteria for 
scoring whether a cue was approached. 
 CSCup rats also showed a decrease in time spent in the food cup both during the 
CS+ period [F(1,17)=8.9, p=0.008] and also during the inter-trial intervals [F(1,17)=15.8, 
p=0.001] across all 6 days of testing, but no reduction in the total number of entries 
during either of these periods [main effect of drug on CS+ and non-CS+ food cup entries: 
F’s <1, n.s.]. This indicates that CSCup rats microinjected with DAMGO were interacting 
more rapidly with their prepotent cue, which perhaps explains how these rats could 
increase their levels of non-prepotent cue behavior while still maintaining levels of 
prepotent cue behavior comparable to vehicle in spite of the constraints of an 8-sec CS+ 
period. 
When DAMGO was administered during autoshaping training, we did not 
observe enhancements of prepotent cue behavior in either behavioral phenotype. It is 
unknown why we did not observe a potentiation of prepotent slow bites, as found when 
DAMGO was administered after training. One possible explanation is that the 
potentiation of prepotent slow bites may be uniquely linked to acute, rather than chronic, 
!-opioid activation. If so, the failure to observe increased slow bites may simply be the 
product of their relative rarity during the early days of learning the autoshaping task. 
Additionally, it is worth noting that, due to the brevity of the autoshaping CS+ period, a 
potentiation of both prepotent and non-prepotent cue behavior would extremely difficult 
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to observe. It may be, then, that the especially robust broadening of ‘wanting’ that we 
observed when DAMGO was administered in accumbens shell during testing precluded a 
simultaneous increase in prepotent cue behaviors. 
 
DAMGO in accumbens shell increases the conditioned reinforcement value of a reward 
CS 
Instrumental conditioned reinforcement after expression. In rats that received 
microinjections after training (within subjects design), subjects again registered at least 
twice as many entries into the active nose port that delivered a brief CS+ presentation 
[F(1,20)=46.3, p=0.001], and DAMGO specifically enhanced entries into the active nose 
port to 250% of vehicle levels, without significantly increasing entries into the other port 
[no main effect of drug; interaction of nose port x drug:  F(1,20)=4.5, p=0.047] (Figure 
4). There was also a significant main effect of prepotent cue preference across both nose 
ports [F(1,20)=23.1, p=0.001], driven by higher responding in general by the CS+ lever 
prepotent animals Yet the effect of DAMGO on the conditioned reinforcement value of 
the CS+ was identical across prepotent cue preference [interaction of drug * prepotent 
cue, and drug * prepotent cue * nose port: all F’s<1, n.s.], indicating that opioid 
stimulation in both CS+ lever and CSCup animals can enhance the conditioned 
reinforcement value of the compound CS+. DAMGO did not alter the number of 
computer-recorded presses on the CS+ lever during its brief presentations in either 
prepotent cue phenotype [t’s<1.1, n.s.]. 
 Across both behavioral phenotypes, there was a roughly 50% decay in entries into 
the conditioned reinforcement nose ports on the second day of testing [main effect of day: 
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F(1,21)=22.2, p=0.001] that was greater for the nose port yielding a brief CS+ 
presentation [interaction of day x nose port: F(1,21)=13.9, p=0.001]. This general decay 
in responding was likely the result of repeated testing under extinction conditions. 
However, there was no difference in the effect of DAMGO on responding for the 
autoshaping CS+ across the two days of testing [interaction of nose port x day of 
DAMGO treatment: F(1,19)=0.7, n.s], so data were collapsed across day. 
 
Instrumental conditioned reinforcement after acquisition. In a between subjects design, 
conducted in rats that had previously received DAMGO or vehicle microinjections 
throughout autoshaping testing, rats worked almost twice as much for a brief presentation 
of the CS+ than they did to receive no response [main effect of nose port: F(1,27)=6.8, 
p=0.014]. DAMGO elevated the total number of nose pokes to ~130% of vehicle levels 
[main effect of drug: F(1,27)=4.6, p=0.04], but this elevation was applied to both nose 
holes  [interaction of nose port x drug: F(1,27)<1.6, n.s.] (Figure 5). 
Although we found only a marginal effect of prepotent cue preference on 
conditioned reinforcement behavior [F(1,27)=3.53, p=0.071], previous research has 
indicated that CS+ lever and CSCup animals respond differently to instrumental 
conditioned reinforcement testing with the CS+ lever, when conducted after autoshaping 
training (Robinson & Flagel, 2008). When analyzed separately, CS+ lever prepotent rats 
showed a similar preference for the active nose port that earned the CS+ lever stimulus 
[main effect of nose port: F(1,12)=12.6, p=0.004].  DAMGO caused a ~200% increase in 
nose pokes for CS+ lever [main effect of drug: F(1,12)=8.2, p=0.014], but also similar 
~200% increase for pokes in other port [interaction of nose port x drug: F<1, n.s.] and no 
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increase in CS+ lever presses [t(12)=0.7, n.s.].  CSCup prepotent animals, conversely, did 
not display a preference for the active nose port, to begin with and were unaffected by 
DAMGO treatment [main effects of drug and nose port, interaction of nose port x drug: 
all F’s<1.7, n.s.]. CSCup animals also showed no change in pressing the CS+ lever during 
its brief extension [t(15)=0.6, n.s.].  
However, it should be noted that there were marked inadvertent imbalances in the 
numbers of aninmal within DAMGO vs. vehicle treated groups within each of the CS+ 
lever (2 DAMGO vs. 12 vehicle) and CSCup phenotypes (15 DAMGO vs. 2 vehicle). Of 
the two sub-groups with the largest n’s (CS+ lever prepotent animals receiving vehicle, 
n=12, and CSCup prepotent animals receiving DAMGO, n=15), both showed greater than 
2:1 preferences for the active nose port [t’s > 3.5, p<0.1]. This is consistent with prior 
reports of effective conditioned reinforcement of the autoshaping CS+ for CS+ lever 
animals (Robinson & Flagel, 2008), but we extend this finding to show that an 
autoshaping CS+ is also an effective conditioned reinforcer for CSCup animals who have 
received DAMGO in accumbens shell. The effectiveness of the autoshaping CS+ as a 
conditioned reinforcer for CSCup animals receiving DAMGO suggests a possible broad 
enhancement of incentive salience (similar to that observed in autoshaping testing), as 
these animals worked significantly more for a brief presentation of the autoshaping CS+ 
even though they did not prefer this cue during prior testing. 
 
BNST Microinjections 
DAMGO in BNST diffuses and disrupts incentive salience 
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DAMGO after autoshaping training. Administering DAMGO in BNST after autoshaping 
caused an increase in approaches and consummatory behavior toward cup and CS lever, 
but primarily outside the CS+ period.  However, during the CS+ period DAMGO in 
BNST actually suppressed approaches and consummatory behaviors of CSs, possibly 
because of a weaking of incentive motivation as ‘wanting’ diffused outside of the CS+ 
period. 
During the non-CS+ period, food cup entries were increased in both behavioral 
phenotypes, reaching 175% of levels observed in the vehicle test day [F(1,13)=6.4, 
p=0.025] (Figure 6). Additionally, all rats showed a nearly 150% increase in prepotent 
cue nibbles and sniffs during the 8 seconds immediately prior to sampled CS+ periods 
[interaction of cue period x drug: F(1,9)=8.5, p=0.017; pre-CS+ period: t(14)=2.8, 
p=0.016]. For CSCup animals, DAMGO elevated prepotent nibbles and sniffs of the 
autoshaping CSCup.  For CS+ lever animals DAMGO in BNST caused an increase in  
sniffing during the ITI of the recessed opening where the CS+ lever resided. These 
measures of enhanced appetitive responding for CS cup in all animals and for CS+ lever 
in rats that preferred it outside the appropriate CS+ window indicate that opioid 
stimulation in BNST facilitates a diffusion of ‘wanting’ for the CSCup outside of the CS+ 
period and sometimes outside of the prepotent CS.  
Interestingly, appetitive and consummatory behaviors were slightly diminished by 
BNST DAMGO toward the prepotent reward CS during the 8-sec CS+ window. 
Prepotent cue nibbles and sniffs during the CS+ period were reduced to 76% of vehicle 
levels [interaction of cue period x drug: F(1,9)=8.5, p=0.017; during CS+ period: 
t(14)=2.2, p=0.042] (Figure 6). This reduction in responding also extended to the non-
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prepotent cue, where behaviors during the CS+ were reduced to 70% of vehicle levels 
[during CS+ period: t(14)=2.2, p=0.049].  
However, it is important to note that DAMGO in BNST did not suppress 
responding during the CS+ period so far as to equalize the motivational magnet quality of 
an animal’s prepotent CS throughout the test session. The rate of appetitive responding 
during the ITI was still markedly lower than during the presentation of the CS+ [main 
effect of cue period on prepotent nibbles and sniffs, prepotent slow bites, prepotent total 
interactions, and probability of approaching prepotent cue: all F’s >37, p=0.001], 
showing that DAMGO was not preventing subjects from detecting the CS+ or showing 
enhanced cue-triggered motivation. Additionally, latency to approach the prepotent cue 
was not changed for either CSCup [t(12)=0.7, n.s.] or CS+ lever animals [t(1)=0.04, n.s.], 
indicating that rats were in proximity to their prepotent cue for similar amounts of time 
yet displayed a less vigorous appetitive response. The latency and probability of approach 
data also suggests that DAMGO-treated rats were not averse to the reward CS’s, as they 
still approached them at similar rates and probabilities. 
 Diminished prepotent cue responding during the CS+ period could simply mean 
that DAMGO was a generally disruptive of locomotor activity, rather than specifically 
affecting appetitive motivation or incentive salience. However, as previously noted, intra-
BNST DAMGO actually enhanced prepotent cue behaviors during the ITI. This suggests 
that intra-BNST DAMGO was not suppressing locomotor responding, but can instead 
disrupting and diffusing the attribution of incentive salience into moments when it would 
not normally be enhanced (due to absence of cue). This is especially clear in the CSCup 
animals, where DAMGO disrupted the selectivity of food cup entries (calculated as [CS+ 
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period entries into the food cup]/[sum of food cup entries in CS+ and non-CS+ periods]), 
reducing selectivity from 0.28 during vehicle treatment to 0.17 after DAMGO 
microinjection [F(1,12)=30.3, p=0.001]. In the two available CS+ lever prepotent 
animals, one showed a sharp decrease in CS+ lever selectivity from 0.98 during vehicle 
treatment to 0.50 during DAMGO treatment (calculated as [CS+ lever presses]/[sum of 
CS+ lever and control lever presses], while the other showed a modest increase in 
selectivity from 0.86 to 0.97. 
 We note that the distribution of CSCup vs. CS+ lever animals was inadvertently 
imbalanced in our group of BNST animals (CSCup n=13; CS+ lever n=2), and so our 
conclusions here are most robust for CSCup animals. However, it is notable that both of 
the BNST CS+ lever prepotent animals showed a reduction in prepotent cue nibbles and 
sniffs during the CS+ period after microinjection of DAMGO (one animal dropped from 
4.6 to 2.2, the other from 3.4 to 2.0). Future studies with a larger number of CS+ lever 
animals will be required to fully confirm that the effect of intra-BNST DAMGO is 
consistent across behavioral phenotypes. 
 In summary, BNST !-opioid stimulation caused a moderate, but not complete, 
disruption of incentive salience during the CS+ period that resulted in diminished 
prepotent and non-prepotent appetitive responding, while at the same time leading to 
diffusion of incentive salience outside the appropriate CS+ window, resulting in 
increased inappropriate prepotent cue responding during the ITI. 
 
DAMGO during autoshaping training. DAMGO in BNST, when administered 
throughout autoshaping training, again increased appetitive and consummatory responses 
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to the cup outside the CS+ period, possibly spilling elevation of incentive salience into 
non-CS+ moments and disrupting the normal requirement of synergy (brain limbic 
activation X cue presence) for enhancement of ‘wanting’. 
 DAMGO in BNST caused a substantial increase in non-CS+ period entries into 
the food cup, which rose to ~140% above vehicle levels across all six days of testing for 
both behavioral phenotypes [main effect of drug: F(1,15)=7.4, p=0.016; main effect of 
prepotent cue and interaction of drug*prepotent cue preference: F<1.8, n.s.] (Figure 7). It 
would be of interest in future studies to investigate the time course of these non-CS+ food 
cup entries to clarify whether the effect is due to a slower decay of the motivational 
magnet qualities of the food cup after CS+ termination (in which case the increase in 
non-CS+ entries should cluster shortly after CS+ offset), to a steady growth of the 
incentive salience of the food cup as the time since the last CS+ period increases (non-
CS+ entries cluster shortly before CS+ onset), or whether the attractiveness of the food 
cup is enhanced uniformly throughout the non-CS+ period. 
 Interestingly, DAMGO microinjection in BNST throughout autoshaping testing 
increased looks at the prepotent cue during the CS+ period for both behavioral 
phenotypes by an average of over 200% above vehicle levels across the first 3 days of 
testing [F(1,15)=9.5, p=0.008]. This suggests that some increases in appropriately timed 
incentive salience for reward cues may accompany the inappropriate enhancements 
observed here during the non-CS+ periods. 
 
DAMGO in BNST does not affect the conditioned reinforcement value of a reward 
CS 
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Instrumental conditioned reinforcement after expression. As in accumbens shell, when 
conditioned reinforcement was conducted within subjects over the 2 days following 
autoshaping testing, responding in both nose ports was reduced [main effect of day: 
F(1,7)=6.8, p=0.035] with an greater absolute reduction in active nose port entries 
[interaction of nose port x day: F(1,7)=9.4, p=0.018], though a similar relative reduction 
of ~50% across both the active and inactive ports. Again, though, there was no impact of 
the day on DAMGO treatment [interaction of nose port x day of DAMGO treatment: 
F<1.1, n.s.], so data were collapsed across days. It should also be noted that, due to 
illness during the extended test schedule, only 9 rats with BNST placement completed 
both days of conditioned reinforcement testing, all of which were CSCup prepotent 
animals. 
 The autoshaping CS+ was an effective conditioned reinforcer for CSCup animals, 
with entries in the active nose port outnumbering inactive nose port entries by 2:1 
[F(1,8)=6.9,p=0.030] (Figure 8). However, intra-BNST DAMGO did not affect the 
conditioned reinforcement value of the CS+ [main effect of drug, interaction of drug x 
nose port: both F’s <1, n.s.]. CSCup animals recorded a very low number of lever presses 
during the brief CS+ presentation (~1 lever press per 40 minute test session), and the 
level of lever pressing was unaffected by DAMGO treatment [t(8)=0.5, n.s.] 
 
Instrumental conditioned reinforcement after acquisition. A subset of BNST animals 
(total n=10, CS+ lever prepotent n=7, CSCup prepotent n=3) were tested for conditioned 
reinforcement value of the autoshaping CS+ after receiving microinjections throughout 
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autoshaping testing. Due to the small number of CSCup subjects tested in this between 
subjects design, these animals were not statistically analyzed. 
 The autoshaping CS+ served as an effective reinforcer for the CS+ lever animals 
tested, with the active nose port preferred over the inactive nose port by nearly 4:1 
[F(1,5)=16.5, p=0.01]. However, DAMGO in BNST had no effect on this preference 
[main effect of drug, interaction of nose port x drug: all F’s < 1.2, n.s.] (Figure 8). 
DAMGO in BNST did, however, approach a marginal suppression of the number of lever 
presses during the brief CS+ presentation, which were reduced to 22% of vehicle levels 
[t(5)=2.0, p=0.103] (Figure 9). 
 
Food UCS consumption is enhanced by DAMGO in both accumbens shell and 
BNST  
 Rats who received DAMGO or vehicle after autoshaping training also received 
separate testing for voluntary intake of a UCS food reward (rats that received 
microinjections during testing were not subjected to food intake testing due to the large 
number of microinjections administered during autoshaping). This testing occurred after 
both autoshaping and conditioned reinforcement testing was complete. A total of 26 
animals were tested for voluntary intake (BNST n=6, all CSCup; accumbens shell n=20, 
CS+ lever=13, CSCup=7). 
In accumbens shell, DAMGO microinjection nearly tripled each of the total 
amount of chow consumed [F(1,18)=78.3, p=0.001], total duration of eating 
[F(1,22)=15.7, p=0.01], and total number of feeding bouts [F(1,22)=14.0, p=0.001] 
(Figure 10). This feeding effect was greater in CS+ lever preferring animals [interaction 
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of prepotent cue x food intake in grams, feeding time, and feeding bouts: all F’s > 11.7, 
p<0.01].  
In BNST, DAMGO similarly enhanced both total chow intake [F(1,5)=23.7, 
p=0.005] as well as total duration of eating [F(1,5)=7.9, p=0.037] to roughly three times 
vehicle levels (Figure 11). The magnitude of feeding effects was comparable across 
BNST and accumbens shell [interaction of drug*placement on food intake in grams, 
feeding time, feeding bouts: all F values <3.2, n.s.].  
Drinking behavior was unaffected by DAMGO microinjection in either 
accumbens shell or BNST (drinking bouts and drinking time: t test values <1.6, n.s.), 
indicating that the increase in UCS ‘wanting’ was specific to the available food reward. 
 
Other behavioral effects of DAMGO in accumbens shell  
Sleep, grooming, and locomotion. Several additional behavioral changes were observed 
during food intake testing following microinjection of DAMGO into accumbens shell. 
The amount of time spent sleeping decreased from ~3 mins under vehicle conditions to 
~0.5 mins [F(1,22)=5.3, p=0.031]. DAMGO also halved the number of observed 
grooming bouts [F(1,22)=14.6, p=0.001]. Conversely, accumbens shell DAMGO 
enhanced more general measures of locomotor activity, roughly doubling both the 
number of cages crosses [F(1,22)=11.9, p=0.002] and rears [F(1,22)=13.2, p=0.001] 
during food intake testing. 
Defensive treading behavior. Defensive treading behavior was observed in 40% of rats 
after accumbens shell DAMGO, and was significantly elevated relative to vehicle 
controls [F(1,22)=4.9, p=0.038]. This treading was light to moderate in intensity – much 
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lower than the treading induced by either DNQX or muscimol in accumbens shell 
(Reynolds & Berridge, 2002, 2008) or by muscimol in BNST (see chapter 2) – and 
directed mainly at the corners and walls of the food intake chamber. Notably, DAMGO 
still increased feeding [food intake in grams, t(7)=4.3, p=0.004; feeding bouts, t(7)=2.6, 
p=0.034] in this sub-set of animals who displayed treading behavior. In fact, several 




Accumbens shell. Microinjection sites in accumbens shell were classified according to 
their position along rostro-caudal and dorso-ventral axes according to previously 
published criteria (Faure et al., 2008; Mahler, Smith, & Berridge, 2007; Pecina & 
Berridge, 2005). For the rostro-caudal axis, a dividing line was placed at 1.4mm anterior 
to bregma, with placement anterior to this line classified as rostral (during training=13; 
after training=16) and placements posterior to this line classified as caudal (during 
training= 7; after training=6). For the dorso-ventral axis, the dividing line was placed at 
7.4mm below skull surface, with microinjection sites above this line classified as dorsal 
(during training=8; after training=13) and sites below this line classified as ventral 
(during training=12; after training=9). 
 Although we observed slight trends towards increased feeding at more ventral 
sties in accumbens shell, none of these effects reached statistical significance [all F’s < 
2.8, n.s.]. For autoshaping and conditioned reinforcement testing, we also did not find 
any significant anatomical variance in the observed enhancement of ‘wanting.’ 
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BNST. Microinjection sites in BNST were classified according to their position along the 
rostro-caudal, medial-lateral, and dorso-ventral axes (see Chapter 2 for details). 
For placements in BNST, there were no significant anatomical effects or gradients 
when microinjections were administered throughout autoshaping training, either on 
autoshaping or on subsequent conditioned reinforcement testing. When microinjections 
were administered after autoshaping training, the inhibitory effect of DAMGO on 
prepotent cue behaviors during the CS+ period was marginally stronger at ventral BNST 
sites [t(13)=1.9, p=0.078]. This may help explain why we observed significant disruption 
of prepotent cue behaviors after intra-BNST DAMGO only in the group that received 
microinjections after training (n=15, 80% ventral BNST placements) and not in the group 
that received intra-BNST DAMGO throughout testing (n=11, 27% ventral BNST 
placements). There was no significant anatomical effect on subsequent conditioned 
reinforcement testing in animals receiving microinjections after training. 
Finally, no significant anatomical gradients were observed in BNST for food 
intake testing following autoshaping testing. This is consistent with our previous food 
intake testing in BNST using DAMGO (see Chapter 2). 
 
Discussion 
Here we compared the effect of !-opioid stimulation in the shell of the nucleus 
accumbens and BNST on two measures of incentive salience ‘wanting’: autoshaping and 
conditioned reinforcement. As predicted, opioid stimulation of accumbens shell both 
broadened and enhanced incentive salience ‘wanting’ for reward CS’s, increasing 
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approach and interaction with each animal’s non-prepotent cue during autoshaping and 
increasing the reinforcement value of the autoshaping CS+ in subsequent conditioned 
reinforcement testing. In contrast, opioid stimulation in BNST diffusely enhanced 
approaches to cup and looks at preferred CS outside the temporal appearance of CS+, and 
robustly enhanced intake of food UCS itself, but if anything disrupted the focused 
‘wanting’ to the most preferred reward CS’s during autoshaping testing, and had little 
impact on responding during conditioned reinforcement. These studies afford an 
interesting comparison of the role of ventral striatal vs. extended amygdala opioid 
transmission in modulating the value of reward CS’s.   
A potential metaphor to assist in describing these varied effects is to imagine the 
attribution of incentive salience as similar to the beam of a flashlight. Under vehicle 
conditions, the beam is directed primarily at an animal’s prepotent cue (once learning is 
complete) and turned on predominately during the CS+ period, with only weak and 
sporadic illumination in non-CS+ periods. After opioid stimulation in accumbens shell, 
the flashlight beam is broadened to more brightly illuminates the non-prepotent cue 
during CS+ periods and in some cases the illumination is intensified at the beams center, 
resulting in increased prepotent cue slow bites. In CeA, opioid stimulation causes an 
intensification, but not broadening, of the beam, resulting in a focused enhancement of 
prepotent cue ‘wanting’ (Mahler & Berridge, 2009). In BNST, !-opioid stimulation 
appears to illuminate the flashlight beam outside the CS+ period, when it would normally 
be turned off, and perhaps as a result of this temporally redistributed intensity the beam 
fails to burn quite as brightly during the CS+ period. These effects produce three unique 
patterns of behavior, and present a striking contrast to the relative homogeneity of opioid 
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activity in ventral forebrain in other reward-related behaviors, such as feeding (Bakshi & 
Kelley, 1993a; Gosnell, 1988; Mahler & Berridge, 2009; Na, 2008; Zhang & Kelley, 
2000).  
 
Broadening and enhancement of ‘wanting’ with accumbens shell opioids 
 Opioid stimulation in accumbens shell has previously been shown to increase the 
hedonic impact, or ‘liking’, of pleasant food rewards like a sweet sucrose solution 
(Kelley et al., 2002; Pecina & Berridge, 2000, 2005; Pecina, Smith et al., 2006; K. S. 
Smith & Berridge, 2007) and also to increase ‘wanting’ for UCS food rewards (Bakshi & 
Kelley, 1993b; Zhang & Kelley, 2000), possibly as a result of increased ‘liking.’ Here we 
show that accumbens shell opioid stimulation can also directly enhance ‘wanting’ for 
Pavlovian CS’s that predict a food reward. Our findings in autoshaping and conditioned 
reinforcement, together with the finding that intra-accumbens (both core and shell) opioid 
stimulation can also increase PIT for a food UCS (Pecina & Berridge, In Preparation), 
demonstrate that accumbens shell opioids can generate enhancements of ‘wanting’ in at 
least three separate behavioral tests of incentive salience (Berridge & Robinson, 2003). 
 In autoshaping, DAMGO in accumbens shell generated a broad enhancement of 
incentive salience that elevated non-prepotent cue responding. Opioid stimulation 
produced enhanced looks at their non-prepotent cue and also increased approach and 
interaction with the non-prepotent cue. This motivational broadening stands in contrast to 
the effects of intra-CeA DAMGO, which selectively increased responding only towards a 
subject’s prepotent reward CS during an identical autoshaping test (Mahler & Berridge, 
2009). This suggests divergent roles for CeA and accumbens shell in the attribution of 
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incentive salience: whereas opioid stimulation in CeA resulted in a ‘winner take all’ 
situation in which additional ‘wanting’ was exclusively directed at an animal’s previously 
learned prepotent CS, accumbens shell opioid stimulation appeared to elevate ‘wanting’ 
for any and all available reward CS’s, similar to a ‘rising tide that floats all boats.’ 
 The broadening and enhancement of ‘wanting’ following opioid stimulation in 
accumbens shell is also support by our finding that DAMGO microinjection increased the 
reinforcement value of the autoshaping CS+ during post-autoshaping conditioned 
reinforcement testing. In animals that preferred the CS+ lever during autoshaping testing, 
opioid stimulation enhanced the value of the lever/light/tone CS+ that was the primary 
motivational magnet for these animals during autoshaping. In CSCup animals, intra-
accumbens shell DAMGO also increased instrumental responding for the autoshaping 
CS+, even though their prepotent CS (the food magazine) was no longer available.  
Our finding replicates earlier work reporting increased conditioned reinforcement 
following intra-accumbens DAMGO across a broad ranges of doses (from 0.1ug – which 
we used here – all the way down to 0.003ug) (Phillips et al., 1994). However, 
microinjections sites in Phillips et al. (2004) study were located in either accumbens core 
or along the boundary of accumbens core and shell. As such, the current results extend 
this prior finding by showing for the first time that opioid stimulation in accumbens shell 
alone is sufficient to support enhanced conditioned reinforcement. 
 We observed increased slow bites of the prepotent cue during autoshaping when 
DAMGO was microinjected into accumbens shell. Slow bites of the prepotent CS are a 
terminal consummatory behavior that mimics the biting action during consumption of a 
UCS food reward. Opioid stimulation in CeA, which shares direct connections to 
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accumbens shell, was recently reported to enhance anticipatory nibbles and sniffs of the 
prepotent autoshaping cue, a behavior that more closely resembles the early approach and 
investigation of a food reward (Mahler & Berridge, 2009). This interesting divergence 
suggests that, in addition to the differential focused vs. broad enhancements of incentive 
salience mediated by CeA and accumbens shell opioids, respectively, opioid 
neurotransmission in these structures may enhance different phases of the prepotent cue 
appetitive response. In support of this view, El-Amamy & Holland (1990) have suggested 
that different behavioral aspects of appetitive Pavlovian conditioning (UCS-dependent 
conditioned responses vs. CS-dependent orienting responses) may be linked to difference 
neural substrates, since CeA lesions disrupted CS-orienting responses but left UCS-
dependent conditioned responses intact. Alternatively, emphasis on terminal slow bites in 
accumbens shell animals may be related to hedonic ‘liking’ enhancements that 
accompany !-opioid stimulation in medial accumbens shell (Pecina, Smith et al., 2006), 
which could conceivably make the prepotent CS take on more of the palatable properties 
of the linked UCS reward and, subsequently, generate more terminal bites. 
 
Diffusion and disruption of ‘wanting’ with BNST opioids 
 Contrary to our predictions, intra-BNST opioid stimulation did not increase 
‘wanting’ for a reward CS. Instead, DAMGO microinjection during autoshaping 
appeared to cause a diffusion of incentive salience outside of the appropriate CS+ period. 
This was seen as increased responding for reward CS’s during the intervening non-CS+ 
intervals and also reduced selectivity of prepotent cue responding during autoshaping 
testing (as measured by the proportion of total food cupe entries or CS+ lever presses that 
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occurred during CS+ period). The diffusion of incentive salience was also accompanied 
by a significant reduction in responding toward both the prepotent and non-prepotent 
cues.  
 The diffusion and disruption of ‘wanting’ following intra-BNST DAMGO is 
particularly interesting because it represents a dissociation between the effect of opioid 
stimulation in BNST and a closely related extended amygdala nuclei, the CeA, on 
behavior towards reward CS’s. Mahler & Berridge (2009) found that DAMGO (at the 
same dose used in our experiment) potently increased the motivational magnet properties 
of a reward CS during autoshaping, focusing and enhancing ‘wanting’ for each animal’s 
prepotent CS target. Thus, it appears that although ‘wanting’ for a UCS food reward is 
increased by DAMGO in both structures (Gosnell, 1988; Na, 2008), opioid stimulation 
has nearly opposite effects on appetitive behavior towards reward CS’s. CeA opioid 
stimulation creates sharper, focused peaks of CS ‘wanting’ while BNST dulls these peaks 
while slightly elevating ‘wanting’ during the intervening ITI valleys. 
Differences in the role of the BNST and CeA, in spite of their strong anatomical 
parallels, has been reported in other behavioral paradigms, including relapse of drug 
seeking and fear conditioning. For example, microinjection of the stress-related 
neuropeptides corticotropin-releasing factor (CRF) into the BNST, but not the CeA, is 
sufficient to induce relapse of cocaine seeking in rats; similarly, antagonism of CRF 
neurotransmission in BNST but not in CeA was sufficient to block relapse in cocaine 
seeking after a stressful foot shock (Erb & Stewart, 1999). Additionally, CRF 
microinjection into BNST potently reduced feeding in food-deprived rats, but had no 
effect on feeding when microinjected into CeA (Ciccocioppo et al., 2003). In fear 
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conditioning, Michael Davis and colleagues have convincingly argued for dissociation 
between the role of the BNST and CeA in mediating the potentiating effects of different 
types of aversive stimuli in an acoustic startle paradigm. Temporary lesions of the BNST 
inhibited potentiation of the startle response by long-duration, unconditioned stimuli 
(such as extended exposure to a bright lighting), but left intact startle potentiation by 
short-duration, conditioned stimuli; temporary lesions of the CeA had precisely the 
opposite effect, impairing response to short, conditioned cues but sparing potentiated 
startle to long, unconditioned cues (Walker & Davis, 1997). Davis and colleagues have 
argued that this distinction indicates a role for BNST in anxiety (a diffuse, long-duration 
and relatively unconditioned behavioral response), whereas the CeA is essential for the 
expression of focused, stimulus-specific fear (Davis, 1998; Davis & Shi, 1999; Davis et 
al., 1997a, 1997b; Walker et al., 2003).  
It is possible, based on our current findings, that CeA and BNST play similar 
roles in their involvement in appetitive motivation, with CeA focusing and enhancing 
motivation for conditioned cues in close phase-lock with CS presentation, whereas BNST 
generates a more temporally diffuse appetitive motivation that results in enhanced 
responding outside of CS+ presentation periods. That the temporal diffusion of ‘wanting’ 
during autoshaping following DAMGO is in BNST, in some cases, accompanied by 
disruption of responding during the 8-sec CS+ window may be the result of direct 
inhibition of CeA by BNST. Indeed, a recent report suggests that excitation of neurons in 
the juxtacapsular region of BNST (a sub-nucleus in the lateral division and a likely target 
of many of our manipulations) sends inhibitory projections to CeA (Francesconi et al., 
2009), which could explain the disruption in prepotent cue that we observed. This 
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interpretation is further supported by the finding that lesions of CeA (both temporary 
lesions with muscimol as well as permanent excitotoxic lesions) lead to a disruption of 
responding during the autoshaping CS+ (Gallagher et al., 1990; Holland & Gallagher, 
2003; Mahler & Berridge, 2009). However, lesions in CeA did not increase responding 
during the ITI, suggesting that the diffusion of CS ‘wanting’ into the ITI observed 
following intra-BNST opioid stimulation is not simply the result of CeA inhibition. 
In contrast to autoshaping, responding for the autoshaping CS+ during subsequent 
conditioned reinforcement testing was unaffected by intra-BNST DAMGO. This 
difference may be related to a difference in the temporal window for appropriate 
responding between autoshaping and conditioned reinforcement testing. During 
autoshaping, animals are presented with extended ITI’s (here they averaged 90-sec) 
interspersed with short, 8-sec CS+ periods. In contrast, during conditioned reinforcement 
the active nose port (which earns a brief 4-sec CS+ presentation) is available throughout 
the session, effectively eliminating the requirement that appropriate responding be phase-
locked to a limited temporal window. If, indeed, the primary effect of DAMGO in BNST 
is to blur the appropriate temporal assignment of ‘wanting,’ then these differences in the 
temporal nature of the two tasks suggests that a deficit in autoshaping is likelier than a 
deficit in conditioned reinforcement. It should be noted, however, that there is one 
behavioral measure in conditioned reinforcement that is only briefly temporally available: 
presses of the active lever during the CS+ presentations. Consistent with our 
interpretation, CS+ lever oriented animals that received DAMGO in BNST displayed 
marginally fewer lever presses during conditioned reinforcement testing than vehicle 




 It will be important to test our hypothesis of broadly enhanced incentive salience 
after accumbens shell opioid stimulation in other behavioral paradigms. A primary 
candidate would be general PIT (Corbit et al., 2001; Glasner, Overmier, & Balleine, 
2005). In this paradigm, animals are trained to associate instrumental responding on two 
or more levers with unique UCS rewards (e.g. banana flavored pellet for lever A, grape 
flavored sucrose solution for lever B, etc.), and then separately trained on the Pavlovian 
association of different cues (such as tones or lights) with the same UCS rewards used in 
instrumental training. In the critical transfer test, the Pavlovian cues are presented in the 
presence of the instrumental outcomes (though no UCS rewards are delivered). Pavlovian 
cues can normally energize instrumental responding on the lever that previously 
delivered the same UCS reward as the Pavlovian cue (Dickinson & Dawson, 1987; 
Rescorla & Solomon, 1967). However, our broadening interpretation also predicts that 
intra-accumbens shell opioid stimulation may also increase ‘wanting’ for all available 
reward cues, which could result in increased responding on all available reward-
associated levers in response to a single Pavlovian cue. 
  In BNST, it will be of interest to explore the potential role of other 
neurochemical systems within BNST on ‘wanting’ for reward CS’s. Although !-opioids 
in BNST appear to mediate diffusion of ‘wanting’, it is possible that more focused 
incentive salience might be modulated via excitatory connections with midbrain 
dopaminergic cell populations (Georges & Aston-Jones, 2001; Massi et al., 2008), or 
even by dopamine release within BNST (Carboni et al., 2000; Kash et al., 2008). 
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Additionally, it will be of interest to explore the role of other extended amygdala nuclei, 
such as the sublenticular extended amygdala (formerly caudal substantia inominata) and 
the interstitial nucleus of the anterior commissure, in incentive salience ‘wanting’ for 



































Figure 3.1. Fos plumes in BNST and accumbens shell. Target Region: 
Highlights the location of BNST and accumbens shell in coronal slices, taken 
from Paxinos & Watson (2007). Fos Sampling: An example of the radial counting 
grid. Each grid square measures 68um x 68um, with 10 squares emanating from 
each radial arm. Grid squares falling in ventricles or over white matter tracts were 
excluded from quantification and analysis. Normal: Representative image from 
uninjected, virgin tissue in BNST and accumbens shell. DAMGO (0.1ug): 
Representative plumes (relative to normal and vehicle controls) from DAMGO 








Table 3.1. Fos plume radii and estimated volumes. Mean radii (left) and 
volume (right) are listed for vehicle, BNST DAMGO (0.1!g), and accumbens 
shell DAMGO (0.1ug) conditions. Plume sizes were calculated compared to 
normal tissue alone for the vehicle condition, and compared to both normal and 

















Figure 3.2. DAMGO in accumbens shell broadens and enhances ‘wanting’ 




Figure 3.3. DAMGO in accumbens shell broadens ‘wanting’ when delivered 





Figure 3.4. DAMGO in accumbens shell increases conditioned reinforcement 
value of the autoshaping CS+. Top panel: Entries into the active and inactive 
nose ports in the same animals under vehicle and DAMGO treatment. Both 
phenotypes are combined in this graph. * indicates significant drug*nose port 
interaction, p<0.05. Bottom panel: Data split to show the separate autoshaping 
phenotypes. Note the similar patterns of behavior, but higher overall responding 
for CS+ lever animals. 
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Figure 3.5. DAMGO in accumbens shell increases instrumental responding 
during conditioned reinforcement testing. Top panel: DAMGO increased 
instrumental responding, but this was applied to both the inactive and active nose 
ports. Both phenotypes are combined here. Bottom panel: Autoshaping 
phenotypes are separated. Due to inadvertently low n’s in two conditions (CScup 
vehicle and CS+ lever DAMGO groups), separate analysis was inconclusive, but 
did indicate significant conditioned reinforcement in CScup DAMGO animals and 




Figure 3.6. DAMGO in BNST diffuses and disrupts ‘wanting’ when 






Figure 3.7. DAMGO in BNST diffuse ‘wanting’ when administered during 












Figure 3.8. Effects of BNST DAMGO on conditioned reinforcement testing. 
Top panel: Conditioned reinforcement following autoshaping expression testing. 
Only CS+ lever animals were present in this group. Bottom panel: Conditioned 
reinforcement following autoshaping acquisition testing. Only CScup animals were 





Figure 3.9. DAMGO in BNST marginally reduced presses of the CS+ lever 
during conditioned reinforcement testing. Only CS+ lever animals were 











Figure 3.10. DAMGO in accumbens shell increases feeding. Feeding time 
enhancements for 0.1ug DAMGO microinjections are mapped rat-by-rat onto a 
sagittal view of accumbens shell, showing both the within-subject change in 
feeding time relative to vehicle day (color) and the functional spread of the 
microinjection based on Fos plume data (size). Each map symbol is composed of 
three nested hexagons; the inner symbol shows the average size of intense 5x 
activation, the middle symbol shows 3x activation, and the outer symbol shows 2x 
activation. Bar graphs along the rostro-caudal and medial-lateral axes show the 
average drug effect within each 0.4mm wide region. Bar graph showing absolute 
comparison of vehicle and drug feeding time (in minutes) can be found above and 







Figure 3.11. DAMGO in BNST increases feeding. Feeding time enhancements 
for 0.1ug DAMGO microinjections are mapped rat-by-rat onto a horizontal and 
sagittal views of BNST, showing both the within-subject change in feeding time 
relative to vehicle day (color) and the functional spread of the microinjection 
based on Fos plume data (size). Each map symbol is composed of three nested 
hexagons; the inner symbol shows the average size of intense 5x activation, the 
middle symbol shows 3x activation, and the outer symbol shows 2x activation. 
Bar graphs along the rostro-caudal and medial-lateral axes show the average drug 
effect within each 0.4mm wide region. Bar graph showing absolute comparisons 
of vehicle and drug feeding time (in minutes) can be found above and to the left 












Opioid Activation in the Bed Nucleus of the Stria Terminalis Increases  
‘Wanting’ Without Enhancement of Hedonic ‘Liking’ 
 
Introduction 
 Taste signals move through cranial nerves to the nucleus of the solitary tract (NST) 
in hindbrain medulla, then to the pontine parabrachial nucleus (PBN) in rodents, and then 
diverge in forebrain into a dorsal pathway to target gustatory thalamus for thalomo-
cortical relay, and into a ventral or pathway to hypothalamus, amygdala, ventral pallidum 
and a variety of related limbic forebrain targets that include BNST (Spector & Travers, 
2005). These ascending signals to the forebrain, as well as top-down modulation of taste 
by cortex (de Araujo et al., 2003; Rolls, 2006), are of interest to the neuroscience of 
reward because they influence how the brain dynamically and adaptively merges a 
sensory stimulus and information about an organism’s current physiological or affective 
state in order to guide behavior.  
 Several sites and neurotransmitter systems in the forebrain have been shown to 
exert control over taste hedonics. The endogenous opioid system, and in particular the !-
opioid receptor, have frequently been linked to specific increases in the hedonic impact, 
or ‘liking,’ of food rewards (Berridge, 2000; Kelley et al., 2002; Pecina, Smith et al., 
2006), including the recent identification of discrete !-opioid hedonic hotspots within 
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rostro-dorsal accumbens shell and caudal ventral pallidum (Pecina & Berridge, 2000, 
2005; Pecina, Smith et al., 2006; K. S. Smith & Berridge, 2005). The accumbens and 
pallidal hotspots appear to act in a cooperative circuit to enhance ‘liking’ (K. S. Smith & 
Berridge, 2007), and may further interact with a more recently identified 
endocannabinoid hotspot that is located in the dorsal half of the medial accumbens shell, 
roughly co-localized with the opioid hotspot (Mahler et al., 2007). 
Here I address the role of the bed nucleus of the stria terminalis (BNST), another 
component of the extended amygdala, which receives direct projections from the pontine 
parabrachial nuclei (PBN) (Norgren, 1976; Spector & Travers, 2005); (Alden et al., 1994; 
Tokita, Inoue, & Boughter, 2009; Whitehead, Bergula, & Holliday, 2000), and sends 
efferent projections back to both PBN and NST, mostly from non-overlapping neuronal 
populations (Kang & Lundy, 2009). Electrophysiological studies have confirmed that 
these BNST efferents modulate firing of taste responsive neurons in both NST and PBN, 
and exert an almost exclusively inhibitory influence on cells in both brainstem regions 
(C. S. Li & Cho, 2006; D. V. Smith, Ye, & Li, 2005). The existence of such functional 
anatomical pathways suggests the hypothesis that previously observed increases in 
feeding after BNST opioid stimulation could be the result of changes in core taste 
processing. Yet it remains unclear precisely how BNST is acting to modulate gustatory 
information and which neurochemical systems are involved. 
 Within the nearby extended amygdala, the central nucleus of the amygdala (CeA) 
possesses reciprocal connections with gustatory PBN (Bernard, Alden, & Besson, 1993). 
However, although !-opioid stimulation in CeA can increase voluntary food intake and 
‘wanting’ for a reward CS (Gosnell, 1988; Mahler & Berridge, 2009), recent evidence 
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from our lab indicates that CeA opioid stimulation does not enhance ‘liking’ for a sucrose 
reward (Mahler & Berridge, 2006). In addition to highlighting the occasionally divergent 
nature of ‘wanting’ and ‘liking’, this finding also indicates a possible divergence between 
ventral-striatal-pallidal and extended amygdala opioid systems in the potentiation of 
hedonic ‘liking’. That is, perhaps activation of NAc and ventral pallidal circuits 
potentiate ‘liking’, whereas activation of extended amygdala systems may not.  However, 
so far in extended amygdala only the impact of opioid stimulation in CeA has been 
studied.   
 Here we test the prediction from the initial hypothesis that opioid and GABA 
stimulation in BNST are able to modulate primary taste reactions to experimenter infused 
oral tastants. We utilized the taste reactivity paradigm to evaluate rapid orofacial 
responses to taste stimuli (Berridge, 2000; Grill & Norgren, 1978), which avoids 
potential motivational confounds that arise when the subject is required to voluntarily 
consume the taste stimulus. We also tested whether our neurochemical manipulations 
affect subsequent voluntary food intake of both highly palatable (milk chocolate M&M’s) 
and standard (lab chow) food sources. 
 
Methods 
Subjects: A total of 8 Sprague-Dawley rats (males, 250-500g at the time of 
surgery) were used for taste reactivity and food intake testing. All animals were housed in 
pairs (~21˚C; 12hr light/dark cyle, lights on at 9am) with ad libitum access to food 
(Purina 5001 chow; Purina Mills, St. Louis, MO) and tap water. All procedures were 
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approved by the University Committee on the Use and Care of Animals at the University 
of Michigan in accordance with National Institute of Health guidelines. 
 
Surgery  
All animals were handled twice for a total of fifteen minutes prior to undergoing 
surgery. Rats were pretreated with atropine (0.04mg/kg) and then anesthetized with 
ketamine (80mg/kg) and xylazine (5mg/kg). Rats were then placed in a stereotaxic device 
and implanted with bilateral, chronic guide cannulae (23 gauge, stainless steel), 14mm in 
length, aimed so that the ventral tip would rest 2mm above the BNST (AP: -0.35 to -
0.4mm; ML: +/-1.4 to 1.6mm; DV: -4.75 to -5.3mm; incisor bar: -3.3mm [flat skull]). 
Guide cannulae were secured to the skull using four stainless steel screws and dental 
acrylic, and fitted with stainless steel stylets to prevent occlusion. 
In the same surgery, all rats were implanted with bilateral oral cannulae (PE-100 
tubing) to allow for oral infusion of liquid solutions during subsequent taste reactivity 
testing. Oral cannulae were attached to a 19-gauge needle, inserted lateral to the first 
maxillary molar, threaded behind the zygomatic arch, and emerged from the dorsal head. 
The 19-gauge needle was removed and replaced with a short section of 19-gauge 
stainless steel tubing. The pair of oral cannulae were loosely laced together with 
soldering wire and cemented to the skull screws with additional dental acrylic (Berridge, 
2000; Grill & Norgren, 1978). 
All rats were given post-operative analgesic (0.3 mg/kg buprenorphine) and 
prophylactic antibiotic (50 mg/kg chloramphenicol) immediately after surgery. Rats 
received a soft mash for 48 hours after surgery (Gerber oatmeal cereal; Michigan, USA), 
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and additional injections of antibiotic every 24 hours for at least 2 days to minimize 
infection. Rats were allowed to recover for at least 7 days before the onset of behavioral 
testing. 
 
Drugs and Microinjections 
 All drugs were dissolved and diluted to dose in artificial cerebrospinal fluid 
(aCSF; Harvard Labs, Cambridge, MA). DAMGO was prepared at 0.05!g and 0.1!g 
doses (total bilateral dose of 0.1!g and 0.2!g, respectively), while muscimol was 
prepared at a 225ng dose (total bilateral dose of 450ng). These doses were chosen based 
on previous experiments showing successful modulation of feeding (see Chapter 2). 
aCSF alone was used for vehicle microinjections. Microinjection schedules were counter-
balanced across subjects using a Latin Square design. 
 On test days, animals were gently handled as the stylets were removed. Rats then 
received bilateral microinjections (0.2!L per side, total 0.4!L bilateral volume) via 
16mm stainless steel microinjection tips (29 gauge), which extended 2mm beyond the 
ventral tip of the guide cannula. Microinjection tips were attached via PE-20 surgical 
tubing to a microinfusion pump, which delivered the infusion over the course of 60 
seconds. Microinjection tips were left in place for an additional 60 seconds after the 
infusion ended to allow for drug diffusion, after which the stylets were replaced and the 






Behavioral Taste Reactivity Tests 
Rats were habituated to the taste reactivity chamber for the 4 days immediately 
prior to the onset of taste reactivity testing. On habituation days, rats were placed in the 
taste reactivity for 30 minutes, and then moved to a food intake chamber for 60 minutes. 
On the final day of habituation, rats received a 60-sec oral infusion of distilled water in 
both oral cannulae to ensure patency. 
On test days, rats received a microinjection of vehicle, DAMGO (0.05ug or 
0.1ug), or muscimol (225ng), and then had tastant delivery tubes (PE-50 tubing attached 
to PE-10 nozzle with a short sleeve of EVA tubing to hold the delivery tube in place) 
attached to the oral cannulae immediately after the completion of drug microinjections, 
and finally the animals were placed in the taste reactivity chamber. The taste reactivity 
chamber consisted of a transparent plexiglass floor and a plexiglass cylinder (diameter 
25cm), with an angled mirror below the transparent floor to allow for recording of 
orofacial reactions via a digital camcorder. 
Rats received two oral infusions during taste reactivity testing: an infusion of a 
sweet 0.03M (1%) sucrose solution 20 minutes after drug microinjection (1mL volume 
infused over 1 minute), and an infusion of a bitter 3x10 M quinine (1mL volume infused 
over 1 minute) 10 minutes later at 30 minutes after drug microinjection. All solutions 
were diluted in distilled water, and brought to room temperature before infusion. The 
order of sucrose and quinine infusion was fixed to ensure that ‘liking’ reactions to the 
sucrose infusion were not contaminated by prior receipt of the bitter quinine solution 
(Mahler et al., 2007; Pecina & Berridge, 2005). All animals received a brief (~30 sec) 
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rinse with distilled water after each oral infusion to prevent lingering of the prior tastant 
in subsequent taste reactivity or food intake testing. 
 
Taste Reactivity Video Scoring 
Throughout the 1 minute oral infusions, rats were recorded with close-up video 
directed at the animal’s mouth. An observer blind to the experimental condition 
subsequently analyzed this video off-line to measure hedonic, neutral, and aversive 
orofacial reactions. Video was scored in slow motion (1/4 to 1/10 speed) using The 
Observer XT 8.0 (Noldus; Netherlands) and following previously described criteria 
(Berridge, 2000). Positive hedonic ‘liking’ reactions included lateral tongue protrusions 
(extensions of the tongue away from the midline accompanied by a retraction of the lip), 
rhythmic midline tongue protrusions (smaller amplitude protrusions along the midline at 
roughly 6-8 Hz), and paw licking. Aversive responses included gapes (large openings of 
the mouth creating a triangular shape), forelimb flails (rapid waving of one or both 
forelimbs), head shakes, chin rubs (contact of the chin with the bottom or walls of the 
taste reactivity chamber), and face washing (cleaning of the face with both forepaws). 
Neutral reactions that cannot be classified as purely hedonic or aversive included mouth 
movements, passive drips of the solution out of the rats mouth, and bouts of grooming. 
Lateral tongue protrusions, gapes, forelimb flails, head shakes, chin rubs, and grooming 
bouts were counted as discrete actions each time they occurred. Other actions were 
counted as continuous and scored in the following time bins: midline tongue protrusions 
(2 sec bins), paw licking (5 sec bins), face washing (5 sec bins), mouth movements (5 sec 
bins), and passive drip (5 sec bins). 
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Behavioral Food Intake Tests 
Immediately following complete of the second infusion on each day of taste 
reactivity testing, rats were placed in clear plastic cages containing a pre-measured pile of 
standard lab chow (~25g), a pre-measured pile of M&M chocolate candies (20 M&M’s, 
~17g), a water spout, and corncob bedding. Rats were habituated to the test environment 
for four days, as described above.  
 On test days, food intake was tested for 1 hour. The entire session was videotaped 
for subsequent offline analysis. When animals were removed from the test chamber after 
1 hour, the experimenter would slowly insert one hand into the test chamber (~1ft/5sec). 
The response of rats to removal from the chamber was recorded, including the presence 
of distress vocalizations, dashing escape attempts, and attempted bites of the 
experimenter (Reynolds & Berridge, 2001). 
After the test was completed, remaining chow and M&M’s (including crumbs) 
were carefully removed from the cage and weighed. Test days were always separated by 
at least 48 hours. 
 
Food Intake Video Scoring 
Video recordings of food intake test sessions were scored offline by observers 
blind to the experimental condition. The following behaviors were recorded: eating time 
(in seconds), eating bouts (triggered by interruptions of eating of more than 5 seconds), 
food sniffing, food carrying, drinking time (in seconds), drinking bouts (same criteria as 
eating bouts), grooming, cage crosses, sleeping, rearing, and defensive treading. All 
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eating measures (time, bouts, total intake, sniffs, and carries) were scored separately for 
chow and M&M’s. Treading is a natural defensive behavior emitted by rodents, and 
involves rapid forelimb strokes away from the body that push debris (e.g. dirt or bedding) 
in the direction of a threat. 
 
Histology 
After testing was completed, rats were deeply anesthetized with sodium 
pentobarbital (0.2mg/kg; Fatal-Plus) and decapitated. Brains were extracted and placed in 
a 10% paraformaldehyde solution for 24-48 hours, and then placed in a 30% sucrose 
solution for 3-5 days, until the brains sank. The brains were then sliced on a freezing 
microtome (Leica) into 60!m coronal sections, mounted onto glass slides, allowed to dry 
for at least 24 hours, and then stained with cresyl violet. Stained slices were viewed under 
light magnification and used to map the microinjection centers in each hemisphere on 
coronal sections taken from a rat brain atlas (Paxinos & Watson, 2007). 
 
Statistical analysis 
Taste reactivity data was analyzed using between subjects ANOVA followed by 
post-hoc comparisons where appropriate. Sucrose and quinine infusion data was analyzed 
separately. Due to difficulties with the oral infusions, three taste reactivity trials with the 
sucrose solution were excluded from analysis (one from 0.05ug DAMGO and two from 
muscimol). Food intake data was analyzed using a within subjects ANOVA (food type, 
drug) followed by post-hoc comparisons where appropriate. In all cases where percent 
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changes over vehicle are calculated or mapped, a fixed value of 1 was added to all data 
points to avoid division by 0. 
 
Results 
DAMGO and muscimol in BNST suppress hedonic ‘liking’ reactions to sucrose 
Microinjection of both the !-opioid agonist DAMGO and the GABAA agonist 
muscimol in BNST significantly decreased the total positive hedonic responses to a sweet 
sucrose solution in half, even though DAMGO microinjections stimulated increases in 
food intake F(3,25)=3.3, p=0.037]. This decrease in total hedonic responding was driven 
primarily by a reduction in the number of rhythmic midline tongue protrusions (MTP) 
[main effect of drug treatment: F(3,25)=3.0, p=0.048].  
 
DAMGO suppression of hedonic reactions to sucrose 
DAMGO (0.05ug and 0.1ug) reduced  MTP by 50% [F(2,20)=3.7, p=0.042] and 
reduced total hedonic responses by 48% [F(2,20)=3.8, p=0.041] (Figure 1,2), suggesting 
that DAMGO treatment was sufficient to cause a reduction in ‘liking’ of a sucrose 
solution. Post-hoc tests indicated that both doses of DAMGO tested were equally 
effective and did not significantly differ from each other. DAMGO also appeared to 
slightly suppress hedonic lateral tongue protrusions, though this decrease did not reach 
the level of statistical significance. Hedonic paw licks were also not affected by DAMGO 
treatment. 
Analysis of DAMGO also revealed a 180% increase in rhythmic mouth 
movements [F(2,20)=4.0, p=0.035], which has been suggested to be a relatively neutral 
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component of taste reactivity (neither positive hedonic nor negative aversive) (Berridge, 
2000).  The increase in mouth movements was highest for the 0.1ug dose (p<0.02) . 
However, the overall effect of DAMGO was specific to hedonic orofacial reactions, as 
neither total aversive nor total neutral expressions were significantly altered relative to 
vehicle treatment [main effect of drug treatment: all F’s<2.0, n.s.]. This suggests that !-
opioid stimulation in BNST specifically disrupts ‘liking’ of a sweet solution, while 
leaving neutral mouth movements and low levels of aversive responding to sucrose 
relatively unaffected (Figure 3). 
 
DAMGO does not change aversive reactions to quinine 
DAMGO microinjection in BNST  did not significantly affect any of the 
measured orofacial reactions during the quinine infusion. This suggests that opioid 
simulation in BNST does not markedly alter  ‘disliking’ for an unpleasant quinine 
solution (Figure 4). 
 
Muscimol suppression of hedonic reactions to sucrose 
Muscimol potently reduced total hedonic responding to a normally pleasant 
sucrose solution (Figure 5), primarily by reducing MTP to just 25% of vehicle levels 
[both F’s>10.0, p<0.01]. By contrast, muscimol modestly elevated the total number of 
neutral responses to almost 200% of vehicle levels [F(1,14)=4.8, p=0.045].  The typically 




Muscimol in BNST may reorganize aversive responding to quinine 
 When presented with an oral infusion of a bitter quinine solution, rats typically 
emit aversive reactions: gapes, forelimb flails, headshakes, and chin rubs.  Muscimol may 
have marginally changed these aversive reactions (Figure 4). 
  Muscimol marginally alters the motor distribution of aversive components. 
Overall, muscimol did not change the total number of aversive reactions to quinine. 
However, it marginally reorganized the relative numbers of particular component 
reactions. Muscimol treatment caused a marginally significant increase of up to 3,000% 
during muscimol treatment (mean = 8.75, mean increase ~1100%). in aversive chin rubs 
[F(1,14)=3.3, p=0.090], which were rarely observed after vehicle control microinjections 
(mean = 0.75). Conversely, muscimol caused a slight decrease in aversive forelimb flails 
[F(1,14)=3.3, p=0.093]. Finally, muscimol also caused a small increase in passive 
dripping of the infusion fluid [F(1,14)=3.6, p=0.080].  
 
DAMGO increases food intake of both highly palatable M&Ms and standard chow 
pellets 
 When animals were tested for intake of a highly palatable food (milk chocolate 
M&M’s) and standard lab chow immediately after taste reactivity testing, there was a 
strong preference for intake of the highly palatable M&M’s [main effect of food type on 
intake in grams, time eating, and eating bouts: all F’s>10.9, p<0.015], with animals 
consuming on average 10 times as many grams of M&M’s than chow pellets across all 
days of testing. Rats were also more likely to carry the M&M’s to other locations within 
the cage [F(1,7)=8.6, p=0.022]. 
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 Analysis indicated significant increases during drug treatment in total feeding 
time [F(1.6, 11.5)=5.2, p=0.029], feeding bouts [F(3,21)=10.0, p=0.001], investigatory 
sniffs of the two food options [F(2.1, 15.3)=4.1, p=0.036], and carrying of the food 
pellets within the cage [F(3,21)=4.1, p=0.019]. Post hoc analyses revealed that both 
DAMGO doses increased feeding time by nearly 300% over vehicle levels (Figure 6,7), 
while simultaneously increasing the number of feeding bouts by at least 200%. As with 
earlier testing in food intake (see chapter 2), there were no significant differences 
between the two DAMGO doses tested here.  
Although we observed a significant increase in total food consumption (both 
chow and M&M’s), we were also interested in whether this increase would be specific to 
the more palatable food option, as has been suggested for opioid stimulation of nearby 
regions of ventral striatum (Zhang & Kelley, 2000). However, no significant interactions 
between drug treatment and food type were found [all F’s < 2.9, n.s.], suggesting that the 
feeding potentiation we observed in response to opioid stimulation in BNST was not 
specific to the more palatable M&M’s, but rather raised intake proportionately for both 
the M&M’s and the standard lab chow. 
  
Muscimol does not affect intake of highly palatable M&M’s 
Previously, muscimol at the dose tested here appeared to possibly disrupt the 
intake of normal lab chow (see chapter 2). Here, we found that muscimol treatment did 
not affect the total amount of food consumed [main effect of drug on food intake intake 
in grams, feeding time (Figure 8), and feeding bouts: all F’s <1, n.s.], nor did it disrupt 
the preference for the palatable M&M’s [main effect of food type on food intake intake in 
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grams, feeding time, and feeding bouts: all F’s >7.5, p<0.05; interaction of food type x 
drug for food intake intake in grams, feeding time, and feeding bouts: all F’s <1, n.s.]. 
Closer examination of case-by-base feeding data revealed that 3 out of 8 animals 
consumed more M&M’s after muscimol treatment than after vehicle (in one case the 
animal consumed all 20 M&M’s in the hour-long test period), while the other 5 animals 
ate less following muscimol treatment (in several cases eating nothing at all). These 
different patterns of behavior were not anatomically segregated.  
 
Other behavioral effects of DAMGO and muscimol 
 When analyzed together, all drug treatment groups markedly decreased sleeping 
during the food intake test, from an average of 20 mins during vehicle test days to an 
average of 3 mins or less during drug microinjection days [F(3,21)=18.6, p=0.001; post-
hoc tests for each drug condition: p<0.05]. This is consistent with findings from our 
earlier food intake experiment (chapter 2), where we found similar reductions in sleep for 
both opioid and GABA stimulation in BNST. 
 DAMGO, when analyzed separately, increased cage crosses to nearly 200% 
above vehicle levels across both doses [F(1.3,9.4)=6.4, p=0.025], though only the lower 
0.05ug dose rose to significance in post-hoc testing. An increase in locomotor behavior 
was not observed with DAMGO in our previous food intake experiment (see chapter 2). 
It is possible that the present increase was linked to the use of M&M’s as a food source, 
as rats were more likely to pick up an M&M, located in the front of the cage, and retreat 
to the back of the cage to consume it before returning to pick up another M&M. With an 
average consumption of ~8 M&M’s during DAMGO treatment sessions, this could result 
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in up to 16 cage crosses simply to retrieve and consume the M&M’s, and may not reflect 
any broad enhancement of locomotor activity. 
 Muscimol, when analyzed separately, showed a 50% reduction in rearing relative 
to vehicle controls [F(1,7)=12.1, p=0.01], but no significant changes in defensive 
treading or cage crosses [all F’s<1.5, n.s.]. However, we did record high rates of distress 
vocalizations (75%) and dashes (25%) in muscimol-treated animals upon removal from 
the food intake chamber in the present experiment; by comparison, we observed no 
distress vocalizations or dashes during any of the vehicle or DAMGO treatment sessions. 
This provides some support for our earlier hypothesis that high doses of muscimol in 
BNST generate an aversive motivational state, despite the absence of a significant 
increase in defensive treading behavior.  
Although both treading and cage crosses were elevated here relative vehicle 
controls, we did not observe the robust enhancements of both measures with muscimol in 
BNST that we previously reported (see Chapter 2). It is possible that the timeline of the 
current experiment, where animals did not enter food intake testing until roughly 30 
minutes after microinjection due to taste reactivity testing, diminished the expression of 
treading and cage crossing. 
 
Anatomical gradients  
 We found that musicmol microinjection at ventral sites in BNST (ventral to -
6.6mm below skull surface) was more effective in suppressing hedonic midline tongue 
protrusion [t(4)=4.8, p=0.008] and total hedonic responses [t(4)3.9, p=0.018]. In dorsal 
regions of BNST, muscimol moderately reduced hedonic MTP to 71% of vehicle levels. 
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However, in ventral regions, MTP was nearly abolished by muscimol treatment, with 
only 4% of vehicle levels being expressed. This indicates that muscimol at ventral sites in 
BNST is more effective at suppressing ‘liking’ for a sucrose solution than similar 
injections in dorsal BNST. 
Muscimol at ventral sites also increased the incidence of passive drip of the 
sucrose solution [t(4)=4.0, p=0.016] 
 DAMGO did not have any differential effects across the dorso-ventral gradient 
for responding to sucrose, and neither DAMGO nor muscimol microinjections had 
different anatomical effects during the infusion of quinine. 
 
Discussion 
 Here I assessed food ‘wanting’ versus ‘liking’, comparing intake effects to taste 
reactivity testing combined with drug microinjections in BNST, which receives rich taste 
input from medial regions of PBN (Alden et al., 1994). Paradoxically, I found that 
stimulation of !-opioid receptors of BNST with DAMGO decreased hedonic ‘liking’ 
reactions to a sweet sucrose solution, even though the same DAMGO microinjections 
caused increased food intake. That dissociation suggests that opioid stimulation in BNST 
can cause increased ‘wanting’ for a food reward without commensurate enhancement of 
reward ‘liking’ in the same animals, and in fact while actually suppressing ‘liking’ 
reactions. GABA-ergic inhibition with muscimol in BNST also decreased hedonic 
‘liking’ reactions to a sweet solution, and sporadically suppressed food intake. Muscimol 
in BNST also caused some animals to emit distress vocalizations and escape dashes when 
handled by experimenters, supporting our previous hypothesis that GABA-ergic 
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inhibition in BNST generates an aversive motivational state in rodents. These findings 
further clarify the role of BNST, and the greater extended amygdala macrosystem, in 
appetitive motivation. 
 
BNST opioids do not amplify hedonic ‘liking’ of a food reward 
 An increase in reward ‘liking’ was a plausible psychological mechanism that 
could have contributed to enhanced food intake following DAMGO in BNST, given the 
involvement of BNST with gustatory projections. Increasing the hedonic impact of a food 
item could make a merely palatable target like standard lab chow seem especially 
delicious, and a highly palatable item like milk chocolate almost irresistibly tasty. 
Increased ‘liking’ can feed back to cause parallel increase in reward ‘wanting’, thus 
driving increased food intake (Berridge et al., 2009; Lundy, 2008), potentially to 
maladaptive levels resulting in excessive weight gain or obsesity (Finlayson, King, & 
Blundell, 2007; Lutter & Nestler, 2009; Zheng & Berthoud, 2007). However, our results 
indicate that DAMGO in BNST is not increasing the hedonic impact of a pleasant food 
reward, and in fact actually decreased ‘liking’ for a sweet sucrose solution.  
The current findings in BNST are in dramatic opposition to the effect of !-opioid 
stimulation at a few other forebrain sites, which has frequently been shown to increase 
the hedonic impact of palatable food rewards (Barbano & Cador, 2007; Glass et al., 1999; 
Kelley et al., 2002). In a pair of recently identified hedonic hotspots in the medial shell of 
the nucleus accumbens and caudal ventral pallidum, DAMGO at doses similar to those 
used here in BNST potently increase ‘liking’ of a sweet sucrose infusion (Pecina & 
Berridge, 2005; K. S. Smith & Berridge, 2005). Our current findings for DAMGO in 
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BNST most closely resemble the effects of opioid stimulation in CeA and basolateral 
amygdala (BLA), where DAMGO stimulation also potently reduced ‘liking’ for a sucrose 
solution while simultaneously enhancing food intake in the same animals (Mahler & 
Berridge, 2006). The congruent behavioral effects of DAMGO in BNST and CeA in taste 
reactivity testing are similar to electrophysiological studies indicating that both structures 
exhibit an almost exclusively inhibitory influence on taste responsive cells in both PBN 
and NST (C. S. Li & Cho, 2006; D. V. Smith et al., 2005), suppressing firing to a range 
of taste stimuli.  
Taken together, this dissociation between the effect of !-opioid stimulation in 
BNST and CeA vs. accumbens shell and ventral pallidum may reflect a broader 
difference in the role of endogenous opioid systems in the anatomical macrosystems of 
the extended amygdala and ventral-striatal-pallidum. However, future studies will do well 
to continue probing the unique roles of nuclei within these macrosystems in taste 
processing, as they are unlikely to be fully homogeneous. For example, although BLA 
lesions dramatically impair the acquisition of condition taste aversion following lithium 
chloride illness (Yamamoto & Fujimoto, 1991), lesions of CeA and BNST have no effect 
on the development or expression of a taste aversion (Roman, Nebieridze, Sastre, & 
Reilly, 2006). 
 
BNST opioids enhance ‘wanting’ for food rewards, but do not favor palatable foods 
 Although we show that DAMGO decreased ‘liking’ of a sweet sucrose solution, 
we also observed significant enhancements of food intake, a measure of reward 
‘wanting’. The DAMGO-induced increase in feeding is consistent with our previously 
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reported study of food intake (Chapter 2). Here, we are able to go further and show 
potently increased ‘wanting’ for a food reward in the same animals that only 10 minutes 
earlier had displayed reduced ‘liking’ under the same neurochemical manipulation, 
providing a noteworthy example of the occasional dissociation between ‘liking’ and 
‘wanting’. Similar dissociations have been reported with !-opioids in CeA (Mahler & 
Berridge, 2006), and in regions of NAc shell outside the cubic-millimeter hedonic hotspot 
(Pecina & Berridge, 2005) as well as with dopamine in the nucleus accumbens (Wyvell 
& Berridge, 2000), but this is the first report of such a distinction within BNST. 
 In the current food intake test, we presented animals with two different sources of 
food: standard lab chow (which rats had ad libitum access to in their home cage 
throughout the experiement) and highly palatable chocolate candies (M&M’s). Previous 
studies have strongly implicated opioids in the preferential potentiation of palatable food 
rewards, with opioid stimulation selectively increasing and opioid blockade selectively 
decreasing palatable food intake, while leaving a simultaneously available standard food 
source unaffected (Glass et al., 1999; Zhang & Kelley, 2000). Here, we found that 
although DAMGO in BNST did increase total food intake, this increase was equivalent 
for both the standard lab chow and the highly palatable M&M’s. This suggests that 
opioid stimulation in BNST does not specifically boost intake of the most palatable food 
source available, but instead enhances feeding at all food sources proportional to the 






BNST muscimol disrupts reward ‘liking’ and reorganizes aversive motivation 
 Like DAMGO, muscimol in BNST also decreased hedonic ‘liking’ reactions to a 
sweet sucrose taste, especially in ventral regions of BNST. However, muscimol also 
resulted in frequent distress vocalizations and occasional escape dashes when animals 
were removed from food intake testing; these latter aversive behaviors were never 
observed during vehicle or DAMGO treatment. These findings slightly resemble the 
aversive effects of muscimol in nearby caudal accumbens shell and in CeA (Reynolds & 
Berridge, 2001, 2002). However, our  previous fos plume analysis suggests that our 
current microinjections remained almost entirely contained within BNST. Therefore, 
BNST is likely to be an independent forebrain site of aversive motivation following 
GABA-ergic inhibition. This is consistent with BNST’s previously identified roles in the 
aversive motivational components of drug withdrawal (Koob, 1999, 2003), as well as its 
role in unconditioned fear responses (M. Davis & Shi, 1999). 
In addition to increased aversive motivation, we previously reported that 
muscimol in BNST also appeared to reduce some measures of feeding overall, especially 
regular chow, but here we saw a wider variance for a highly palatable food, chocolate 
M&M candies (Chapter 2). We found a range of feeding outcomes after muscimol 
microinjection, ranging from complete suppression of feeding to consumption of twenty 
M&M’s within a single hour of testing. It is possible that some animals responded to the 
aversive muscimol condition with enhanced intake of the highly palatable M&M’s 
(which were not available in our previous food intake experiment) as a type of self-




 Although BNST and CeA opioids have been shown to suppress ‘liking’, it 
remains unclear what role other extended amygdala nuclei, including the sublenticular 
extended amygdala and the interstitial nucleus of the posterior limb of the anterior 
commissure, play in reward ‘liking’. Additionally, it would be of great interest to explore 
potential interactions between BNST and other brain sites that modulate reward ‘liking’, 
including CeA and accumbens shell. The opioid hedonic hotspots in accumbens shell and 
ventral pallidum appear to be jointly necessary to support enhanced ‘liking’, since opioid 
antagonism with naloxone in either hotspot can veto hedonic enhancement by !-opioid 
stimulation of the other (K. S. Smith & Berridge, 2007). Future studies could be designed 
to evaluate whether the decrease in ‘liking’ generated by DAMGO in BNST or CeA can 
be overruled by opioid stimulation of accumbens or ventral pallidum, and also whether 
suppression of ‘liking’ by opioids in extended amygdala involved concerted or 











Figure 4.1. DAMGO (0.05!g) reduces ‘liking’ for a sweet sucrose solution. 
Horizontal (top) and sagittal (bottom) maps showing within-subjects changes in 











Figure 4.2. DAMGO (0.1!g) reduces ‘liking’ for a sweet sucrose solution. 
Horizontal (top) and sagittal (bottom) maps showing within-subjects changes in 










Figure 4.3. Summary of taste reactivity responding for sucrose infusion. 
Summary of all dependents variables (top) and the sum of each valence category 
(bottom) for all drug conditions. TP=midline tongue protrusion; LTP=lateral 
tongue protrusion; PL=paw licks; G=gapes; FF=forelimb flails; HS=head shakes; 





Figure 4.4. Summary of taste reactivity responding for quinine infusion. 
Summary of all dependents variables (top) and the sum of each valence category 
(bottom) for all drug conditions. TP=midline tongue protrusion; LTP=lateral 
tongue protrusion; PL=paw licks; G=gapes; FF=forelimb flails; HS=head shakes; 






Figure 4.5. Muscimol (225ng) reduces ‘liking’ for a sweet sucrose solution. 
Horizontal (top) and sagittal (bottom) maps showing within-subjects changes in 











Figure 4.6. DAMGO in BNST increases feeding. Feeding time enhancements 
(combined M&M and chow) for 0.05ug DAMGO microinjections are mapped rat-
by-rat onto a horizontal (top) and sagittal (bottom) views of BNST, showing both 
the within-subject change in feeding time relative to vehicle day (color) and the 
functional spread of the microinjection based on Fos plume data (size). Each map 
symbol is composed of three nested hexagons; the inner symbol shows the 
average size of intense 5x activation, the middle symbol shows 3x activation, and 
the outer symbol shows 2x activation. Bar graphs along the rostro-caudal and 
medial-lateral axes show the average drug effect within each 0.4mm wide region. 
Bar graph showing absolute comparisons of vehicle and drug feeding time (in 
minutes) can be found above and to the left the horizontal anatomical map. * 




Figure 4.7. DAMGO in BNST increases feeding. Feeding time (combined 
M&M and chow) enhancements for 0.1ug DAMGO microinjections are mapped 
rat-by-rat onto a horizontal (top) and sagittal (bottom) views of BNST, showing 
both the within-subject change in feeding time relative to vehicle day (color) and 
the functional spread of the microinjection based on Fos plume data (size). Each 
map symbol is composed of three nested hexagons; the inner symbol shows the 
average size of intense 5x activation, the middle symbol shows 3x activation, and 
the outer symbol shows 2x activation. Bar graphs along the rostro-caudal and 
medial-lateral axes show the average drug effect within each 0.4mm wide region. 
Bar graph showing absolute comparisons of vehicle and drug feeding time (in 
minutes) can be found above and to the left the horizontal anatomical map. * 









Figure 4.8. Muscimol in BNST does not affect feeding. Feeding time 
(combined M&M and chow) enhancements for 225ng muscimol microinjections 
are mapped rat-by-rat onto a horizontal (top) and sagittal (bottom) views of 
BNST, showing both the within-subject change in feeding time relative to vehicle 
day (color) and the functional spread of the microinjection based on Fos plume 
data (size). Each map symbol is composed of three nested hexagons; the inner 
symbol shows the average size of intense 3x activation, the middle symbol shows 
50% inhibition, and the outer symbol shows 25% inhibition. Bar graphs along the 
rostro-caudal and medial-lateral axes show the average drug effect within each 
0.4mm wide region. Bar graph showing absolute comparisons of vehicle and drug 










Opioid Stimulation in the Bed Nucleus of the Stria Terminalis  
is Not Inherently Stressful 
 
Introduction 
 We have shown in three prior experiments that !-opioid stimulation in BNST can 
potently increase voluntary food intake of standard chow pellets (see Chapters 2 & 3) and 
also of palatable M&M’s (see Chapter 4), even in animals that are not food deprived. 
This increased feeding suggests a role for BNST in appetitive motivation, which is 
supported by the neuroanatomy of BNST. In addition to sharing reciprocal connections 
with a variety of sub-cortical sites implicated in taste and feeding, including the nucleus 
accumbens (de Olmos & Heimer, 1999), lateral hypothalamus (Alheid, 2003), and 
hindbrain taste nuclei (Alden et al., 1994; Bernard et al., 1993; C. S. Li & Cho, 2006), 
BNST also sends excitatory projections to midbrain dopaminergic centers that have been 
repeatedly implicated in appetitive motivational processes (Barbano & Cador, 2007; 
Berridge, 2007; Carlezon & Thomas, 2009; Heinz, Beck, Grusser, Grace, & Wrase, 
2009). Further, the emerging anatomical concept of the extended amygdala links BNST 
with other forebrain nuclei, most notably the medial and central nuclei of the amygdala, 
that play prominent roles in the motivation for rewards such as food (Gosnell, 1988; 
Mahler & Berridge, 2009), social behavior and sexual partners (Kirkpatrick, Carter, 
Newman, & Insel, 1994), and drugs of abuse (Fattore, Fadda, Spano, Pistis, & Fratta, 
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2008; Rezayof, Golhasani-Keshtan, Haeri-Rohani, & Zarrindast, 2007). Taken together, 
these anatomical and behavioral findings seem to suggest a role for BNST in appetitive 
motivation. 
Yet it could be questioned whether BNST truly mediates appetitive motivational 
processes.  The issue is complicated because some appetitive behaviors can also be 
stimulated by aversive or stressful stimuli.  Hedonic self-medication has sometimes been 
suggested as a mechanism for stress-induced appetitive behaviors (Kreek & Koob, 1998; 
Markou, Kosten, & Koob, 1998).  That is, individuals in a dysphoric state might consume 
a hedonic reward such as food simply in order to escape the aversive state and return to a 
neutral hedonic baseline.  Appetitive behavior motivated purely by escape from distress 
is not fully appetitive, in a positive incentive motivation sense of that term.  
The BNST is one of a number of nuclei that compose the aforementioned network 
of stress-responsive nuclei (Dallman et al., 2003). It contains a high density of CRF-
positive cell bodies (including both receptors and neurotransmitter pools) (Koob & 
Heinrichs, 1999), and receives significant CRF input from other limbic structures, 
including central amygdala (CeA) (Erb et al., 2001). BNST also contains the highest 
density of norepinephrine terminals in the forebrain (Aston-Jones et al., 1999; Aston-
Jones & Harris, 2004), and these ascending projections interact with CRF in BNST to 
modulate the hypothalamic-pituitary-adrenal (HPA) axis (Forray & Gysling, 2004). 
Interestingly, and of great relevance to motivation, a robust link exists between BNST 
CRF and brainstem dopamine: not only does BNST send CRF projections directly to 
dopaminergic cells in the ventral tegmental area (Rodaros, Caruana, Amir, & Stewart, 
2007), but ascending dopamine also enhances rapid excitatory transmission in BNST via 
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a CRF-dependent process (Kash et al., 2008). Due to the unique convergence of limbic 
inputs in BNST and its strong output channels to medial and lateral hypothalamus, some 
have argued that it serves as a critical relay between limbic brain regions and the HPA 
axis (Herman & Cullinan, 1997; Herman et al., 2005). 
 Much stress-induced behavior is ambiguous in this respect.  Rats will run for 
miles on a running wheel after exposure to stressors such as food restriction (Altemus, 
Glowa, & Murphy, 1993; Uchiumi, Aoki, Kikusui, Takeuchi, & Mori, 2008). Changes in 
food intake are known have a particularly strong link to stress (Torres & Nowson, 2007). 
Acting via a network of central and peripheral nervous system substrates, glucocorticoids 
dramatically alter feeding strategies, shifting intake towards energy dense food options 
(high in fat and calories) and causing robust increases in abdominal fat stores (Dallman, 
Warne, Foster, & Pecoraro, 2007; Warne, 2009). High energy foods, in turn, help to 
inhibit central nervous system levels of stress-related neuropeptides such as CRF, and can 
act as “comfort food” to reduce the anxiety and dysphoria associated with enduring stress 
(Dallman et al., 2003).  
On the other hand, even some ‘stress components’ can play a dual role in positive 
incentive motivation. Microinjection of the stress-related peptide corticotropin releasing 
factor (CRF) in BNST can increase drug-seeking behavior, and enhance cue-triggered 
‘wanting’ for a food conditioned stimulus when delivered in the nearby nucleus 
accumbens (Erb et al., 2001; Erb & Stewart, 1999; Pecina, Schulkin, & Berridge, 2006). 
Similarly, Dallman and colleagues have suggested that stress may activate incentive brain 
systems to promote ‘wanting’ of incentives such as food (Dallman et al., 2007).    
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 Here we test the hypothesis that !-opioid stimulation of BNST has positive 
incentive motivation qualities. We test that idea against the alternative that BNST 
activation is an inherently aversive neural manipulation, which rats would avoid if they 
could, and which subsequently stimulates feeding to ameliorate this aversive motivational 
state. In order to assess the motivational valence of our !-opioid manipulation, we will 
use the conditioned place preference paradigm. Though this testing procedure is perhaps 
best known as a broad measure of the rewarding properties of drugs and other neural 
manipulations (Bardo & Bevins, 2000), it can also be used as an effective assay of the 
aversive motivational properties of neurochemical manipulations. If !–opioid stimulation 
in BNST is indeed stressful, we predict that pairing microinjection of the !-opioid 
agonist DAMGO with a unique environmental context will result in the avoidance of that 
drug-paired environment in a subsequent drug-free test day. In contrast, if opioid 
stimulation of BNST promotes positive incentive motivation , we expect to find 
potentially a conditioned place preference.  I also compared the ability of DAMGO in 
BNST to establish a conditioned place preference or avoidance to its ability to promote 




A total of 7 Sprague-Dawley rats (females, 250-500g at the time of surgery) were 
used for conditioned place preference testing. All animals were housed in pairs (~21˚C; 
12hr light/dark cyle, lights on at 9am) with ad libitum access to food (Purina 5001 chow; 
Purina Mills, St. Louis, MO) and tap water. All procedures were approved by the 
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University Committee on the Use and Care of Animals at the University of Michigan in 
accordance with National Institute of Health guidelines. 
 
Surgery 
All animals were handled twice for a total of fifteen minutes prior to undergoing 
surgery. Rats were pretreated with atropine (0.04mg/kg) and then anesthetized with 
ketamine (80mg/kg) and xylazine (5mg/kg). Rats were then placed in a stereotaxic device 
and implanted with bilateral, chronic guide cannulae (23 gauge, stainless steel), 14mm in 
length, aimed so that the ventral tip would rest 2mm above the BNST (AP: -0.15 to -
0.45mm; ML: +/-1.6mm; DV: -4.8mm; incisor bar: -3.3mm [flat skull]). Guide cannulae 
were secured to the skull using four stainless steel screws and dental acrylic, and fitted 
with stainless steel stylets to prevent occlusion. 
All rats were given post-operative analgesic (0.3 mg/kg buprenorphine) and 
prophylactic antibiotic (50 mg/kg chloramphenicol). Rats were allowed to recover for at 
least 7 days before the onset of behavioral testing. 
 
Drugs and Microinjections 
All drugs were dissolved and diluted to dose in artificial cerebrospinal fluid 
(aCSF; Harvard Labs, Cambridge, MA). DAMGO was prepared at a 0.1!g dose (total 
bilateral dose of 0.2!g). aCSF alone was used for vehicle microinjections. Microinjection 
schedules were counter-balanced across subjects using a Latin Square design. 
 On test days, animals were gently handled as the stylets were removed. Rats then 
received bilateral microinjections (0.2!L per side, 0.4!L total bilateral volume) via 
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16mm stainless steel microinjection tips (29 gauge), which extended 2mm beyond the 
ventral tip of the guide cannula. Microinjection tips were attached via PE-20 surgical 
tubing to a microinfusion pump, which delivered the infusion over the course of 60 
seconds. Microinjection tips were left in place for an additional 60 seconds after the 
infusion ended to allow for drug diffusion, after which the stylets were replaced and the 
rat placed immediately in the conditioned place preference chamber. 
 
Conditioned Place Preference Procedure 
Apparatus: Testing was conducted using a three-chamber apparatus. Two large 
outer chambers (28 x 21 x 21 cm) were connected via a small middle “starting” chamber 
(12 x 21 x 21 cm). Each of the large outer chambers had different visual and tactile 
characteristics. One side had black walls, a wire grid floor, and was brightly illuminated 
(intensity 1,300 lux) using a Fiber-Lite MI-150 fiber optic surgical lamp (Dolan-Jenner 
Industries; Massachusetts, USA). The other side had white walls, a wire mesh floor, and 
was illuminated only by overhead lights in the testing room (intensity 550-650 lux). The 
middle chamber had solid gray walls and solid gray floor, and was only available to 
subjects on testing days. The three chambers were separated by removable divider walls, 
which remained in place on conditioning days and were removed on testing days. Each 
compartment had a clear Plexiglass lid that prevented the rats from escaping during 
conditioning and testing, but allowed an unobstructed view of the chamber to monitor the 
animal’s position. Prior to the experiment, the effectiveness of the place conditioned 
apparatus and my procedures was verified in a separate group of rats using diazepam 
(1mg/kg, i.p.) (Spyraki, Kazandjian, & Varonos, 1985). 
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Habituation and natural preference testing: After recovery from surgery and two 
days of handling (5 mins the first day, 10 mins the second day), rats were habituated to 
the test apparatus for three consecutive days. During the habituation sessions, the divider 
walls were removed and animals were allowed to freely explore the test chamber for 30 
mins under standard testing conditions, and then returned to their home cages. Animals 
received no microinjections during habituation days, but were briefly handled and their 
stylets were cleaned. 
The third and final day of habituation was recorded using a digital camcorder 
mounted above the testing apparatus and centered on the crucial transition area of the 
chamber (the middle chamber that transitioned between the two larger chambers). This 
tape was later scored offline to establish each animal’s natural preference for the two 
large conditioning chambers. After the final habituation session, each animal received a 
mock infusion of aCSF to accustom them to the microinjection procedure. 
Place conditioning training procedure: After habituation and natural preference 
testing were completed, rats were assigned in a counterbalanced manner to have one large 
chamber of the testing apparatus paired with vehicle microinjection, and the other side 
paired with DAMGO microinjection. Rats then received four consecutive daily 
conditioning sessions, consisting of two vehicle microinjections (days 1 and 3) and two 
DAMGO microinjections (days 2 and 4). On each conditioning day, rats received the 
appropriate microinjection and then were immediately placed in the corresponding large 
chamber for 30 mins. On these conditioning days, the dividing walls were in place, so 
animals were confined solely to the appropriate large chamber. Between test sessions, 
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chambers were thoroughly cleaned with 70% ethanol to remove odors and excrement 
from the testing apparatus. 
Conditioned place preference test: On the day immediately following the final 
conditioning session, rats were tested for conditioned place preference. As with 
habituation days, rats were gently handled and their stylets were cleaned, but they did not 
receive any microinjections. All dividing walls were removed, making all three chambers 
of the testing apparatus available on test day. After being briefly handled, rats were 
placed in the central starting chamber and allowed to freely explore the apparatus for 30 
mins. This session was again recorded using a digital camcorder for offline analysis. 
Place preference video analysis: Eat rat’s natural preference and conditioned 
place preference videotape was scored offline for time spent in each of the three 
chambers, by an observer blind to the experimental condition. A rat was considered to be 
in a chamber of the apparatus whenever its head and both forelimbs were inside that 
chamber and on the ground for more than two seconds. Therefore, a rat that traveled 
directly from one large chamber to the other and spent less than two seconds in the 
central chamber was considered to have moved directly from one conditioning chamber 
to another, and no time in the central compartment would have been scored. After 30 
minutes the total time (in seconds) spent in each chamber was recorded. 
 
Food intake testing 
Apparatus: Food intake testing was conducted in clear plastic cages (23 x 20 x 45 
cm) containing a pre-measured pile of standard lab chow (~30g), a water spout, and 
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corncob bedding. Each was assigned the same food intake cage throughout habituation 
and testing. 
Food intake testing: Rats were habituated to the food intake chamber for 3 
consecutive days prior to testing. On habituation days, rats were briefly handled and had 
their stylets cleaned, and were then placed immediately into the food intake chamber for 
1 hour. 
On test days, food intake was tested for 1 hour immediately following 
microinjection of vehicle or DAMGO. The entire session was videotaped for subsequent 
offline analysis. After the test was completed, remaining chow (including crumbs) was 
carefully removed from the cage and weighed. Test days were always separated by at 
least 24 hours. 
 Food Intake Video Scoring: Video recordings of food intake test sessions were 
scored offline by observers blind to the experimental condition. The following behaviors 
were recorded: eating time (in seconds), eating bouts (triggered by interruptions of eating 
of more than 5 seconds), food sniffing, food carrying, drinking time (in seconds), 
drinking bouts (same criteria as eating bouts), grooming, cage crosses, sleeping, rearing, 
and defensive treading. Treading is a natural defensive behavior emitted by rodents, and 
involves rapid forelimb strokes away from the body that push debris (e.g. dirt or bedding) 
in the direction of a threat. 
 
Histology 
After testing was completed, subjects were deeply anesthetized with sodium 
pentobarbital (0.2mg/kg; Fatal-Plus) and decapitated. Brains were extracted and placed in 
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a 10% paraformaldehyde solution for 24-48 hours, and then placed in a 30% sucrose 
solution for 3-5 days, until the brains sank. The brains were then sliced on a freezing 
microtome (Leica) into 60!m coronal sections, mounted onto glass slides, allowed to dry 
for at least 24 hours, and then stained with cresyl violet. Stained slices were viewed under 
light magnification and used to map the microinjection centers in each hemisphere on 
coronal sections taken from a rat brain atlas. (Paxinos & Watson, 2007)  
 
Statistical analysis 
Analysis indicated that data for both conditioned place preference and food intake 
were distributed non-normally, so nonparametric Wilcoxon signed-rank tests were used 
to compare changes in place preference, and also to compare vehicle and drug conditions 
for all food intake dependent variables. Due to illness during testing, one animal was 
excluded from both conditioned place preference and food intake data analysis. 
 
Results 
DAMGO in BNST generates a conditioned place preference 
 When rats were conditioned to associate a unique environmental context with 
DAMGO microinjection in BNST, these rats subsequently expressed a strong preference 
for the drug-paired context. On average, rats more than doubled the amount of time they 
spent in the DAMGO-paired chamber, in comparison to their natural preference for that 
chamber (Z=1.99, p=0.05). Increased preference of the place associated with BNST 
stimulation was observed both in animals who initially preferred the chamber 
subsequently paired with DAMGO as well as in animals that initially preferred the other 
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chamber (the one not paired with DAMGO), indicating that our preference effect is not 
simply the result of either 1) a decay in the aversiveness of the non-preferred chamber 
with additional exposure or 2) the strengthening over time of initially established 
preferences. This result supports the hypothesis that opioid stimulation in BNST 
primarily triggers appetitive motivation, rather than a stressful or aversive response. 
 
DAMGO in BNST increases feeding 
 In the same animals that displayed a conditioned place preference to a DAMGO-
paired chamber, we also found that DAMGO increased feeding on standard lab chow in a 
60-min voluntary feeding test. Consistent with our prior experiments (see Chapters 2, 3, 
and 4), opioid stimulation in BNST increased time spent feeding by an average of ~500% 
over vehicle controls (Z=2.02, p=0.04), and marginally increased the total intake of food 
in grams (Z=1.83, p=0.07) and investigatory sniffs of the chow pellets (Z=1.75, p=0.08). 
This demonstrates that, in the same animals that DAMGO generated a conditioned place 
preference, opioid stimulation also increased ‘wanting’ for a UCS food reward, and 
further supports the appetitive nature of opioid stimulation in BNST.  
DAMGO did not significantly affect drinking, defensive treading, or locomotor 
behaviors such as cage crossing, rearing, or grooming. I also examined whether an 
animal’s place preference score positively correlated with feeding behavior; however, 





Here we report that DAMGO in BNST actually caused a conditioned place 
preference, and not the conditioned place avoidance that an aversively stressful 
manipulation would be expected to generate. In addition to supporting our previous 
hypothesis that BNST is involved in appetitive motivational processes, this finding may 
also suggest a role for BNST in the acute rewarding effects of opioids. 
 
Opioid stimulation in BNST is not inherently stressful 
In this experiment we used conditioned place preference to examine the motivational 
valence of !-opioid stimulation in BNST. Previous experiments in our lab using food 
intake have suggested that BNST opioids can increase appetitive motivation, but robust 
associations between BNST and brain stress networks raised the possibility that our 
observed increase in food intake was primarily the result of increased stress, which only 
secondarily enhanced appetitive desire to feed. Stress is well known to potentiate food 
intake, especially of energy dense and palatable food options. 
However, we demonstrate here that opioid stimulation in BNST is not aversive, as 
evidenced by the absence of a conditioned place aversion. In fact, we found that 
DAMGO microinjection in BNST leads to the formation of a conditioned place 
preference, increasing the time spent in a drug-paired environment. Importantly, this 
finding supports our previously advanced hypothesis that BNST, in addition to its 
established roles in stress, anxiety, and drug withdrawal, is also associated with general 
appetitive motivation and reward. Although to date we have only shown a role for BNST 




The role of BNST in reward and withdrawal of opiate drugs 
The current experiment also increases our understanding of the role of BNST as a 
substrate for the effects of opiate drugs. Previous studies have shown BNST to impact 
both the aversive and rewarding aspects of opiates. Lesions of noradrenergic cell 
populations in the A1 and A2 regions of caudal medulla (which richly innervate BNST), 
as well as direct disruption of norepinephrine in BNST, both dramatically reduce 
aversion to an environment paired with precipitated opiate withdrawal (Delfs et al., 
2000). Additionally, opioid antagonism in BNST with methylnaloxonium reduced the 
self-administration of heroin, though only in rats previously made dependent on opiates 
with system morphine pellets (Walker et al., 2000). Both of these results may be linked 
by a later study showing that low doses of the opioid antagonist naltrexone can 
dramatically decrease norepinephrine efflux in the forebrain following opiate withdrawal, 
including in BNST (Van Bockstaele, Qian, Sterling, & Page, 2008). These findings 
suggest that, at least in dependent animals, BNST is an important node in mediating both 
reinforcing and aversive properties of opiate drugs. Taken together with reports of 
BNST’s function in stress-induced relapse of cocaine seeking behavior, long after 
withdrawal symptoms have subsided (Erb et al., 2001; Erb & Stewart, 1999), BNST 
appears to play a role at all stages of drug use. The appetitive findings here in BNST and 
throughout out regions of the extended amygdala, including CeA, will necessitate 
additional studies to further characterize the role of the extended amygdala outside the 
late-stage processes of drug dependence, withdrawal and relapse (Koob & Le Moal, 
2008) 
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Here we show a possible novel role for BNST in the positive motivation 
properties of !-opioid receptor stimulation in drug naïve animals, as well as a role in 
potentiating appetitive motivation for a natural reward, food.  Thus, regardless of the role 
of BNST in addiction, it seems also to be a mechanism that participates in generating true 













Figure 5.1. Anatomical maps showing the difference in time spent in the drug-paired side 
between the natural preference test and conditioned place preference test. Symbol 
placements are based on based on position of microinjection cannula in the BNST, shown 
in horizontal (top) and sagittal views (bottom). Fos plumes are adapted from previously 
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Figure 5.2. Stacked bar graph showing the distribution of time spent in each chamber for 
each rat during both the conditioned place preference (CPP) and natural preference (NP) 
test. The average for both natural preference and conditioned place preference tests is 
displayed as the final pair of bars. Five of the six rats tested displayed a conditioned place 
preference, and for some the difference in time from natural preference to conditioned 









Figure 5.3. Anatomical maps showing within-subjects changes in feeding time 
relative to vehicle treatment day. Symbol placements are based on based on 
position of microinjection cannula in the BNST, shown in horizontal (top) and 
sagittal views (bottom). Fos plumes are adapted from previously reported values 









Summary of experimental findings 
 In this series of studies, I first showed that BNST plays a role in appetitive 
motivation for natural rewards. I then subsequently explored some of the possible reward 
processes that BNST opioid stimulation may influence.  
 First, I showed that stimulation of !-opioid receptors in BNST can potently 
increase voluntary food intake, a broad measure of appetitive motivation and incentive 
salience ‘wanting.’ Intake of standard laboratory chow was roughly tripled by both doses 
of DAMGO tested, even though the animals had not been food deprived in advance of 
testing. I also found that temporary inactivation of BNST with a high dose of the GABAA 
agonist muscimol disrupted some measures of feeding, while simultaneously stimulating 
robust increases in defensive treading and cage circling. These apparently aversive effects 
of muscimol are consistent with the BNST’s role in aversive motivational processing, and 
together with the DAMGO feeding effect suggest that BNST may be able to generate 
oppositely valenced motivated behaviors in response to different types of neurochemical 
input. Although previous reports have shown inhibition of feeding following BNST 
microinjection with CRF (Ciccocioppo et al., 2003), to our knowledge this is the first 
demonstration of increased feeding following a manipulation of BNST. 
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 Following the finding of increased feeding with !-opioid stimulation in BNST, I 
conducted a series of experiments to explore specific psychological mechanisms that 
could contribute to enhanced food intake. One potential candidate was an increased 
attribution of incentive salience and so I tested the ability of DAMGO in BNST to 
increase incentive motivation in two separate tests of ‘wanting’: autoshaping and 
conditioned reinforcement. Additionally, I included a comparison group of animals with 
cannulae aimed at the medial shell of the nucleus accumbens, which allowed me to both 
1) directly compare and contrast the effects of !-opioid stimulation across extended 
amygdala and ventral striatal macrosystems and 2) test a novel hypothesis about the 
ability of accumbens shell opioids to amplify reward cues. I found that DAMGO in 
BNST caused a diffusion of incentive salience during autoshaping testing, resulting in 
increased ‘wanting’ for reward CS’s during non-CS+ inter-trial intervals and a decrease 
in appetitive behaviors toward both prepotent and non-prepotent cues during the CS+ 
period. The effect of accumbens shell opioid stimulation, in contrast, was to broadly 
enhance incentive salience ‘wanting,’ resulting in increased looks at and approaches to 
the non-prepotent cue and sometimes also the prepotent cue. In conditioned 
reinforcement testing, I found that accumbens shell opioid stimulation again broadly 
enhanced ‘wanting’ for the autoshaping CS+, as evidenced by increased responding in a 
novel instrumental task; DAMGO in BNST did not affect responding during conditioned 
reinforcement. In summary, this experiment demonstrated that BNST opioid stimulation 
increases ‘wanting’ for reward cues in a temporally diffuse way, while accumbens shell 
opioids appeared to act as a “rising tide that floats all boats” by elevating ‘wanting’ for 
both prepotent and non-prepotent rewards CS’s. 
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 Another possible explanation for an increase in food intake is the enhancement of 
the hedonic impact, or ‘liking,’ of the food reward. If a neurochemical manipulation were 
to make food seem more palatable and delicious, intake of that food would be expected to 
rise. In order to test whether DAMGO in BNST increased reward ‘liking,’ I utilized the 
taste reactivity paradigm (Berridge, 2000; Grill & Norgren, 1978). By measuring the 
orofacial reactions elicited by direct oral infusion of taste solutions, I found that opioid 
stimulation in BNST actually decreased ‘liking’ for a sweet sucrose solution; similar 
results were observed following temporary inactivation of BNST with muscimol. In 
subsequent food intake testing, I found that DAMGO in BNST again potently increased 
feeding, but did not preferentially stimulate intake of a preferred palatable food source 
(M&M’s) over standard lab chow. This experiment suggests that opioid stimulation in 
BNST does not increase feeding via an increase in hedonic ‘liking,’ in contrast to the 
effect of !-opioids at nearby hedonic hotspots in accumbens shell and ventral pallidum 
(Pecina & Berridge, 2005; K. S. Smith & Berridge, 2005). 
 Finally, it was important to confirm that the apparently appetitive feeding effect 
following opioid stimulation of BNST was not instead the result of a direct increase in 
stress. Indeed, BNST has a well-established role in brain stress networks, and stressful 
manipulations can often stimulate appetitive behavior, including feeding. In order to 
investigate whether DAMGO in BNST was inherently stressful, I utilized a conditioned 
place preference/avoidance procedure, where animals were conditioned to associate a 
unique environmental context with opioid stimulation of BNST; a separate environment 
was paired with vehicle microinjection. If, indeed, opioid stimulation of BNST is 
stressful, then I predicted that animals would avoid the DAMGO-paired environment on 
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a subsequent drug-free test day. However, I found that rats actually preferred an 
environment associated with !-opioid stimulation of BNST over an environment 
associated with vehicle microinjections, suggesting that DAMGO in BNST is not a 
stress-inducing manipulation and supporting our assertion that our initial feeding increase 
was primarily appetitive. In addition, our finding of a conditioned place preference also 
suggests a possible novel role for BNST in the acute reinforcing aspects of opiate drugs, 
in addition to its known role as a mediator of reinforcement and withdrawal in drug-
dependent animals (Delfs et al., 2000; J. R. Walker et al., 2000). 
 These experiments are a first step in clarifying how the BNST, in addition to its 
established role in aversive motivational processes, might act as a link in the brain’s vast 
reward network. 
 
BNST as a site of appetitive and aversive motivational building blocks 
 It is important to emphasize that our findings, which suggest a relatively novel 
role for BNST in appetitive motivation, should not be considered as contradictory to the 
array of findings that implicate BNST in aversive motivation, including stress and 
anxiety. There is no reason to expect that the brain would be constructed of nuclei or 
macrosystems that only mediate emotions or motivation of a particular valence. Instead, 
the present findings, taken together with data from studies of anxiety and stress, suggest 
that BNST should be considered one of several sites in the brain capable of providing the 
motivational building blocks for both appetitive and aversive behaviors. These basic 
components of motivated behavior can then be dynamically combined with both internal 
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information (e.g. physiological state) and external information (e.g. presence of 
threatening or rewarding stimuli) to generate adaptive behavior. 
 The juxtaposition of appetitive and aversive motivation has been described in 
several other brain regions, including additional sub-cortical nuclei in the extended 
amygdala. Like BNST, CeA is perhaps best known for its role in aversive motivation, in 
particular its role in the expression of Pavlovian fear conditioning to discrete CS’s such 
as a tone that has previously predicted an aversive footshock (Fendt & Fanselow, 1999; 
Goosens & Maren, 2001; D. L. Walker & Davis, 1997). However, CeA has also been 
shown to mediate a variety of appetitive motivational processes, such as the orientation 
response to conditioned stimuli that predict reward (Gallagher et al., 1990), the transfer of 
incentive motivation from Pavlovian reward cues to an instrumental action associated 
with the same reward (Corbit & Balleine, 2005; Mahler & Berridge, 2007), and food 
intake (Gosnell, 1988). 
 Outside the extended amygdala, the shell of the nucleus accumbens has also been 
shown to mediate both appetitive and aversive motivation. Rostro-caudal gradients have 
been discovered following GABA-ergic stimulation with muscimol, with microinjections 
in rostral shell eliciting robust feeding, conditioned place preference, and increased 
hedonic ‘liking’ (Reynolds & Berridge, 2001, 2002; Zhang et al., 2003) while identical 
injections in caudal shell result in suppressed feeding, conditioned place avoidance, 
increased ‘disliking’ of taste solutions, and dramatic increases in defensive treading 
(Reynolds & Berridge, 2002). A similar rostro-caudal gradient in accumbens shell has 
also been identified following disruption of glutamate (Reynolds & Berridge, 2003), and 
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more recently this glutamatergic gradient has been shown to be critically dependent upon 
dopamine signaling (Faure et al., 2008). 
 
Appetitive building blocks 
 Although a variety of neuroanatomical evidence suggested that BNST would play 
a role in reward, including strong links to midbrain dopamine and upstream nuclei such 
as CeA, there was relatively little behavioral evidence strongly supporting this potential 
appetitive role. Data from c-Fos expression experiments showed enhanced activity in 
BNST following several appetitive activities, including exposure to a sexual reward CS, 
food intake, and stimulation of other food reward nuclei (B. H. Li et al., 1994; Mullett et 
al., 2000; Mungarndee et al., 2008; Park & Carr, 1998; Taziaux et al., 2008). Yet 
although c-Fos expression can provide useful data about circuit activity, it does not 
convey specific information about what role a nuclei might play in the elicited behavior, 
nor does it conclusively rule out the possibility of elevated activity due to a factor 
secondary to the target manipulation. Stronger support for the appetitive role for BNST 
comes from studies utilizing direct manipulation, such as permanent or temporary 
lesions, to tease apart the role of BNST in male sexual behavior (Newman, 1999). Yet 
even these studies only report decreases in appetitive motivation following disruption or 
destruction of BNST. 
 Here, using direct pharmacological stimulation, I show for the first time that 
BNST can increase appetitive motivation for a food reward and also cause diffuse 
‘wanting’ for a reward cue. This suggests that, in addition to being considered a limbic 
relay for stressful and aversive information, BNST may also convey or directly stimulate 
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appetitive responses in downstream hypothalamic nuclei. As noted earlier, the lateral 
division of BNST projects robustly to regions of lateral hypothalamus, which has been 
strongly implicated in appetitive responding for food and other rewards (Harris, Wimmer, 
& Aston-Jones, 2005; Mullett et al., 2000; Zheng, Patterson, & Berthoud, 2007).  
 
Aversive building blocks 
 In addition to the finding that BNST is directly involved in the generation of 
appetitive motivation, I also present further evidence of aversive motivational building 
blocks in BNST. Previous reports have suggested that BNST is part of a distributed 
network mediating the response to fearful environmental stimuli. In particular, some have 
argued that BNST is critically involved in the response to diffuse, unconditioned stimuli 
and corresponds most closely to the human state of anxiety, a nonspecific aversive 
response to an impending or suggested environmental threat (M. Davis, 1998; M. Davis 
& Shi, 1999). In support of this aversive role, I found that temporary inactivation of 
BNST with muscimol caused an intense increase in a defensive treading behavior (see 
Chapter 2). Interestingly, this aversive behavior was directed throughout the testing 
chamber and was accompanied by almost constant circling of the chamber perimeter, 
almost as if the animals were constantly monitoring their environment in anticipation of 
an impending threat. 
 I also found evidence that muscimol in ventral regions of BNST may be particular 
effective at evoking aversive motivational building blocks. During food intake testing, 
our lower dose of muscimol (75ng per side) in ventral regions of BNST showed increased 
defensive treading and reduced feeding relative to microinjections in dorsal BNST. In 
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taste reactivity testing, the highest dose of muscimol (225ng per side) was a more potent 
suppressor of hedonic ‘liking’ responses to sweet sucrose solutions when delivered in 
ventral regions. Several electrophysiological studies have suggested differences in the 
characteristics of dorsal and ventral neuronal populations (Egli & Winder, 2003), 
including higher responsivity in ventral areas to morphine, acetylcholine, and 
norepinephrine (Casada & Dafny, 1993). Interestingly, anatomical studies have also 
shown that ventral BNST receives dense norepinephrine from caudal medulla, and this 
catecholamine input has been repeatedly linked to stressful and aversive events (Aston-
Jones et al., 1999; Delfs et al., 2000; Forray & Gysling, 2004; Leri et al., 2002; Pacak et 
al., 1995). It has been shown that norepinephrine in BSNT triggers GABAA inhibition 
(Dumont & Williams, 2004), suggesting the aversive motivational effects we observed 
following musicmol in ventral BNST may mimic the aversive characteristics of 
norepinephrine release. 
 
Overlap of appetitive and aversive building blocks with muscimol in anterior BNST? 
 Most of the examples presented so far regarding elicitation of bivalent motivation 
involve either different neurochemicals delivered at the same location (such as DAMGO 
and muscimol in BNST) or the same neurochemical delivered at different locations (such 
as GABA/glutamate gradients in accumbens shell). Can the same drug also elicit both 
appetitive and aversive building blocks when delivered at the same location? 
 This may be the case when muscimol is delivered at different doses in anterior 
portions of BNST. At a lower dose (75ng per side), muscimol microinjection resulted in 
slightly increased feeding relative to vehicle, while a higher dose of muscimol (225ng per 
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side) delivered at the same location in the same rats resulted in decreased feeding 
(Chapter 2). Somewhat similar modulation at the same site has been reported in 
accumbens shell, where GABA-ergic and glutamatergic inhibition in the middle of the 
rostro-caudal axis can occasionally elicit both appetitive eating and fearful defensive 
treading during the same test session, sometimes within second of eachother (Reynolds & 
Berridge, 2001, 2003). The glutamatergic appetitive and aversive zones in accumbens 
shell have also shown some flexibility in the face of environmental manipulations, with 
appetitive regions expanding in the presence of a comfortable home environment while 
aversive zones increase in size when the environment is loud and bright (Reynolds & 
Berridge, 2008). It will be of interest in future studies to evaluate the sensitivity of BNST 
aversion to environmental context; early pilot data from our lab seem to indicate that 
testing in a home environment can, indeed, diminish some of the aversive measures that 
accompany muscimol microinjection, including the onset of defensive treading (Berridge 
lab, unpublished data). 
 
Homogeneity and heterogeneity in basal forebrain !-opioid function 
 Part of the reason for exploring appetitive behaviors in BNST was its anatomical 
relationship with a variety of forebrain nuclei linked to reward and motivation. Given my 
findings in BNST, it is of interest to re-evaluate the broad role of !-opioids in basal 
forebrain. The result is an interesting pattern of results across feeding, incentive salience 






 The distribution of sites where !-opioids can stimulate feeding is the most 
homogeneous and widespread throughout basal forebrain. In addition to the already 
identified locations in nucleus accumbens (Bakshi & Kelley, 1993a; Zhang & Kelley, 
2000), ventral pallidum (K. S. Smith & Berridge, 2005), and central amygdala (Gosnell, 
1988), data presented here adds BNST to this list. Other data from our lab not presented 
here also implicates additional sites in extended amygdala, including SLEA and IPAC 
(Na, 2008), suggesting an almost unbroken corridor of opioid-sensitive feeding sites 
beginning at accumbens and stretching caudo-laterally all the way to central amygdala. 
 One slight divergence I observed in !-opioid stimulation of feeding in BNST, as 
compared to nearby sites in accumbens or central amygdala (Glass et al., 1999; Zhang & 
Kelley, 2000), was the inability to selectively increase feeding for highly palatable foods. 
In BNST, I found that although palatable M&M’s were strongly preferred to standard 
chow under both vehicle and DAMGO conditions, !-opioid stimulation increased feeding 
on both foods and not just the M&M’s. 
 
CS ‘Wanting’ 
 Though food intake serves as a broad measure of ‘wanting’ for a UCS reward, I 
also present data here on ‘wanting’ for learned CS’s that are associated with a sweet 
sucrose reward. In BNST, it appears that !-opioid stimulation generates a temporally 
diffuse ‘wanting’ for rewards CS’s that is not phase-locked to CS+ presentation. In 
accumbens shell, opioids appear to stimulate broad ‘wanting’ for all available reward 
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cues, while in central amygdala opioid stimulation generates focused ‘wanting’ for only 
an animal’s prepotent CS (Mahler & Berridge, 2009). Thus, although !-opioid receptors 
at several sites in basal forebrain appear to mediate ‘wanting’ for reward CS’s, the 
precise structure of this CS motivation is dependent upon exactly which region is 
stimulated. The diversity of opioid-dependent CS ‘wanting’ is particularly interesting 
within extended amygdala, and may mirror dissociations between BNST and CeA in 
other behavioral contexts. Indeed, as previously noted, it has been suggested by some that 
BNST lesions appear to affect different classes of stimuli (primarily unconditioned, 
temporally diffuse) than CeA (primarily conditioned, temporally discrete) in fear 
conditioning and potentiated startle paradigms (M. Davis & Shi, 1999). 
 
‘Liking’ 
 Forebrains sites where !-opioids can act to increase the hedonic impact, or 
‘liking,’ of food rewards appear to be the most scarce as well as the most anatomically 
restricted. So far, only two brain regions – the medial shell of the nucleus accumbens and 
ventral pallidum – have been shown to support !-opioid enhancements of ‘liking,’ and 
even these hedonic hotspots are restricted to small sub-regions within these nuclei. In 
contrast, !-opioid stimulation in CeA has been shown to decrease ‘liking’ for a sweet 
sucrose solution (Mahler & Berridge, 2006). Here I report that !–opioid stimulation in 
BNST also suppresses ‘liking’ for a normally pleasant sucrose taste, similar to CeA. This 
suggests that although opioids within the ventral-striato-pallidum macrosystem can 
dynamically and transiently enhance ‘liking’ for a pleasant food reward, opioids within 
the extended amygdala macrosystem cannot make an already ‘liked’ reward even better, 
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and in fact actually diminish hedonic responding. Although the mechanism for this 
reduction in ‘liking’ after extended amygdala !-opioid stimulation is currently unknown, 
in BNST at least it may be linked to descending, predominantly inhibitory connections to 
hindbrain taste nuclei (Kang & Lundy, 2009; C. S. Li & Cho, 2006; Lundy, 2008). 
 
Revisiting the Extended Amygdala Concept 
 Prior to the current studies, BNST was a relatively unknown entity in reward and 
appetitive motivation. Outside of a limited series of studies that had implicated BNST as 
a necessary node in the network responsible for male sexual behavior (Newman, 1999), 
little direct evidence existed to link BNST with the generation of purely appetitive 
behavior. In fact some data, including studies of feeding, suggested that BNST might be 
involved in the suppression of appetitive behavior in response to stress-related 
neuropeptide signaling (Ciccocioppo et al., 2004; Ciccocioppo et al., 2003). Given our 
current findings that show a direct role for BNST !-opioid receptor stimulation in the 
generation of appetitive behavior for food rewards, how does this impact the broader 
concept of the extended amygdala? 
 First, the current experiments provide further support for the hypothesis that the 
entire extended amygdala, and not just CeA, is involved in the generation and assignment 
of appetitive behaviors (Waraczynski, 2006). Indeed, pilot data from our laboratory 
suggests that all regions of the extended amygdala, including CeA, BNST, IPAC, and 
SLEA, can all support increased feeding in response to !-opioid stimulation (Na, 2008). 
IPAC and SLEA are more unknown entities in reward and motivation than even BNST, 
and future studies will be required to clarify their specific roles in appetitive behavior. 
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The relative homogeneity of feeding and taste reactivity results in extended amygdala 
further supports the utility of this neuroanatomical macrosystem as a springboard for 
behavioral investigation, though it should also be noted that the appetitive role of each 
extended amygdala nuclei is unlikely to be redundant. For example, although previous 
research has shown that CeA !-opioid stimulation yielded a focused enhancement of 
incentive salience on an animal’s prepotent reward CS during autoshaping testing, I 
reported in Chapter 3 that BNST !-opioid activation generated a more diffuse ‘wanting’ 
that was not linked to the phasic presentations of the autoshaping CS+. 
 Second, the current findings suggest that both the central (CeA through lateral 
BNST) and medial (MeA through medial BNST) divisions of extended amygdala are 
involved in appetitive motivation for a food reward. These parallel sub-systems within 
extended amygdala show sparse cross-connection relative to the dense interconnections 
within each of the central and medial divisions (Alheid, 2003; de Olmos & Heimer, 
1999), and previous research strongly implicating CeA in appetitive motivation suggested 
that perhaps only more lateral regions of BNST would play a role in appetitive processes 
(Gallagher et al., 1990; Gosnell, 1988; Holland & Gallagher, 2003; Mahler & Berridge, 
2009). However, though we did show increased feeding and diffuse ‘wanting’ following 
!-opioid stimulation in lateral BNST, we also observed similar effects after stimulation in 
medial BNST regions (see Chapters 2, 3, and 4). This finding is again consistent with the 
observed role of medial extended amygdala regions in the generation of male sexual 
behavior (Newman, 1999), and also with the suggestion that the medial extended 
amygdala system may play a particular role in reward valuation more generally 
(Waraczynski, 2006). One notable limitation here to our ability to distinguish clearly 
 190 
between the role of medial vs. central extended amygdala are the small size of these 
anatomical sub-regions; indeed, in spite of the relatively small Fos plumes observed in 
our experiments, many of the microinjections in the present study likely stimulated at 
least some receptors in both lateral and medial regions of BNST. Future studies could 
potentially use modified microinjection doses or volumes to further restrict the region of 
functional impact in order to more carefully tease apart the roles of central vs. medial 
extended amygdala. 
 Third, although the extended amygdala does appear to generate enhanced 
‘wanting’ for both unconditioned rewards and also reward cues, the present studies and 
other related data suggest that this macrosystem does not play a role in increasing the 
hedonic impact of food rewards once they are received and consumed. In Chapter 4, I 
reported that !-opioid stimulation in BNST potently reduced the number of hedonic 
orofacial responses to an oral infusion of a sweet sucrose solution, reducing the total 
number of hedonic reactions by almost 50%. Nearly identical behavioral results have 
been reported following !-opioid stimulation in CeA (Mahler & Berridge, 2006). These 
results stand in contrast to the !-opioid hedonic hotspots that have been indentified in 
rostro-dorsal accumbens shell and caudal ventral pallidum (Pecina & Berridge, 2000, 
2005; Smith & Berridge, 2005), components of the nearby ventral striato-pallidal 
macrosystem. 
Finally, although the extended amygdala has frequently been implicated in the 
aversive components of addiction and drug seeking (Aston-Jones & Harris, 2004; Delfs 
et al., 2000; Koob, 2003), the present studies and related experiments suggest that 
extended amygdala may also contribute to more purely appetitive drug-seeking. For 
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example, CeA opioid stimulation has recently been shown to enhance the motivational 
magnet quality of previously learned reward cues, focusing appetitive responses on a 
prepotent cue and offering a potential neural substrate for linking learning with 
motivation to approach and interact with cues that predict drug delivery. BNST opioid 
stimulation, in contrast, may act more broadly to enhance incentive motivation, perhaps 
making the entire environment seem more attractive and pleasant. Interestingly, as 
demonstrated in our autoshaping study in Chapter 3, this could potentially contribute to 
instances where ‘wanting’ appears to spill-over beyond learned boundaries, similar to 
rare cases of dopamine dysregulation disorder where patients not only develop addictive 
patterns of dopamine replacement but can also exhibit excessive motivation for other 
activities such as gambling (O'Sullivan, Evans, & Lees, 2009). 
 
Future directions 
Other neurochemical substrates for appetitive motivation in BNST 
 The current series of experiments focuses primarily on appetitive motivation after 
!-opioid stimulation within BNST. However, there are other potential neurochemical 
targets for reward and appetitive processes in BNST that deserve consideration in future 
studies. Foremost on the list is dopamine, a perennial target in affective neuroscience that 
has been implicated in several aspects of reward (Barbano & Cador, 2007; Berridge, 
2007; Redish, 2004; Salamone, 2007; Schultz et al., 1997). BNST shares reciprocal 
connections with midbrain dopaminergic nuclei (Fudge & Haber, 2001; Georges & 
Aston-Jones, 2001), and both intrinsic stimulation of BNST as well as incoming 
stimulation from infralimbic cortex relayed via BNST can potently modulate firing in 
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VTA dopaminergic cell populations (Georges & Aston-Jones, 2001). Cannabinoid 
receptors, which have also been implicated in appetitive motivation (Fattore et al., 2008; 
Mahler et al., 2007), in BNST have recently been shown to modulate downstream 
activitiy in this infralimbic-BNST-VTA circuit, making them another potential target for 
future investigation.  
 
The role of BNST in mediating conditioned cues 
 One particularly thorny issue worthy of future study is the role of BNST in the 
behavioral response to conditioned cues. Although some have argued that BNST is 
primarily involved in the response to unconditioned cues (especially in the context of 
anxiety) (M. Davis, 1998), a number of studies appear to show at least some role for 
BNST in the response to conditioned cues. For example, elevated c-Fos expression is 
found in BNST following exposure to a cue associated with a sexual reward (Taziaux et 
al., 2008), and presentation of a tone paired with stressful immobilization elicited 
increased responding in BNST neurons (Henke, 1984). Perhaps it could be argued in both 
these cases that activity in BNST was merely a relay node in a larger circuit, or was 
stimulated primarily by upstream activity in CeA, but it has also been shown that lesions 
of BNST, though they impair fear conditioning to a discrete tone stimulus, do not impact 
contextual fear expression for an environment previously paired with aversive shocks 
(Sullivan et al., 2004).  
I presented evidence earlier that BNST opioid stimulation can increase ‘wanting’ 
for a reward CS in an autoshaping task (Chapter 3), though this ‘wanting’ was temporally 
diffuse and spread outside the CS+ periods where ‘wanting’ is normally expressed. The 
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temporal qualities of the cue may be particularly relevant to explaining the role BNST 
plays. For example, one key difference between the tone CS and environmental CS in the 
fear conditioning experiment described above are their temporal character: the former is 
brief and phasic, the latter extended and enduring. Perhaps, then, the key distinction 
between BNST and other regions involved in the processing of environmental cues (such 
as CeA) is not conditioned vs. unconditioned, but brief vs. extended or phasic vs. tonic. 
 
Role of BNST opioids in mediating other natural rewards 
 In several experiments I showed that BNST !-opioid stimulation could robustly 
increase ‘wanting’ for UCS food rewards, including both standard rat chow and more 
palatable M&M’s. Can !-opioid stimulation also increase the incentive motivational 
value of other natural rewards, like sex or social interaction? 
 As previously noted, there is considerable evidence to support a role for BNST in 
sexual motivation, especially in males (Newman, 1999), though direct infusion of beta-
endorphin (an endogenous !-opioid agonist) in BNST has been reported not to impact the 
performance of sexual behavior in male rats (Hughes, Everitt, & Herbert, 1987). In 
collaboration with an undergraduate honors student, I attempted to investigate in male 
rats whether DAMGO microinjection in BNST could enhance 1) appetitive investigation 
of a receptive female (and effect recently demonstrated in CeA – Berridge Lab, 
unpublished data) and 2) increase the preference for an opposite sex odor. Although we 
were able to replicate the finding of enhanced food reward, we did not find any increases 
in sexual or social odor preference. I believe that methodological issues (including 
problems with our ovariectomized females and subsequent hormone replacement) may 
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have contributed to this null finding, though based on the finding by Hughes et al. (1987) 
it is possible that BNST may not be sufficient to increase sexual behavior, even if BNST 
is a necessary part of the network that controls sexual behavior and reward. 
 
Circuit interactions within extended amygdala 
In this dissertation I have presented data showing that focused neurochemical 
manipulation of BNST can influence appetitive motivation, and referenced data 
suggesting that targeted manipulations of other extended amygdala nuclei, especially 
CeA, can do the same. However, as the anatomical concept of extended amygdala 
continues to grow and gain additional support, it will be important to begin investigating 
the circuit functions with this macrosystem. How do extended amygdala sub-regions act 
together to generate motivated behavior? 
One such study has already been conducted examining the role of BNST and CeA 
in stress-induced relapse. Using asymmetrical bilateral lesions, it was shown that CeA 
acts in concert with BNST to generate the CRF-dependent relapse in extinguished drug-
seeking that follows exposure to an acute stressor (Erb et al., 2001). This methodology 
could easily be adapted to evaluate the appetitive behaviors by, for example, testing 
whether the effect of DAMGO microinjection in CeA on feeding was influenced by 
simultaneous blockade of opioid function in the BNST, or vice versa. A similar design 
has recently revealed that hedonic hotspots in accumbens shell and ventral pallidum 
appear to work together in generating enhancements of ‘liking.’ Opioid blockade in one 
spot can veto hedonic enhancement normally caused by opioid activation in the other, 
though interestingly the effect of DAMGO on feeding is asymmetrical (K. S. Smith & 
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Berridge, 2007). Such studies will be necessary in extended amygdala to fully 




 In summary, I present here some of the first evidence that BNST opioid 
stimulation plays a direct role in the generation of appetitive motivation. This finding, 
together with its established role in aversive and stressful motivation processes, suggests 
that BNST should be considered a forebrain site of both appetitive and aversive 
motivational building blocks. Future studies will be required to fully characterize the role 
of BNST in various reward processes, though I do show here that it participates in UCS 
reward ‘wanting,’ diffuse ‘wanting’ for reward CS’s, and possibly the acute rewarding 
effect of !-opioid stimulation. BNST !-opioid stimulation did not stimulate hedonic 
‘liking,’ actually diminishing the pleasantness of a sweet sucrose solution in a manner 
similar to opioid stimulation in CeA. The possibility that these apparently appetitive 
effects were instead the result of stress was diminished following the discovery that 
opioid stimulation in BNST generated a conditioned place preference. Together, these 
findings support a role for BNST in appetitive motivational processes, and increase our 
knowledge of the function of !-opioid stimulation in the emerging anatomical 
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